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ABSTRACT

Chandrasekhar, Saradha. Ph.D., Purdue University, August 2015. Thiol-Disulfide
Exchange in Human Growth Hormone. Major Professor: Elizabeth M. Topp.
The biopharmaceutical industry has been growing at a tremendous rate, with sales of $63.6
billion 2012 in the US [1]. Nevertheless, the successful development of many protein drugs
has been impeded by physical and chemical instabilities arising from their inherent
chemical complexity and often leading to protein aggregation. The formation of non-native
disulfide bonds is a common route to covalent aggregation of therapeutic proteins and other
biologics [2, 3]. Disulfide bonds participate in hydrolytic and oxidative degradation
reactions that form non-native disulfide bonds and other reactive species. The mechanisms
responsible for protein aggregation are poorly understood and formulations are currently
optimized on a trial and error basis. This approach contributes to high development costs
and increases the time to market. The main goal of our research is to elucidate the
mechanisms of thiol-disulfide exchange and disulfide scrambling in therapeutic proteins.
To accomplish this goal, model peptides derived from human growth hormone (hGH) and
intact hGH were used to investigate reaction mechanisms and kinetics in solution and solidstate environments. The results will be useful in the rational development of stable, safe
and efficacious protein formulations that contain free cysteines and disulfides.

xxii
Chapter 1 of this dissertation focuses on background information and explains the
role of disulfide bonds in proteins, their advantages and limitations and different
degradation pathways. Research objective and specific aims are also outlined in Chapter
1. Model hGH-derived tryptic peptides were used to investigate reaction mechanism and
kinetics in aqueous solution (Chapter 2). RP-HPLC was used as a quantitative tool and
product identity was further confirmed on the LC-MS. The effects of pH, temperature,
oxidation suppressants and peptide secondary structure on thiol-disulfide exchange were
also explored.
Protein drugs are also manufactured as lyophilized powders to improve stability
and retain potency during storage. In Chapter 3 of this dissertation, thiol-disulfide exchange
during lyophilization and storage in the solid state using model peptides are discussed.
Comparisons are drawn to the aqueous solution studies in Chapter 2. We also investigated
the effect of factors that may contribute to thiol-disulfide exchange during lyophilization
and these include; initial peptide concentration, temperature, buffer type and concentration,
length of primary drying time and peptide adsorption to ice.
In Chapter 4, thiol-disulfide exchange in intact hGH was investigated to understand
the effects of higher-order structure on reaction kinetics. Free thiol containing peptides of
different length and sequence and GSH were used to facilitate thiol-disulfide exchange in
intact hGH and hGH-derived peptides with a disulfide bond. Finally, concluding remarks,
future perspectives and implications for protein formulations are discussed in Chapter 5.
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CHAPTER 1. OVERVIEW OF THERAPEUTIC PROTEINS

1.1

Introduction

Many low molecular weight drugs are chemically manufactured and processed into
tablets and capsules that are easily ingestible. In contrast, protein drugs are macromolecules
that contain many labile groups and have fragile, dynamic three-dimensional structures.
Protein pharmaceuticals have been gaining widespread importance as new treatments for
serious diseases such as cancer, cardiovascular and autoimmune diseases. The growth of
protein therapeutics has been facilitated by the rapid development of recombinant DNA
(rDNA) technology since the approval of recombinant insulin. The different categories of
biologic drugs and their 2012 U.S. sales are shown in Figure 1.1.

Figure 1.1: Categories of biologic drugs in terms of US sales in 2012. Adapted
with permission from [1].
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Protein drugs and other biologics are the fastest growing sector of the U.S.
pharmaceutical industry, with sales expected to increase to $144 billion by 2016 [1]. Nine
new biopharmaceutical entities (NBE) were approved by the FDA in 2012 [4] and industry
pipelines suggest the potential for many more protein drugs in the future. Protein instability
presents many challenges to the development of new protein drug products which
ultimately increase the time and cost required. Recent data suggest that approximately
$400 million is associated with pre-clinical development of new biopharmaceuticals, a cost
ultimately borne by the public [5].
Protein drug development is further complicated by the fact that formulations often
contain an ensemble of protein conformations, which include the native state, partially
unfolded states and even completely denatured states. This heterogeneity stems from the
dynamics and thermodynamics of protein folding, the source of the protein (usually a
complex biological mixture of proteins from cells), and the effects of upstream and
downstream processing conditions. An ideal protein formulation would contain the pure
protein in its native state; however, structural complexity and the presence of numerous
reactive centers in proteins make it almost impossible to identify optimum conditions to
maintain this ideal. In addition, the mechanisms of most aggregation pathways have not
yet been investigated in detail and aggregates of protein drugs are typically classified as
covalent and non-covalent [6]. This broad classification of protein aggregates precludes the
mechanistic details of aggregation pathways like thiol-disulfide exchange and is a
limitation in designing rational approaches to improve protein stability during manufacture,
processing and storage.
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1.2

Recombinant DNA technology

Therapeutic proteins are now produced using recombinant DNA (rDNA)
technology, where a vector containing the gene of interest is transformed into a host cell
for protein expression. The protein of interest is then purified from the cell lysate; this
process varies depending on the type of protein, the way it is expressed (secreted vs.
inclusion bodies) and the host cell in which it is expressed. Insulin was the first recombinant
product to be licensed for therapeutic use in 1982. FDA approved recombinant proteins for
therapeutic use includes hormones, growth factors, coagulation factors, interferons,
interleukins and enzymes [7]. Theoretically any protein can be produced using rDNA
technology.

However,

the

protein

may

undergo

changes

during

manufacture/purification/processing (Figure 1.2) that make it unstable and unsuitable for
therapeutic use. During a typical protein manufacturing process, nearly 20-30 unit
operations are performed and these steps increase the chances of variability in the final
protein product [8]. Protein properties are also affected by post-translational modifications
such as glycosylation, amidation, carboxylation, sulfation and hydroxylation [9]. Overall,
the process of expressing and purifying proteins is a rate-limiting process in research,
demanding expertise and making protein therapeutics very expensive.
Different factors associated with the host cell and manufacturing process can affect
protein drug quality [8]. Some of these undesirable modifications are: i) undesirable host
cell and process modifications: truncation, glycation, methylation and isomerization, ii)
undesirable process modifications: aggregation, oxidation, deamidation and misfolded
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forms of protein and impurities from host cell and process related impurities: host cell
proteins and endotoxins.

Figure 1.2: a) Monoclonal antibody structure showing regions that are prone to undergo
chemical modifications, resulting in product heterogeneity. b) Schematic showing a typical
protein manufacturing process. Adapted with permission from [8].

1.3

Stability of protein drugs

Challenges associated with the development of protein pharmaceuticals arise from
the unique flexible structure of proteins that enable them to interact with other biological
molecules and also adapt to changes in their microenvironment. Structural flexibility
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promotes conformational changes, chemical modifications (via exposure to reactive
species like ROS), aggregation and precipitation. Such modifications have been associated
with loss of biological activity and immunogenicity [10-12]. Aggregation is known to occur
both in solution [13] and the solid state [14-16] and can be induced by chemical and/or
physical changes. Chemical instabilities that involve bond formation or cleavage include
deamidation, thiol-disulfide exchange, proteolysis and oxidation. Physical instabilities
result in changes to higher order structure without covalent modification; these include
denaturation, aggregation, adsorption to surfaces and precipitation [6]. The onset of
aggregation is protein specific and the effect of stabilizers on therapeutic proteins must be
studied on a case-by-case basis, which further retards drug development and increases
manufacturing costs. Different chemical and physical degradation pathways in proteins and
peptides are discussed below.

1.3.1

Physical degradation
Denaturation: protein denaturation is the loss of tertiary or secondary structure or

both, which can then lead to any of the other degradation pathways listed below. Protein
denaturation is further classified as thermal, cold, chemical or pressure-induced [6].
Thermal denaturation occurs at elevated temperatures and is irreversible, these thermally
unfolded proteins have a tendency to associate and form aggregates. There are few reports
on cold denaturation of proteins; nevertheless it is an important phenomenon as even at 20 oC and in the presence of stabilizers, they have mobility. Chaotropes like guanidine
hydrochloride and urea are used to chemically denature proteins. These reagents are used
in studies to determine the free energy associated with unfolding events. For pressure-
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induced denaturation to occur, proteins must be exposed to pressures in the range of 20004000 bar. A lower pressure range (1000-1500 bar) is typically employed to dissociate
aggregates. Pressure-induced denaturation is usually reversible, unlike the other types of
protein denaturation described above [17].
Aggregation: involves the formation of non-native bonds following disruption of
native bonds. Loss of native protein conformation during purification, formulation, freezethawing and freeze-drying often leads to the exposure of hydrophobic residues in unfolded
and partially unfolded states that can then promote aggregation [6]. Both non-covalent and
covalent interactions can result in protein aggregation, which ultimately affects biological
activity and can result in a severe immunogenic response after administration. Proteins do
not aggregate via a single pathway and this adds to the challenges associated with
investigating the mechanism of aggregation. There are five general mechanisms of protein
aggregation: 1) association of native monomers, 2) aggregation of conformationally altered
monomers, 3) aggregation of chemically-modified monomers, 4) nucleation-controlled
aggregation and 5) surface-induced aggregation [18]. Typically, protein conformational
stability is considered to be a significant factor in regulating aggregation; a partially
unfolded state is the aggregation initiator (also the rate-limiting factor) [6, 19]. Stabilizing
agents like sucrose and Tween have been used to effectively suppress aggregation in human
interferon- γ13 and human growth hormone respectively [20].
Surface adsorption: proteins are exposed to a multitude of surfaces to which they
can adsorb during manufacture, processing and storage. The physical state of a protein can
be altered when it adsorbs to a surface or is exposed to interfacial stress [6]. Though both
the native and partially unfolded states can adsorb to surfaces, adsorption of a partially
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unfolded protein may be energetically favored due to the exposure of more hydrophobic
residues when compared to the native state, in which they are buried within the core. A
combination of interfacial structure perturbation and desorption of partially unfolded
proteins can set off nucleation and result in aggregation [21-24]. The effects of surface
adsorption on protein function and conformation have been reported previously [25, 26].
Precipitation: there are two different mechanisms by which proteins can precipitate.
First, salting out of proteins in the presence of an excluded solvent can result in
precipitation, a process that is usually reversible upon dilution [27]. Further, salted-out
proteins retain activity similar to that of the native protein. Second, aggregates can grow
so large in size that they are no longer soluble and manifest as haziness or cloudiness. The
observed haziness is termed particulate formation and is typically irreversible. Particulate
identification and detection is a major concern to the pharmaceutical industry and
regulatory agencies as the particles may have immunogenic implications [28]. It is
important to distinguish particulates formed from protein aggregates and foreign materials.

1.3.2

Chemical degradation
Oxidation: amino acids His, Trp, Met, Cys and Tyr can undergo oxidation in the

presence of a reactive oxygen species (ROS) [29]. Oxidation reactions in proteins are
classified as sit-specific (metal catalyzed) and non-site specific (photooxidation and free
radical cascades). Methionine (Met) is oxidized easily to its sulfoxide and sulfone in the
presence of ROS and molecular oxygen. Met oxidation has been reported in mAbs,
particularly in the Fc region [30]. Oxidation of Trp generates kynurenine derivatives and
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can occur both in the presence and absence of light. Yang et al. determined Trp oxidation
in mAbs using RP-HPLC as an analytical tool [31].
Deamidation: is one of the most common pathways for chemical degradation in
peptides and proteins. Asn and Gln can undergo deamidation to form Asp and Glu
respectively at neutral to alkaline pH. Gln deamidation is less common due to the formation
of a less stable six-membered ring intermediate. Primary structure effects on deamidation
have been explored, and faster deamidation is observed when smaller amino acids are
present after (e.g., N+1) residues due to minimal steric effects [6]. Deamidation is also
favored in polypeptide regions that are known to be flexible and when amino acid side
chains that can act as hydrogen bond donors are present in the N+1 position. Asn-Gly is
frequently the most reactive sequence for deamidation to occur in peptides and proteins.
Preceding (e.g., N-1) amino acids typically have little effect on deamidation in solution,
however, in the solid-state deamidation is accelerated with a Gln or Glu residue.
Deamidation has been observed in therapeutic proteins like rhGH [32], glucagon [33] and
mAbs [34]. Asp residues can also participate in isomerization and racemization reactions,
which follow mechanisms similar to that for deamidation.
Proteolysis/hydrolysis/clipping: hinge region hydrolysis can occur in mAbs and
peptide backbone hydrolysis can occur near Asp residues. Asp hydrolysis in the solid state
has been observed for recombinant bovine growth hormone [35]. Hinge region hydrolysis
facilitated by hinge region flexibility and Fab region conformational instability has been
reported in mAbs.
Dityrosine formation and formaldehyde mediated cross-linking: Formaldehyde
can form covalent bonds with a nitrogen atom of Lys or His to produce a hydroxylmethyl
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derivative, which is then transformed into a Schiff base imine upon condensation. The
imine is reactive and facilitates a cross-linking reaction with Tyr [36]. Dityrosine can be
formed by photoactivation or enzyme catalysis. Dityrosine formation between two tyrosyl
residues has been identified in calmodulin [37].
Thiol-disulfide exchange and disulfide scrambling: Thiols and disulfides in
proteins have functional roles and can participate in oxidative and hydrolytic pathways.
Disulfide scrambling has been observed in therapeutic proteins like mAbs [38], insulin [39]
and hGH [40]. However, very little is known about the effect of higher order structure on
the mechanism and kinetics of thiol-disulfide exchange and disulfide scrambling. As the
number of antibodies and antibody- or albumin-fusion drug products increases, the need to
control thiol/disulfide reactivity becomes more acute. This reaction is the focus of the work
presented in this dissertation and is discussed in detail in below.

1.4

Thiols and disulfide bonds

There are three types of Cys: i) free SH groups, ii) ligand SH groups and iii)
disulfides (cystines) [41]. Cysteine is similar to Serine but is a poorer hydrogen bond donor.
In vivo, free Cys are present only in reducing environments that make them less harmful,
for example in bacterial and viral proteins [41]. A common location for free Cys is on a β
strand, pointing inward and buried. They are rarely found on the surface of proteins due to
their reactive nature. Wolfenden et al. have shown Cys to be neutral or mildly hydrophobic
and this could also explain their tendency to be the most buried amino acid [42]. Ligand
Cys can bind to different metals and prosthetic groups like Fe, Cu, Zn, Fe-S clusters and
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hemes. Typically, ligand Cys are found in coil regions and in helices, they are quite rare in
β-sheets. Mettalothionien is an example of a protein that contains ligand Cys with 20 Cys
that can bind to seven metals [41]. Disulfide bonds stabilize native protein structures by
crosslinking distant regions into a compact three- dimensional structure and reducing
conformational entropy of the unfolded state. However, in their reduced forms (as free
thiol groups) they may have very little role in the early folding process. The Cα-Cβ vectors
are either antiparallel or perpendicular in the most common disulfide conformations, the
left-handed spiral and right-handed hook respectively. In addition to the vector orientation,
the distance between the α-carbons of the cysteines must be 4-7.5 Å.

1.5

Disulfide bond formation in proteins

In eukaryotes, protein disulfide bonds are formed in the endoplasmic reticulum (ER)
where the redox state is more favorable when compared to the cytosol. Oxidation of
cysteines is initiated when proteins are translocated into the ER lumen. The rate of disulfide
bond formation in living cells is faster than the rate of formation in vitro (in air), this has
been attributed to the role of enzymes in the catalysis of protein oxidative folding in
addition to the role of small-molecule redox buffers (GSH/GSSG) [43]. GSH provides
reducing equivalents that are necessary to optimize folding conditions and counterbalance
conditions of oxidative stress [43]. Protein disulfide isomerase (PDI) is an enzymatic
catalyst that facilitates disulfide bond formation, reduction and isomerization. At the active
site of PDI is a Cys-x-x-Cys motif similar to thioredoxin. When the cysteines are oxidized,
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PDI transfers disulfide bonds to proteins in the ER (Figure 1.3). Disulfide scrambling is
catalyzed when the cysteines in PDI are in the reduced state.
Similarly, in prokaryotes, DsbA (thioredoxin-like oxidoreductase, disulfide bond
A enzyme) and DsbB (a membrane protein) initiate disulfide bond formation in periplasmic
proteins. DsbA oxidizes cysteines in periplasmic proteins with the reduction of its own
disulfide bond, DsbA is then reoxidized by DsbB. Components of the electron transport
system help maintain DsbB in its oxidized state. DsbC reduces non-native disulfides in
protein substrates, this is followed by re-oxidation of the Cys residues in the substrate by
DsbA or DsbC. The role of DsbD is to maintain DsbC in its oxidized state, and cytoplasmic
thioredoxin then reduces DsbD.

Figure 1.3: A pathway for protein disulfide bond formation in the endoplasmic reticulum
(ER). Oxidizing equivalents flow from Ero1p to Pdi1p, and then from Pdi1p to secretory
proteins through a series of thiol-disulfide exchange reactions. Adapted with permission
from [43].
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Disulfide bond formation in proteins is typically favored at neutral to alkaline pH
and the rate of oxidative folding is increased in the presence of an oxidizing agent. A
common oxidizing agent that is used to facilitate oxidative folding of proteins is oxidized
glutathione (GSSG). Denaturing agents like guanidine hydrochloride and urea disrupt the
folding process [3]. One exception to this general rule is murine prion protein (mPrP),
which has only one intramolecular disulfide bond. At alkaline pH and in the absence of a
denaturing agent, disulfide bond formation in mPrP is very slow [44]. However, at pH 8.0
in the presence of both a denaturing agent and glutathione, mPrP folds correctly. The
optimum pH for oxidative refolding of mPrP is 4.0-5.0. In the absence of a denaturant,
mPrP is in a stable conformation at pH 8.0, where the Cys residues are isolated from one
another and cannot form a disulfide bond. In the denaturant-mediated unfolded state, the
Cys residues are in close enough proximity to form a stable disulfide bond. This is a good
example of both intrinsic and extrinsic factors (discussed below in section 1.6) contributing
to disulfide bond formation.
Many therapeutic proteins like antibodies, enzymes and hormones contain disulfide
bonds that crosslink distant regions to help maintain the native fold and stabilize the threedimensional structure of proteins [45, 46]. Other roles of disulfide bonds include enzyme
catalysis [47], regulation of biological activity [46], structural stabilization of extracellular
proteins [47] and protection against oxidative damage [45]. It is not always easy to predict
the effect a disulfide bond can have on a protein. In some cases, engineered disulfide bonds
can have destabilizing effects, if the entropy of the folded state is decreased by reduced
flexibility [3]. In the same way, mutating Cys to other amino acid residues may not
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necessarily impede degradation via other pathways and in addition may be accompanied
by a loss of biological activity.
Figure 1.4 shows how disulfide bond stability and stability provided to the folded
protein by a disulfide bond are thermodynamically linked; ΔG of this cycle is zero [45]. In
one pathway, formation of disulfide bonds occurs first by organizing the unfolded protein
in such a way that the entropy loss accompanying protein folding is less than that of the
unfolded state [45]. In an alternative pathway, the protein folds first bringing together
distant Cys residues that can then be oxidized to form stable disulfide bonds.

Figure 1.4: Thermodynamic cycle linking disulfide bond stability in the reduced and
oxidized folded structure with the stability of the folded and unfolded states [45].
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1.5.1

Disulfide bond disruption and rearrangement
Disulfide bonds are prone to undergo cleavage because they have 0.4-fold lower

dissociation energy than C-C and C-H bonds [49]. Some of the mechanisms by which
disulfide bonds may be disrupted include thiol-disulfide exchange, alkaline hydrolysis,
photodegradation, thioether formation and trisulfide variants.
Thiol-disulfide exchange: This reaction typically occurs at alkaline pH [50], as the
reactive species is the thiolate anion with pKa 8-9. Reactivity of the thiol group can
however be increased by a decrease in pKa, influenced by surrounding amino acid residues.
This means that thiol-disulfide exchange reactions cannot be ruled out even under
physiological conditions or lower pH. Thiol-disulfide exchange involves the nucleophilic
attack (SN2) of a thiolate anion (RSH-) on a disulfide bond (S-S) to form a transition state
(TS), expelling a thiol group (with lower pKa) and forming a new disulfide bond [45]. In
the TS, negative charge is delocalized over the three sulfur atoms, with more negative
charge on the terminal sulfurs than the central sulfur atom [51]. The energy barrier between
the reactants and TS is the activation energy (Ea) of the reaction and the potential energy
difference between reactants and products in ∆E (Figure 1.5). Thiol-disulfide exchange is
reversible at room temperature and at physiological pH. In the presence of oxygen, metal
and reactive oxygen species (ROS) other products of thiol oxidation like sulfenic, sulfinic,
sulfonic acids and thiosulfonate (Figure 1.6) may be generated [52, 53]. Both intra- and
intermolecular disulfide bonds can undergo scrambling reactions (Figure 1.7).
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Figure 1.5: Energy diagram for thiol-disulfide exchange reactions.

Figure 1.6: Oxidative pathways for thiols, adapted with permission from [52].
Copyright 2003 American Chemical Society.
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Direct hydrolysis: The direct attack of a hydroxyl ion on a sulfur atom generates
sulfenic acid (RSOH) and thiolate anion (RS-). RS- is a reactive nucleophile which can
react with another disulfide bond (R′SSR″) to form RSSR″ and release R′S- (Figure 1.8B).
β-elimination: involves proton abstraction from the α-carbon on Cys to form
dehydroalanine and thiocysteine. Removal of a sulfur atom from the thiocysteine generates
a thiolate anion and hydrosulfide ion. Thiolate anion can then participate in the formation
of non-native disulfide bonds via thiol-disulfide exchange or oxidative pathways. The
hydrosulfide ion can initiate disulfide scrambling via thiol-catalyzed exchange.
Dehydroalanine can react further with lysine to form lysinoalanine cross-links.
α-elimination: involves proton abstraction from the β-carbon of the Cys residue to
form thiolate and thioaldehyde. Thioaldehyde can react further to form an aldehyde or
imine group. Thiolate anion can also react further with disulfides, reactive oxygen species
to form the products shown in Figure 1.6.

Figure 1.7: Different thiol-disulfide exchange reactions: A) intramolecular, B)
intermolecular and C) intermolecular disulfide bond disrupted by thiol-disulfide exchange.
Adapted with permission from reference [54].
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At low pH: Protons can cleave disulfide bonds to give sulfenium ions (RS+) under
strong acidic conditions (Figure 1.8D). Sulfenium ions can then react with a sulfur atom in
another disulfide bond via an electrophilic displacement to form a scrambled disulfide,
expelling another sulfenium ion (R′S+ + RSSR ↔ R′SSR + RS+).
Photodegradation: Photoionization of tyrosine/tryptophan generates a solvated
electron which can then reduce a disulfide bond to thiyl radical (RS●) and thiolate anion
(RS-) 1. Thiyl radicals are reactive and can form disulfide bonds (RSSR) with other thiyl
radicals or a reductive disulfide radical anion (RSSR●-) with a thiolate.
Thioether formation: Tous et al. identified thioether (-C-S-C) linkages (also called
lanthionine) that are formed by the removal of a sulfur atom from a disulfide bond (-C-SS-C-) in monoclonal antibodies (mAbs) during production and storage [55]. Thioetherlinked antibodies have been detected even in endogenous antibodies [56]. The effect of
thioether formation on the safety and efficacy of mAbs has not been reported; nevertheless
it may affect protein conformation and biological activity and should be characterized in
recombinant therapeutic proteins.
Trisulfide variants: Formation of trisulfides in proteins is not a common posttranslational modification. Proteins that are known to form trisulfide variants include
superoxide dismutase [57], mutein of interleukin [58], monoclonal antibodies [59] and hGH.
A trisulfide variant (-C-S-S-S-C-) of hGH was identified only in recombinant protein
expressed in E.coli and not in hGH preparations from human pituitaries [60]. Although the
trisulfide variant did not affect the biological activity of hGH and converted completely
into disulfides in IgG1 upon intraperitoneal injection in rats, the identification and
characterization of such variants is still critical in determining protein drug quality.
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Figure 1.8: Different pathways that lead to disulfide bond disruption. A) Thiol-disulfide
exchange (nuc: nucleophile, c: central sulfur and lvg: leaving group). B) Direct attack of
hydroxyl ion on disulfide bond generates sulfenic acid and thiolate anion. C) Acid-base
assisted hydrolysis of disulfide bond. D) Disulfide bond disruption under acidic conditions.
1.6

Factors that influence disulfide bond reactivity

Both intrinsic (physicochemical properties of the protein) and extrinsic factors
(environmental factors like pH, temperature, mechanical force and in the presence of low
molecular weight thiols in serum) can affect disulfide bond stability.

1.6.1

Intrinsic factors
These are factors that are innate to the protein itself. Primary sequence and higher

order structure have been shown to affect thiol-disulfide exchange [61, 62]. Introduction of
a positively charged amino acid neighboring a Cys residue in a model redox-sensitive
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yellow fluorescent protein promoted electrostatic interactions with glutathione disulfide
(GSSG) and decreased thiol pKa such that the rate of thiol-disulfide exchange increased
13-fold [62]. In another study with cyanogen bromide fragments of hen egg white lysozyme,
for a Cys with two positively charged neighbors, the rate of thiol-disulfide exchange
increased 6.5-fold in a 20 mM ionic strength medium relative to a lower ionic strength
medium [63]. In a high ionic strength medium (≥ 20 mM), the rate of thiol-disulfide
exchange was reported to decrease by 700-fold. Ionic influences from distant residues are
minimized at a high ionic strength (≥ 20 mM), thus reducing the rate of thiol disulfide
exchange.
In a thioredoxin from E.coli, disulfide reactivity is 102-103 times greater than that
of normal disulfides due to the presence of a lysyl residue nearby with a positively charged
group [47]. Similarly, in seminal ribonuclease, the presence of positively charged groups
nearby (from Lys) was found to influence reactivity of the Cys31-Cys32 disulfide in
addition to contributions from adjacency of the thiols and protein tertiary structure [64]. In
peptides with the sequence Cys-X-Cys (where X is any amino acid), Zhang et al. have
shown that disulfide bonds can be reduced rather easily. In contrast, in peptides with 4-5
residues between terminal Cys residues, the disulfide bonds were more resistant to
reduction and formed stable loops [65]. The equilibrium constant for ring closure in
dipeptide (-Cys-Cys-) and tripeptide (-Cys-Val-Cys-) models was not affected by the
addition of an Ala residue C-terminal to Cys [65].
Disulfide reactivity can also be influenced by geometric strain that the protein
native state imposes on a disulfide bond. For example, α-lactalbumin has four native
disulfides of which Cys6-Cysl20 was reported to be 140 times more reactive in the fully
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unfolded state; observed super reactivity of this disulfide bond was attributed to the
geometric strain imposed on it in the native folded state [66]. Zavialov et al. elucidated the
relationship between protein structure and the formation of a disulfide bond between small
heat shock protein 25 (Hsp25) and GSH [67]. Hsp25 has a free Cys residue at position 41,
in a redox environment; Hsp25 in its reduced form (PSH) is in equilibrium with a mixed
disulfide (PSSG) and its oxidized dimer (PSSP). Tertiary and/or quaternary structural
changes induced by protein denaturation prevent Hsp25 from forming the dimer (PSSP)
due to changes in proximity of the 2 subunits. This study shows the importance of the
proximity of a disulfide bond to a Cys residue to undergo thiol-disulfide exchange. The
authors also demonstrated the effect of steric and electrostatic hindrances on thiol-disulfide
exchange. Figure 1.9 below shows the formation of a mixed disulfide between heat shock
protein and GSH; steric and electrostatic hindrances appear after the formation of this
mixed disulfide, entry of another GSH molecule is inhibited thus resulting in an
intersubunit disulfide [67].

1.6.2

Extrinsic factors
Extrinsic factors like pH (neutral to alkaline) will influence the rate of disulfide

interchange by affecting the formation of the reactive species. Thiol-disulfide exchange in
general is accelerated under neutral to alkaline pH [45], however it can also occur in strong
acidic media facilitated by a sulfenium ion (Figure 1.8D). Benesch and Benesch have
reported that disulfide exchange is rapid in concentrated HCl and the rate drops below a
concentration of 9 N. At lower acid concentrations, the amount of RS+ generated also
decreases thus affecting the overall rate of interchange [68]. Similar observations favoring
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sulfenium ion mediated exchange in strong acidic media (7-12 N HCl) were reported by
Ryle and Sanger [69]. In moderately acidic solutions disulfide interchange is not observed.
The effects of temperature on thiol-disulfide exchange reactions have been studied
in small organic molecules and proteins [70, 71]. Thiol-disulfide exchange follows
Arrhenius behavior with activation energies in the range of 30-70kJ/mol [70]. The effects
of urea and temperature on the formation of the disulfide-linked dimer of Hsp25 are shown
in Figure 1.10; the fraction of subunits forming the dimer decreases with increasing urea
concentration and temperature [67]. In addition to pH and temperature, recent studies have
shown the effects of an external mechanical force on thiol-disulfide exchange. Using
cardiac titin domain as a model protein, Wiita et al. have shown that an applied mechanical
force > 100 pN promotes thiol-disulfide exchange [70].

Figure 1.9: Scheme showing assumed effects of the appearance of steric and electrostatic
hindrances after the formation of a mixed disulfide on thiol-disulfide exchange in Hsp25.
The two subunits that form the subunit are shown in black. Adapted with permission from
reference [67].
Disulfide exchange can also occur in the presence of low molecular weight thiols
both in vitro and in vivo. Thiols in serum like GSH, cysteine and cystine are known to

22
mediate thiol-disulfide exchange [72]. The formation of correct disulfides inside cells is
regulated by a redox environment, typically consisting of GSH and GSSG, and where the
ratio of GSH/GSSG varies from 30: 1 to 100:1 [39]. Once the protein is secreted from the
cell, it is no longer exposed to a reducing environment. Instead, exposure to small amounts
of thiols can initiate disulfide interchange that results in altered conformations and thus
reduced protein activity [39, 49]. Disulfide-linked dimers have been reported in IgG2 both
in cell culture and in human serum [73]. Disulfide isoforms have also been observed in
IgG4, a phenomenon known as Fab-arm exchange. Fab-arm exchange occurs in the
presence of GSH concentrations as low as 0.5 mM in vitro and results in the formation of
bispecific antibodies that can bind only monovalently even to repeating antigens [74]. Thus,
disulfide exchange may be favored in the reducing environment in cell culture during
recombinant protein expression and in blood after administration of protein therapeutics.

Figure 1.10: Dependence of fraction of subunits forming the inter-subunit disulfide bond
(PSSP) on urea concentration (left) and on temperature (right). Adapted with permission
from reference [67].
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1.7

Impact on protein physical stability and biological activity

The effect of disulfide bonds on protein stability can be advantageous or
disadvantageous; some of these effects are discussed in this section. In general, the native
state of a protein (N) and its unfolded state (U) are in equilibrium such that N↔U. The
introduction of a disulfide bond in a protein increases the free energy of U, with the
assumption is that there is no difference in the enthalpies of the disulfide-linked protein
and the reduced form of the protein. The contribution of an intramolecular disulfide bond
to the decrease in entropy of U can be calculated using the equation: ΔS = -2.1-(3/2)R ln n,
where R is the gas constant and n is the number of residues between the two Cys residues
that form the intramolecular disulfide bond. An engineered intramolecular disulfide bond
(Cys61-S-S-Cys98) in subtilisin E improved protein stability with a 4.5 oC increase in the
melting temperature and a longer half time while there was no significant effect on
enzymatic activity [75].
There have been numerous reports of how disulfide scrambling can lead to
aggregation [76-79]. Aggregates can affect therapeutic efficacy, biological activity and
safety of protein drugs. Atypical disulfide bond formation can lead to misfolded forms of
proteins that are dysfunctional [55]. Proteins like bovine pancreatic trypsin inhibitor [80],
bovine pancreatic ribonuclease A [81] and human proinsulin [82] fold into their native
conformations only after most of their native disulfide bonds have been formed. This has
provided a useful approach to studying the folding pathways of these proteins in detail by
trapping the different disulfide intermediates. In natriuretic peptide receptor-A, an
intermolecular disulfide bond functions as an allosteric bond where the formation of a
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disulfide-linked dimer (undesirable in protein therapeutics) is essential for its activation
[83]. Dillon et al. measured in vitro binding ability and biological activity of different IgG2
disulfide isoforms. The authors reported significant differences in biological activity of the
isoforms and attributed these differences to changes in conformational angles and
flexibility of the Fab region of IgG2 [38]. In another study, Qiao et al. reported that human
insulin requires the correct formation of both intra- and interchain disulfide bonds to
function properly [82]. Thus non-native disulfide bonding patterns can introduce
conformational changes in proteins that may be detrimental to their therapeutic activity.
Disulfide bonds can also have a positive impact on biological activity. For example,
recombinant immunotoxins (RITs) are anti-cancer agents that contain the Fv region of an
antibody and a protein toxin from bacteria or plants. Liu et al. observed that engineering a
disulfide bond into an RIT significantly lowered immunogenicity in mice while retaining
cytotoxicity and anti-tumor activity [84]. HA22-LR-DB, formed by anti-CD22 Fv fused
to domain III of pseudomonas exotoxin A, with a disulfide bond in domain III improved
thermal stability and altered the kinetics of antibody formation in mice. In another study,
the aggregation propensity in IgG1 antibodies was found to be significantly lower when
compared to IgG2 antibodies, though they share 95% sequence identity [85]. This was
attributed to the presence of an interchain disulfide bond in IgG1. Thus it is important to
understand the roles of disulfide bonds in therapeutic proteins before suitable formulation
strategies can be employed.
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1.8

Formulation strategies for Cys-containing proteins

As described in the section above, disulfide bonds can be advantageous or
disadvantageous to protein function/activity. Different strategies have been employed to
minimize disulfide exchange and disulfide-mediated aggregation in proteins that contain
free thiols and/or disulfide bonds [3]. Some of these approaches are discussed below.

1.8.1

Formulating proteins with a reducing agent
There have been reports of covalent dimer formation in E-Cadherin via a disulfide

bond which ultimately leads to protein degradation [86]. Dithiothreitol (DTT), a reducing
agent, and thiol group derivatizing agents like iodoacetamide and polyethylene-glycol
malemide were used in formulations to improve protein stability [86]. Addition of DTT
prevented dimer formation and further inhibited protein precipitation. This strategy may
not be suitable for all proteins, especially if the protein also contains a functional disulfide
bond. Addition of a reducing agent could reduce the native disulfide bond and change
protein conformation, exposing reactive centers to a myriad of degradation pathways.

1.8.2

Chemical modification of thiol groups
Another strategy to formulate proteins that contain unpaired cysteine residues is to

derivatize the thiol group in order to prevent thiol mediated aggregation. The thiol group
on Cys residues is a reactive species that can participate in oxidation reactions in addition
to thiol-disulfide exchange. Some of the derivatizing agents that have been used are
iodoacetate,

iodoacetamide,

1,3-propane

sultone,

methyl

methanethiosulfonate,
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methoxycarbonylmethyl disulfide, maleimide, tetrathionates, and dinitrophenyl alkyl
disulfides. Ruegg et al. have used 1,3 propane sultone to derivatize thiol groups on [Lys8]
vasopressin, human serum albumin, bovine insulin and bovine pancreatic ribonuclease,
increasing their stability to acid hydrolysis [87]. Some commonly used Cys-derivatizing
agents are shown in Figure 1.11. Cys residues can also be PEGylated with PEG-maleimide,
PEG-iodoacetamide and PEG-epoxide [3]. Proteins generally have fewer Cys than Lys
residues thus making Cys-PEGylation more selective. PEGylated proteins have improved
physicochemical stability, pharmacokinetic and pharmacodynamic properties.
PEG can also react with disulfide bonds; PEG-monosulfone forms a three carbon
bridge with the native disulfide bond-sulfurs. For example, the native disulfide bond in
interferon α-2b was conjugated with PEG and retained its biological activity and tertiary
structure [88]. Although thiol derivatization is an attractive option, it is not a feasible one
for proteins where free Cys and/or the native disulfide bond are important in biological
activity and protein stability.
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Figure 1.11: Thiol derivatizing agents that are commonly used to derivatize thiols in
proteins to prevent reaction with other groups [3].
1.8.3

Protein engineering
Disulfide bond heterogeneity in therapeutic proteins can be reduced by mutating

Cys residues with other non-reactive amino acids like Ser. Antibodies have a large number
of disulfide bonds and they are classified by the number and type (inter/intra) of bonds.
Allen et al. have shown that Cys→Ser mutations in IgG2 reduce disulfide bond
heterogeneity while maintaining in vitro activity [89]. Browning et al. observed disulfide
scrambling in interleukin-2 (IL-2) with one disulfide bond and a free Cys residue, under
denaturing and alkaline conditions (Figure 1.12). The scrambled forms were less active
than the native form [90]. A Cys125Ser mutant of IL-2 was found to be more stable to
disulfide scrambling at alkaline pH.
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Figure 1.12: Thiol-disulfide exchange in interleukin-2. Adapted with permission from
reference [90].
Junnila et al. determined the role of the C-terminal solvent exposed disulfide bond
(Cys182-Cys189) in hGH by mutating the Cys residues with Ala. The hGH analogs were
found to have reduced receptor binding affinity and stability compared to the wild type
[91]. Although biological activity did not change drastically with this mutation, decreased
stability of the mutants could lead to other degradation pathways, including aggregation.
In other proteins, disulfide bonds have been introduced to improve overall stability [92].
Introducing an intermolecular disulfide bond is usually associated with increased protein
stability. However, the effect of an intramolecular disulfide bond or the presence of an
unpaired Cys can be unpredictable [93]. For example, Hsu et al. observed that deletion of
a free Cys residue in recombinant keratinocyte growth factor affected protein stability [94].
This Cys (residue 40) was found to play an important role in maintaining protein stability
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and structural integrity. Protein engineering may not always be a practical option,
especially if the role of the Cys/disulfide bond is unknown. In addition to the strategies
mentioned above (that cannot be applied to all therapeutic proteins), targeting specific
mechanisms that contribute to and processing conditions that facilitate disulfide-mediated
aggregation is instrumental in designing rational approaches to stabilize protein
formulations.

1.9

Lyophilization of peptide and protein drugs

Therapeutic proteins are often lyophilized to improve storage stability. However,
aggregation is known to occur even in the solid state [14, 79, 95, 96]. Proteins can undergo
conformational changes during lyophilization, particularly during dehydration. Different
effects of dehydration on protein conformation have been reported. Desai et al. observed
freeze-drying induced partial denaturation in bovine pancreatic trypsin inhibitor [97]. In
another study by Rupley et al., no difference in protein conformation was observed for
lyophilized lysozyme when compared to the protein in aqueous solution [98]. Costantino
et al. observed that the process of lyophilization itself induced structural changes in
recombinant human albumin (rHA) [95]. During lyophilization of rHA, there was an
increase in both β-sheet content and unordered structural elements resulting in partial
protein unfolding. Such conformational changes can expose hydrophobic regions and
reactive groups, facilitating aggregation via hydrophobic interactions and other covalent
and non-covalent pathways.
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Cryoprotectants and lyoprotectants such as sugars, polyols, polymers and
surfactants are typically used to protect peptides and proteins from process induced
degradation [99]. Solid properties of the excipients themselves must be investigated before
they can be used with a protein or peptide. Mannitol, for example can crystallize into three
different polymorphic forms (α, β and δ) as well as a hemi-hydrate. The type of polymorph
that is generated will depend on lyophilization conditions and the presence of other
excipients. The mannitol hemi-hydrate may release its crystal water during storage. Unlike
mannitol, sucrose is amorphous after lyophilization. For some therapeutic proteins a
combination of both amorphous and crystalline excipients may be advantageous. Prior
knowledge of protein aggregation mechanisms may be beneficial to the process of
excipients screening and selection to add further stability during freeze- and spray drying.
This highlights the importance of understanding the effect of processing conditions and the
use of excipients/stabilizers on chemical modifications in addition to determining storage
stability under accelerated conditions.

1.9.1

Thiol-disulfide exchange in the solid-state
Lyophilized protein powders in the ‘dry state’ or ‘anhydrous state’ are thought to

exhibit behavior and ionization states similar to pH conditions in aqueous solution before
lyophilization, thus demonstrating a “pH memory” [100]. Alkaline hydrolysis of disulfide
bonds and thiol-disulfide exchange are favored at neutral to alkaline pH, with the thiolate
anion being the reactive species. Thus, formulating proteins with free thiols and/or
disulfides in neutral to alkaline buffers prior to lyophilization would be expected to
facilitate disulfide-mediated aggregation during lyophilization and storage in the solid state.
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In addition, the three dimensional structure of proteins can influence disulfide-mediated
degradation. Any structural rearrangement of proteins (perturbation during lyophilization)
can have a profound effect on the pKa of reactive residues. Structural changes induced by
process stresses can be probed using Fourier transform infrared spectroscopy (FTIR) [101].
FTIR spectra of human growth hormone lyophilized with and without excipients are shown
in Figure 1.13. In addition, the presence of moisture and high storage temperatures can
further influence reaction rates.
Thiol-disulfide exchange has been reported in lyophilized proteins like bovine
serum albumin (BSA) when exposed to moisture at 37 oC [96]. Similarly, Constantino et
al. investigated the mechanism of aggregation in recombinant human albumin (rHA)
during storage in the solid state at 37 oC and 96% RH [95]. They attributed the formation
of insoluble aggregates to disulfide exchange in the absence of any stabilizing excipients.
Both BSA and rHA contain a free thiol in addition to disulfide bonds.
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Figure 1.13: FTIR spectra of human growth hormone. 1- hGH in solution, 2- hGH
lyophilized with sucrose, 3- hGH lyophilized with trehalose and 4- hGH lyophilized alone.
Adapted with permission from reference [101].
Disulfide mediated aggregation can also occur in proteins with no free thiols but
with disulfide bonds. One such example is insulin, in which β-elimination followed by
thiol-catalyzed disulfide exchange results in the formation of insoluble aggregates during
storage at 50 oC and 96% RH. These studies show how structural perturbations during
lyophilization can have a profound effect on the storage stability of therapeutic proteins
and disulfide bond reactivity, especially when exposed to high relative humidity and
temperature.

1.10 Disulfide bond mapping

Recombinant proteins that are expressed in different systems like E.coli and CHO
cells can have incorrectly folded, scrambled forms. Thus, it is important to identify the
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presence and extent of scrambling in protein therapeutics to assess the quality of the final
drug product, particularly for biosimilars. Conventional methods for disulfide bond
determination such as NMR and Edman sequencing typically require large amounts of
protein samples. Mass spectrometry coupled with ionization methods for ionizing large
molecules has emerged as a novel analytical tool for characterizing protein structure and
disulfide bond analysis/mapping.
The first step in disulfide bond mapping is to determine the number of disulfide
bonds, by comparing MS spectra before and after protein reduction and the mass shift
between the two samples. In recombinant human granulocyte-macrophage colonystimulating factor (GM-CSF), ESI MS analysis before and after protein reduction revealed
a 4Da shift in reduced protein spectra [102], suggesting that GM-CSF has two native
disulfide bonds. Using an alkylating agent in addition to a reducing agent will confirm the
presence of any free Cys residues when compared to the MS spectra of the native and nonreduced protein. The next step in disulfide bond mapping is to identify the location of these
disulfide bonds and free Cys. This can be achieved with proteolytic and alkylating agents,
comparing HPLC-UV chromatograms followed by tandem MS [103]. A combination of
two or more proteolytic agents may be required for proteins where disulfide bonds are
found to hinder proteolysis to form simple disulfide-linked peptides. Different ionization
methods such as FAB/liquid secondary ion, plasma desorption (PD) and MALDI have been
used to map disulfide bonds recombinant human interferon α-2b, human growth hormone
and IL-4 [103].
Disulfide scrambling can occur even during analysis of disulfide bonding patterns
in proteins and peptides. Suitable quench conditions (low pH) and thiol derivatizing agents
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(described under formulation strategies for cysteine-containing proteins) can be employed
to minimize these effects. Tang and Speicher describe four steps for disulfide bond
mapping in proteins: i) cleaving proteins using proteases or other chemical reagents (shown
in Table 1.1) under acidic and non-reducing conditions, ii) chromatographic separation of
cleaved fragments, iii) use of disulfide reducing agents to confirm disulfide containing
complexes and iv) characterizing disulfide-linked peptides using mass spectrometry (MS)
and N-terminal Edman sequencing [104]. For large proteins (> 50 kDa) or proteins with
multiple disulfide bonds and large domains that are typically resistant to denaturation and
proteolysis, cyanogen bromide (CNBr) cleavage can be used. In this method, fragmentation
occurs C-terminal to Met residues and large fragments are usually generated. Further, the
low pH employed for CNBr cleavage prevents disulfide bond scrambling.
More recently, MS-based approaches (tandem-MS) for disulfide bond
identification in proteins are becoming popular. Collision-induced dissociation (CID) in
MS results in amide bond cleavage to yield b- and y- ions and is the most common tandem
MS approach that is used to obtain protein structural information [105]. Disulfide bonds
can either be broken or remain intact during CID. In addition to b/y ions, disulfide bonds
can fragment (S-S or S-C bonds) to form free Cys residues, thioaldehydes, dehydroalanines
and persulfides. Using CID as the fragmentation mode eliminates the need for sample
reduction prior to MS analysis and high- end MS instruments. However, the formation of
different cysteinyl peptide combinations can complicate analysis of the spectra and
disulfide bond assignment, particularly for proteins for which the native disulfide linkage
is unknown.
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Haitao et al. have described a method for direct disulfide bond cleavage in the gas
phase using electron transfer dissociation (ETD) [106]. Disulfide bond cleavage is
preferred to peptide bond cleavage in ETD due to the fact that sulfur atoms capture
electrons easily during the electron transfer process. This approach eliminates the need for
two separate experiments, i.e., enzymatic digestion with and without reducing agents to
determine the exact location of disulfide bonds. ETD and ECD are more suitable for
disulfide bond identification, particularly for proteins in which the disulfide-bonding
pattern is unknown. 16 disulfide bonds in an anti-HER2 mAb (Herceptin®) were mapped
using ETD fragmentation followed by CID-MS3 on the dissociated peptides to further
verify the disulfide arrangement. However, the authors report that a disadvantage of using
ETD for disulfide bond identification is that for precursor ions with m/z > 900, in this case,
the charge-reduced species is the dominant form and not the disulfide-dissociated peptide.
Nevertheless, this analytical technique has been used to effectively map disulfide bonds in
recombinant proteins such as human growth hormone and tissue plasminogen activator
[106].
Zhang et al. used an electrolytic reduction approach coupled with desorption
electrospray ionization mass spectrometry (EC/DESI-MS) to analyze disulfide linkages in
insulin and somatostatin [107]. The EC/DESI-MS method could effectively map disulfide
bonding patterns and determine the role of disulfide bonds in maintaining protein
conformation based on charge state distributions. Use of a selenamide derivatizing agent
with EC/DESI-MS facilitated the analysis of intra- and interpeptide disulfide bonds.
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Table 1.1: Chemical cleavage reagents and proteases commonly used for disulfide
mapping in proteins [104].
Protease

Cleavage site

Chymotrypsin

Trp, Tyr, Phe

Endoproteinase Glu-C

Glu, Asp

Endoproteinase Lys-C

Lys

Pepsin

non-specific

Subtilisin

non-specific

Thermolysin

non-specific

Trypsin

Lys, Arg

Trypsin (immobilized)

Lys, Arg

Buffer conditions
50 mM sodium
phosphate, pH 5.5
100 mM sodium acetate,
pH 4.0
25 mM Tric-HCl, pH 6.8
0.02N HCl, pH 2.0
50 mM sodium
phosphate, pH 6.5
0.1 M triethylamine-HCl,
pH 6.0
50 mM sodium
phosphate, pH 6.0
50 mM sodium
phosphate, pH 6.5

Temperature
o

37 C
o

24 C

Reference
Schnaible et al (2002a)
[108]
Lippincott and apostol
(2002) [109]

o

Lead et al (1999) [110]

o

Bures et al (1998) [111]

o

Chong et al (2002) [112]

o

Bures et al (1998) [111]

37 C
37 C
37 C
37 C
o

37 C
o

23 C

Schnaible et al (2002a)
[108]
Chong and Speicher
(2001) [113]

1.11 Research objectives and specific aims

The main objective of this research is to elucidate the mechanisms of thiol-disulfide
exchange and identify factors that determine reaction rate in solution, during lyophilization
and storage in the solid-state using model peptides derived from human growth hormone
(hGH) and the intact protein. The studies test the central hypothesis that the rate of thioldisulfide exchange differs in solution and amorphous solids and is affected by higher order
structure. To test the hypothesis, the following specific aims were proposed:
Specific Aim 1: To elucidate the mechanism of thiol-disulfide exchange in aqueous
solution and to determine the effect of pH, temperature, oxidation suppressants and peptide
secondary structure on reaction kinetics. Thiol-disulfide exchange can result in protein
aggregation via the formation of scrambled inter- and intramolecular disulfide bonds.
Previous studies of thiol-disulfide exchange have been based on reactions between
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proteins/peptides and low molecular weight thiols such as glutathione and DTT. However,
these species are not representative of free thiol groups in larger proteins, and very little is
known about the reaction mechanisms in these materials. Our hypothesis was that the
reaction in solution will proceed primarily through the thiolate anion when oxidative
pathways are inhibited and will be affected by secondary structure. To test this hypothesis,
the effects of pH, temperature, oxidation suppressants and peptide secondary structure were
explored in detail using model tryptic peptides derived from human growth hormone
(hGH). The results provide mechanistic detail for thiol-disulfide exchange in aqueous
solution, and are reported in Chapter 2.
Specific Aim 2: To elucidate the mechanism of thiol-disulfide exchange during
lyophilization and storage in the solid state. To improve storage stability and shelf-life,
many protein drugs are marketed as lyophilized powders. However, protein aggregation is
known to occur even in the solid-state. Tryptic peptides derived from hGH and containing
disulfide bonds were co-lyophilized with peptides containing free thiols to determine the
effect of processing conditions on the thiol-disulfide exchange reaction and comparisons
were drawn to aqueous solution studies. The results provide insights into the effects of
lyophilization on thiol-disulfide exchange and peptide secondary structure contribution to
reaction kinetics.
Specific Aim 3: To determine the effects of higher order structure on the kinetics
of thiol-disulfide exchange using intact hGH. To test the applicability of studies with model
peptides to a therapeutic protein, the studies of Aims 1 and 2 were extended to intact hGH.
The studies in Aim 3 test the null hypothesis that the rates and mechanisms of thioldisulfide exchange are unaffected by higher order structure and are identical in hGH and
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in the model peptides. hGH has two disulfide bonds and no free cysteine residues. The
results are expected to provide a qualitative measure of the effects of structure on the thioldisulfide exchange reaction and an indication of the degradation propensity of disulfide
bonds in hGH in comparison to model peptides.

1.12 Research Significance

The rate of failure of candidate drug molecules to successfully obtain regulatory
approval to treat patients is significant, with only one in ten biopharmaceuticals reaching
the market between 2003 and 2010 [114]. Selecting a promising molecule rather than one
with inadequate developability characteristics can reduce the total cost of drug
development and deliver greater value to a larger number of patients. Reducing the attrition
rate of candidate drug molecules is dependent upon the selection of quality leads.
Candidate drug molecules are evaluated for stability and shelf-life by assessing their
potential to degrade by various physical and chemical pathways, including aggregation.
Different aggregation pathways are often grouped together because of the lack of
information on the mechanism of individual pathways. This can result in overlooking a
relevant aggregation pathway, such as disulfide exchange, during candidate evaluation.
The aggregation of therapeutic proteins has been a major concern for the
biopharmaceutical industry and regulatory agencies alike, since aggregates have been
associated with adverse immune responses in patients. To make matters worse, aggregates
are often difficult to detect and control. Strategies to determine aggregation propensity and
to inhibit protein aggregation include molecular dynamics simulations [115], protein
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engineering and process optimization [116] and formulation design [117, 118]. In addition,
new analytical techniques are being developed to detect protein aggregates formed during
manufacturing and storage. While these strategies are effective for some proteins, the
inherent structural complexity of these large molecule drugs makes it challenging to devise
a general approach that can be adapted to all classes of therapeutic proteins.
The development of protein therapeutics currently involves a trial and error
paradigm, which is often the rate-limiting step in getting a drug approved and to the market.
In order to effectively control aggregation in therapeutic proteins, the mechanisms of
relevant degradation pathways must be understood in detail. Detailed mechanistic studies
of protein aggregation pathways like thiol-disulfide exchange, in combination with
computational methods will facilitate successful development of protein pharmaceuticals
and minimize associated costs.
Thiol-disulfide exchange and disulfide scrambling are widely recognized as
common routes to covalent aggregation in protein drugs. While there are reports of thioldisulfide exchange reactions between low molecular weight thiols like GSH [67, 119] and
CySH [120] and proteins, they are not entirely applicable to disulfide-mediated aggregation
in proteins since steric effects may influence reaction rates and these low molecular weight
thiols may not always be present in protein formulations. Thus, understanding the
mechanisms of thiol-disulfide exchange in aqueous solution and in the solid-state will
improve our ability to control aggregation in therapeutic proteins. Understanding the
mechanism of chemical reactivity of a protein is strategic in that it will steer protein
formulation development away from a trial and error paradigm. The results obtained will
facilitate the design of rational approaches to control disulfide-mediated aggregation in
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solution and lyophilized formulations and decrease the likelihood of immunogenic effects
after administration.
Finally, biosimilars are proteins that are intended to be similar to the innovator drug
with respect to quality, safety and efficacy. Variations in biosimilars production include
manufacturing, cell culture and purification processes and the type of formulation used.
These differences can have significant effects on the quality of a protein drug. There are
many analytical tools that are currently being used to characterize follow-on protein
products [121, 122]. A combination of these analytical methods and the knowledge of
disulfide rearrangement mechanisms and kinetics are expected to provide improved
screening.
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CHAPTER 2. ELUCIDATING THE MECHANISM AND KINETICS OF
THIOL-DISULFIDE EXCHANGE IN PEPTIDES DERIVED FROM
HUMAN GROWTH HORMONE IN AQUEOUS SOLUTION

This work was published in the Journal of Pharmaceutical Sciences DOI
10.1002/jps.23906, content reproduced with permission from Wiley.

2.1

Abstract

Disulfide bonds stabilize proteins by crosslinking distant regions into a compact
three-dimensional structure. However, disulfide bonds can participate in degradation
pathways that can contribute to protein aggregation. In this chapter, experimental data for
the mechanism of thiol-disulfide exchange in tryptic peptides derived from human growth
hormone in aqueous solution is presented. Reaction kinetics were monitored to investigate
the effect of pH (6.0-10.0), buffer concentration (10, 20 and 40 mM), temperature (4-50
o

C), oxidation suppressants (EDTA and N2 sparging) and peptide secondary structure

(linear vs. cyclic). The concentrations of free thiol containing peptides, scrambled
disulfides and native disulfide-linked peptides generated via thiol-disulfide exchange and
oxidation reactions were determined using RP-HPLC and LC-MS Concentration vs. time
data were fitted to a mathematical model using non-linear least squares regression analysis.
Excluding oxidation suppressants (EDTA and N2 sparging) did not influence the intrinsic
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rate of thiol-disulfide exchange. In addition, peptide secondary structure was found to
influence the rate of thiol-disulfide exchange.

2.2

Keywords

Protein, peptide, human growth hormone, oxidation, kinetics, aggregation and
thiol-disulfide exchange.

2.3

Introduction

In therapeutic proteins, correct disulfide linkages are critical to the biological
activity and stability of this growing class of drugs [54]. For example, non-native disulfide
bonding patterns in IgG antibodies have been associated with changes in receptor binding
affinity, stability, and circulating half-life [123]. A disulfide-linked homodimer of human
growth hormone (hGH) showed reduced receptor binding affinity and attenuated cell
proliferative activity [124]. Human albumin or albumin fusion proteins, which contain 17
disulfides and may contain a free-thiol, also may be prone to deleterious disulfide-mediated
events [125]. The fundamental mechanism of thiol-disulfide exchange has been defined in
previous reports using low molecular weight thiols and proteins [45, 61, 119, 120];
however, controlling these reactions in therapeutic proteins still remains challenging. It is
often difficult to predict the most labile disulfide bonds based on structure alone [126],
suggesting that the structural determinants of thiol-disulfide exchange may be weaker than
for other reactions such as deamidation [127, 128]. An intact IgG antibody can have more
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than 20 disulfide bonds, with the potential to form more than 200 species with a single
scrambled intra- or intermolecular disulfide. While “reducible” aggregates are common in
protein drug formulations, the disulfide bonds involved are not often identified. There have
been reports from our group [129] and others [70] that thiol-disulfide exchange is sensitive
to process-induced stresses such as freezing and fluid shear, but the mechanisms of these
effects and their interplay with protein structure and fluid composition have not been fully
elucidated.
Different factors were critical in designing experiments relevant to achieving the
overall goals of this project. First, human growth hormone (hGH) is a 4-helix bundle
protein that belongs to the cytokine family with 191 amino acids and two disulfide bonds
(no free cysteine residues). The C-terminal disulfide bond is known to have a functional
role [91]; hence the common formulation strategies for Cys-containing proteins (discussed
in Chapter 1) are not applicable for hGH. Further, hGH is known to aggregate in solution
[130,131] and the solid state [132-134], facilitated by the formation of scrambled disulfides
[91, 135] and/or protein unfolding [130, 136]. Thus, hGH is a tractable model system for
detailed mechanistic studies. Trypsin digestion map for hGH is shown in Figure 2.1 with
the disulfide linked peptides; i) T6 and T16 and ii) T20 and T21. Tryptic peptides derived
from the solvent exposed disulfide bond (T20, T20-T21 and cT20-T21, Table 2.1) in hGH
were used as model compounds to elucidate the mechanism of thiol-disulfide exchange
(Scheme 2.1). The T20 peptide contains Cys182, which has been identified as the most
reactive thiol in hGH [137].
Second, physical and chemical instabilities are interrelated, for example a chemical
modification can lead to an unfolding event and vice versa, both modifications contribute
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to the overall drug decomposition rate. In a review by Waterman and Adami, the authors
state that drug shelf-life is determined by the rate of formation of individual products and
rarely by the overall drug decomposition rate [138]. The use of peptide model compounds
allows determination of mechanisms and rate constants for a specific chemical
modification in the absence of higher order structure and other degradation pathways, thus
facilitating better molecular and formulation design approaches.
Finally, elucidating the reaction mechanism in solution will provide a basis for
better understanding reactions in solid state systems and determining the influence of other
external factors like processing and storage conditions. T20 was used in its reduced form
to react with linear (T20-T21) and cyclic (cT20-T21) peptide models of the native disulfide
bond. The results show that for these hGH tryptic peptides, the mechanism of thioldisulfide exchange is pH independent and the reactions follow Arrhenius behavior.
However, the observed rate constant (kobs) depends on the concentration of thiolate anion
and hence the solution pH. Intrinsic rates of thiol-disulfide exchange are not affected by
oxidation of free thiol-containing peptides even in the absence of oxidation suppressants.
Additionally, cyclization of the peptide is shown to influence the kinetics of thiol-disulfide
exchange, with the cyclic peptide having 10-fold lower reactivity when compared to the
linear peptide.
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Figure 2.1: hGH-trypsin digestion map, tryptic fragments are labeled T1 to T21 starting
from the N-terminus. Disulfide bonds are represented by the two solid lines between T6T16 and T20-T21. Adapted with permission from [139].
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Table 2.1: Abbreviations and amino acid sequences of hGH-derived peptides used in
studies of thiol-disulfide exchange.

Abbreviation

Description

Amino acid sequence

Theoretical mass

Observed mass

T20

Monomeric peptide, free
SH group

NH 2 - IVQCR-OH

617.3319

617.3290

T21

Monomeric peptide, free
SH group

NH 2 - SVEGSCGF-OH

784.3062

784.3067

T20-T20

Homodimer, disulfidelinked

1232.6482

1232.6247

1566.5978

1566.5984

1399.6225

1399.6247

Homodimer, disulfidelinked

T21-T21

T20-T21

Heterodimer, disulfidelinked

NH 2 - IVQCR-OH
NH 2 - IVQCR-OH
NH 2 - SVEGSCGF-OH
NH 2 - SVEGSCGF-OH
NH 2 - IVQCR-OH
NH 2 - SVEGSCGF-OH

cT20-T21

Cyclic peptide, disulfide
linked

NH 2 -IVQCRSVEGSCGF -OH

1381.6118

1381.6201

rT20-T21

Linear peptide, free SH
groups

NH 2 -IVQCRSVEGSCGF -OH

1383.6275

1383.6344

2.4

Materials

Model peptides T20, T21, T20-T21 and cT20-T21 (see Table 2.1 for structures)
were purchased from GenScript (Piscataway, NJ) with > 95% purity and supplied as a
lyophilized powder. HPLC grade acetonitrile (ACN), NaCl and KCl were purchased from
Fisher Scientific Co. (Pittsburgh, PA). H2O2 and Na2CO3 (anhydrous granules) were
obtained

from

Mallinckrodt

Baker

Inc.

(Phillipsburg,

NJ).

K2HPO4

and

ethylenediaminetetraacetic acid (EDTA) were purchased from Sigma Chemical Co. (St.
Louis, MO). Trifluoroacetic acid (TFA) and formic acid were obtained from Thermo
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Scientific (Rockford, IL). Double-distilled water (DDI) used for buffer preparation and as
HPLC mobile phase was deionized and purified using a Milli-Q water system, Millipore
Ltd (Billerica, MA) and filtered with a 0.2 µm filter.

2.5

2.5.1

Methods

Preparation of peptide stock solutions and disulfide linked peptides for kinetic
studies
All peptides were used as provided by the manufacturer. Stock solutions were

prepared in a 0.1% formic acid solution in DDI. T20, T21, T20-T21 and cT20-T21 stock
solutions were stable at 4 oC for up to 2 weeks and T20-T20, T21-T21 solutions (pH <3.0
after quenching with a 0.5% formic acid solution) were stable for 4 days at 4 oC. Far-UV
(190-260 nm) CD analysis with a J-815 CD spectrometer (JASCO, Easton, MD) was used
to assess peptide secondary structure.
2.5.2

Homodimer formation
T20-T20 and T21-T21 homodimers (Table 2.1) were synthesized in-house using

H2O2 as an oxidizing agent according to a method described by Luo et al. [140]. H2O2 in
phosphate buffer (pH 8.0, 2 mM) was added to solutions of T20 or T21 (4 mM) monomers
in a 1:2 molar ratio (total reaction volume < 1 mL) and allowed to react for 1 day. The
reaction was then quenched with a 0.5% formic acid solution (2x reaction volume).
Conversion of monomer to homodimer was > 98% for both monomers, as determined by
both RP-HPLC (Figure 2.2) and LC-MS. These homodimers were then used to construct
calibration plots and synthetic standards were not purchased from GenScript. Attempts to

48
produce the T20-T21 heterodimer using a similar method resulted in very low yields, so
synthetic T20-T21 was purchased from GenScript (Piscataway, NJ).

Figure 2.2: HPLC chromatograms showing T20-T20 formation over time at pH 6.0 in 50
mM phosphate buffer with H2O2 as the oxidizing agent.
2.5.3

Buffer preparation
Phosphate buffers (PB) for pH 6.0-8.0 and carbonate buffers (CB) for pH 9.0-10.0

were prepared at different concentrations (10, 20 and 40 mM) to enable extrapolation of
rate constants to zero buffer concentration. The ionic strength of all buffers was adjusted
to 0.08 M using KCl for PB and NaCl for CB. To minimize oxidation of free thiols, 0.5
mM EDTA and N2 were used. Buffers were sparged with N2 for 30 min and then degassed
and filtered with a 0.2 µm (Millipore, MA) filter before use. For reactions without
suppression of oxidation, PB (pH 7.0, 10 mM) was used without EDTA and N2.
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2.5.4

Quantification of reactants and products by HPLC
RP-HPLC assays were developed to detect and quantify each of the seven species

(T20, T20-T20, T20-T21, T21, T21-T21, cT20-T21, rT20-T21) with baseline resolution
(Figure 2.3). Samples were analyzed using reverse-phase high-performance liquid
chromatography (RP-HPLC, Agilent 1200 series). The system was equipped with a UV
detector operating at 215 nm for all studies. Agilent Chemstation software was used for
data acquisition and analysis. A ZORBAX Eclipse plus C18, 5 µm (4.6 X 250 mm)
analytical column (Agilent Technologies, Santa Clara, CA) was used with gradient elution
(column temperature was maintained at 25 oC). Solvent A was 0.1% TFA (pH~2.5) in
water and Solvent B was 0.1 % TFA in acetonitrile. Elution was performed at 1 mL/min
starting with 14% Solvent B, which was increased to 47% in 5.2 min, then held at 47% for
3 min and finally returned to 14% at 8.3 min. Total run time for each sample was 12 min.
The retention times for T20, T20-T20, T20-T21, T21 and T21-T21 were 4.7 min, 5.2 min,
6.5 min, 7.2 min and 7.9 min respectively (Figure 2.3), as confirmed by mass spectrometry
(ESI-QTOF-MS, Agilent). For studies with the cyclic peptide, a similar gradient elution
was used with a total run time of 13 min. The retention times for T20, T20-T20, cT20-T21
and rT20-T21 were 4.8 min, 5.3 min, 7.3 min and 7.7 min, respectively, as confirmed by
MS. Calibration curves were linear in the following concentration ranges: 20 µM -1 mM
(T20), 10-500 µM (T20-T20), 5-500 µM (T20-T21), 20-180 µM (T21), 10-200 µM (T21T21), 5-500 µM (cT20-T21), and 5-500 µM (rT20-T21). Limits of detection (S/N = 2)
were 15 µM (T20), 2.5 µM (T20-T20), 1 µM (T20-T21), 5 µM (T21), 5 µM (T21-T21)
and 5 µM (cT20-T21 and rT20-T21). No cleavage of disulfide bonds was observed at pH
levels above the Cys thiol pKa, as has been previously reported [141].
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At the end of each experiment, the total mass of the identified products was >98%
for pH 6.0-9.0 and >95% for pH 10.0 of the total initial mass of the reactants. Based on the
limits of detection and linear ranges of the calibration curves, initial reactant concentrations
of 350 µM (T20) and 250 µM (T20-T21) were used. The amount of T20-T20 and T20-T21
formed via oxidative pathways was determined by mass balance. For example, in the
absence of oxidation, the amount of T20-T20 generated will equal the amount of T20-T21
consumed. Any additional T20-T20 formed is assumed to occur via oxidation.
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Figure 2.3: HPLC chromatograms (215nm) at various times during the reaction of T20
with T20-T21 at pH 7.0, 10 mM phosphate buffer with 0.5 mM EDTA. A) 0 mins. B) 180
mins and C) 1440 mins.
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2.5.5

Determination of reaction order
The initial reaction rates were monitored at room temperature (22 oC) and pH 7.0

(10 mM PB, 0.5 mM EDTA, 0.08 M ionic strength, N2 sparged) in a 2 mL microcentrifuge
tube with a total reaction volume of 1250 µL. Initial volumes of T20 were 500 µL, 500 µL
and 250 µL, respectively and initial concentrations were calculated based on final
concentrations listed below. To determine the reaction order with respect to T20, a final
concentration of T20-T21 of 250 µM was used and kinetics monitored at different initial
concentrations of T20 (80, 250, 370 and 630 µM). In the same way, the reaction order with
respect to T20-T21 was determined using a fixed initial concentration of T20 (350 µM)
and different initial concentrations of T20-T21 (130, 270, 410 and 600 µM).

2.5.6

Thiol-disulfide exchange reactions
Reaction kinetics were monitored at five different pH values (6.0, 7.0, 8.0, 9.0, and

10.0). For the reaction, 500 µL of T20 (875 µM), 500 µL of T20-T21 (625 µM) and 250
µL of buffer (50, 100 and 200 mM) were added to a 2 mL microcentrifuge tube and mixed
by pipetting. The final pH of the reaction mixture was adjusted using NaOH or HCl (exact
volume to be added was determined from pilot studies at each pH) after a 100 µL aliquot
was removed and quenched to verify initial concentrations (t = 0 min). Samples were
withdrawn in triplicate at all time points and quenched with 10 µL of 20% formic acid
solution in DDI to prevent further scrambling. 30 µL of this quenched solution was then
used for RP-HPLC analysis. Dilution factors from total reaction volume, addition of
NaOH/HCl for pH adjustment and quench solution were accounted for in determining final
peptide concentrations. No measurable changes in concentration were observed in
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quenched samples within the time scale of the experiment. The cyclic peptide cT20-T21
(see Table 2.1) was reacted with T20 in 10 mM PB and CB (0.08 M ionic strength, 0.5 mM
EDTA and N2 sparged). The reaction was monitored kinetically at 22 oC and at 40 oC at
pH 7.0 and 9.0 for 6 hours. Initial reactant concentrations were [T20] = 450 µM and [cT20T21] = 45 µM. Quench conditions were the same as in studies with T20-T21 and aliquots
were withdrawn in triplicate and analyzed using RP-HPLC.

2.5.7

Determining activation parameters for the reaction of T20 with T20-T21
Reaction kinetics were also monitored at five different temperatures (in triplicate):

4, 15, 25, 40 and 50 oC at pH 7.0 (PB, 10 mM with 0.5 mM EDTA). Initial reactant
concentrations, quench conditions and sample analysis were identical to those in the pH
studies. Arrhenius parameters obtained from accelerated storage conditions are generally
used to predict protein stability at low temperatures [142]. However, for proteins, nonArrhenius behavior is not uncommon due to the complexity of the aggregation process
itself. In simpler model compounds like peptides, we expect the reaction to follow
Arrhenius behavior in a narrow temperature window. Use of high temperatures (≥ 60 oC)
can lead to degradation of the peptides. Thus, for the hGH-derived peptides used in studies
here, Arrhenius behavior was investigated from 4 to 50 oC using Equation 2.1 below.

k = A exp [-(Ea/RT)]

Eq. 2.1

Where, k- rate constant, A- preexponential factor, R- gas constant, T-temperature and Ea
is the activation energy.
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The Eyring equation (Eq 2.2) provides molecular insight into how a reaction
progresses with changing temperature. Activation energy, Ea and enthalpy of activation
(ΔH‡) only have small differences in their values and are often used interchangeably.

ln (k/T) = (-ΔH‡/T)(1/T) + ln (kB/h) + (ΔS‡/R)

Eq. 2.2

Where, k- rate constant, T-temperature, ΔH‡ - enthalpy of activation, ΔS‡ - entropy of
activation, kB – Boltzmann constant, h – Planck’s constant and R – gas constant.

2.6

Data analysis

For the reaction of T20 with linear T20-T21, the data were consistent with a
reaction scheme involving: (i) equilibrium ionization of T20 and T21, (ii) reversible thioldisulfide exchange reactions of the ionized thiolate forms of T20 and T21 (i.e., T20-S-,
T21-S-) with T20-T21 and (iii) oxidation of the ionized thiolate forms of T20 and T21
(Scheme 2.1). A system of equations corresponding to this scheme was used to describe
the time-varying concentrations of each species and to estimate values of the microscopic
rate constants.

T20S- = T20 / {1 + (10-7)/ (10-pKa)}

Eq. 2.3

T21S- = T21 / {1 + (10-7)/ (10-pKa)}

Eq. 2.4
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d [T20-T21]/dt = -k1 [T20S-][T20-T21] + k2 [T20-T20] – k3 [T21S-][T20-T21] + k4 [T21T21][T20S-] + k5 [T20S-]3 [T21S-]

Eq. 2.5

d [T20-T20]/dt = k1 [T20S-][T20-T21] – k2 [T20-T20][T21S-] + k5 [T20S-]3 [T21S-]
Eq. 2.6

d [T21-T21]/dt = k3 [T21S-][T20-T21] – k4 [T21-T21][T20S-] + k6 [T21S-]2

Eq. 2.7

d [T20S-]/dt = –k1 [T20S-][T20-T21] + k2 [T20-T20][T21S-] + k3 [T21S-][T20-T21] – k4
[T21-T21][T20S-] – k5 [T20S-]3 [T21S-]

Eq. 2.8

d [T21S-]/dt = k1 [T20S-][T20-T21] – k2 [T20-T20][T21S-] – k3 [T21S-][T20-T21] +
k4[T21-T21][T20S-]

– k5 [T20S-]3[T21S-] - k6 [T21S-]2

Eq. 2.9

In the kinetic model, time is the independent variable, reactant and product
concentrations are dependent variables, and the rate constants (k1, k2, k3, k4, k5 and k6) are
treated as parameters to be determined by non-linear regression. The model returned a
value of 8.3 for thiol pKa when it was defined as a parameter to be determined by regression
of pH 7.0 data. Thus, the pKa values for the ionization of the T20 and T21 thiol groups
(Ka20, Ka21) were fixed at 8.3 for all reaction conditions, consistent with previous reports
for cysteine [143, 144]. Rate constants k1, k2, k3, and k4 are second-order rate constants for
thiol-disulfide exchange; k5 is a composite rate constant for the production of T20-T21 and
T20-T20 by the oxidation of T20S- and T21S-. A composite oxidation rate constant (k5)

56
was used to minimize model parameters. This composite reaction (R5, Scheme 2.1) was
sufficient to describe the minor oxidation observed when oxidation was suppressed (i.e.,
with EDTA and N2 sparging). Kinetic data were fitted to the model (Equations 2.3-2.9)
using non-linear regression (SCIENTIST®, Micromath Research, St. Louis, MO).
SCIENTIST® reports Model Selection Criterion (MSC) values to determine the most
appropriate models; a greater MSC value represents a better model. MSC is independent
of the scaling of data points and is similar to the Akaike Information Criterion (AIC), which
is considered to be a better measure of model validity than R2 values for non-linear models
[145]. MSC value for the model with composite k5 was greater than the MSC value for a
model with two separate oxidation rate constants. When oxidation was not suppressed, the
additional parameter k6 for the oxidation of ionized T21 to T21-T21 (R6, Scheme 2.1) was
included to compare data to oxidation suppressed studies and to obtain better model fits
based on MSC values.
Average values of the measured concentrations of each of the five species (i.e., T20,
T21, T20-T20, T21-T21 and T20-T21), as measured by RP-HPLC in triplicate at each time
point, defined the data set. In studies of the effect of pH, kinetic studies were repeated at
several buffer concentrations and the values of the rate constants extrapolated to zero buffer
concentration. An Arrhenius plot was constructed from reactions at various temperatures
to estimate the activation energy (Ea) of the reactions. All calculated Ea values were
evaluated by one-way ANOVA using SAS, a statistical analysis software (SAS Institute,
Cary, NC) at 95% confidence to determine significant differences in Ea among the four
thiol-disulfide exchange reactions (R3 and R4, Scheme 2.1).For the reaction of T20 with
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cT20-T21, the data were fitted to the equation (Eq. 2.10) for first order irreversible reaction
to give kobs.

A/A0 = exp (-kobs t)

Eq. 2.10

Here, A = [T20-T21] or [cT20-T21] and A0 is the initial concentration of the respective
disulfide. A reaction scheme was proposed for the reactions with cT20-T21 (Scheme 2.2).

2.7

2.7.1

Results

Addition of oxidation suppressants to favor the thiol-disulfide exchange reaction
Peptides derived from hGH were used to investigate thiol-disulfide exchange in

aqueous solution. Initial studies of the reaction of T20 with T20-T21 in buffer without
EDTA or N2 sparging (pH 7.0) showed that the reactants and products did not appear to
reach equilibrium (Figure 2.4), suggesting another reaction pathway in addition to thioldisulfide exchange. In reactions of T20 and T20-T21, only five species (i.e., T20, T21,
T20-T20, T20-T21, and T21-T21) were detected at all reaction conditions studied (Figure
2.3). Similarly, in reactions of T20 and cT20-T21, only four species were detected (i.e.,
T20, T20-T20, cT20-T21, rT20-T21). No additional oxidation products (e.g., sulfenic,
sulfinic, or sulfonic acids) were detected with either RP-HPLC or LC-MS both in the
presence and absence of oxidation suppressants, strongly suggesting that the additional
reaction pathway is the formation of T20-T20, T20-T21 and T21-T21 from their respective
monomers via oxidation. In order to isolate the thiol-disulfide exchange reaction for further

58
investigation, PB buffers (pH 7.0) were sparged with N2 for 30 minutes, degassed, and
different concentrations of EDTA (0.5 mM, 1 mM and 2 mM) were evaluated for their
ability inhibit the oxidation reactions. Because the reactions were unaffected by higher
EDTA concentrations (data not shown), 0.5 mM was chosen for all subsequent studies in
which oxidation was suppressed. Although the rates of the oxidation reactions were
significantly attenuated (see below), oxidation could not be eliminated completely using
EDTA and N2 sparging. Other methods to inhibit oxidation like using a nitrogen controlled
atmosphere were not investigated as <10% of T20 and T21 participate in the oxidation
pathways in the presence of EDTA and N2 (based on mass balance from RP-HPLC data).
Oxidation of rT20-T21 to cT20-T21 is the major reaction (Figure 2.5, concentration
of cT20-T21 increases while rT20-T21 decreases beyond 500 min), even in oxidation
suppressed conditions, after 6 hours. As the main aim was to study thiol-disulfide exchange,
we monitored the reaction for up to 6 hours, a time period within which oxidation of T20
to T20-T20 or rT20-T21 to cT20-T21 does not occur to an appreciable extent (determined
from pilot studies that were monitored at later time points, Figure 2.5). Also, mass balance
showed that the amount of T20-T20 formed was equivalent to the amount of cT20-T21
consumed, further supporting thiol-disulfide exchange as the major pathway for disulfide
scrambling for t < 6 h. For studies with cT20-T21 at pH 7.0 and T20 and T20-T21 at pH
7.0 and 9.0, a similar sampling schedule was used
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Figure 2.4: The concentration of reactants and products for a kinetic study with T20 and
T20-T21 at pH 7.0, 10 mM PB and 0.08 M ionic strength (without EDTA or N2 sparging).
Initial concentrations of peptides were: [T20] = 350 µM; [T20-T21] = 250 µM. The
symbols represent actual data points obtained from samples at different times (n=3, +/-SD).
Solid lines are model predictions for the reactions in Scheme 2.1.

Figure 2.5: Concentrations of cT20-T21 (▲) and rT20-T21 (●) for the reaction of cT20-T21 with
T20 in 10 mM carbonate buffer, pH 9.0, and 0.08 M ionic strength (with EDTA and N2 sparged) at
22 oC.
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2.7.2

Apparent order of reaction; reaction of T20 and T20-T21
To estimate the order of the disulfide exchange reaction and guide the development

of a proposed reaction scheme (Scheme 2.1), reactant and product concentrations were
monitored in the early stages of the reaction (pH 7.0, 10 mM PB, 0.5 mM EDTA and N2
sparging) where <5% change in both reactants was observed. The apparent first-order
reaction rates were estimated for a range of initial concentrations. Slopes of log-log plots
of the rate of reactant disappearance versus reactant concentration were 0.99±0.01 for T20
and 0.93±0.03 for T20-T21 (Figure 2.6), indicating that the reaction is first-order with
respect to the thiol and disulfide reactants and second-order overall. Kuwajima et al.
investigated disulfide bond reduction in α-lactalbumin with DTT [66]. The authors
reported that the kinetics of disulfide bond reduction is rate-limited by inter-molecular
disulfide exchange between α-lactalbumin and DTT and that such a reaction is secondorder [66], consistent with our findings using hGH-derived peptides. This report and our
observation that thiol-disulfide exchange is a second-order reaction are also consistent with
other literature reports [45, 119].
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Reaction schemes for thiol-disulfide exchange in hGH-derived peptides
Scheme 2.1: Reaction of T20 with T20-T21
Thiol ionization
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T20-S- + H+
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T21-SH
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Scheme 2.2: Reaction of T20 with cT20-T21
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Figure 2.6: Thiol-disulfide exchange initial rate studies in which the concentration of one
reactant (either T20 or T20-T21) was fixed while the concentration of the second reactant
(either T20 or T20-T21) was varied (see text). Reaction kinetics was monitored at pH 7.0,
10mM PB, 0.08M ionic strength with EDTA and N2 sparging at 22 oC. Log-log plots of
rate of loss of T20 versus T20 concentration (■) and rate of loss of T20-T21 versus T20T21 concentration (♦).
2.7.3

Effect of oxidation suppressants on thiol-disulfide exchange
To determine the effect of oxidation on the rate and mechanism of thiol-disulfide

exchange at pH 7.0, the rate constants for the exchange and oxidation reactions were
estimated by fitting the experimental data from reactions with and without EDTA and N2
sparging to the model described in Scheme 2.1 (Figures 2.4 and 2.7). The oxidation
suppressed thiol-disulfide exchange data of T20 with T20-T21 were well described by the
model in Scheme 2.1 without R6 (R2 ≥0.95, see below), as T21-T21 was formed only via
thiol-disulfide exchange in the presence of oxidation suppressants at all pH 6.0-10.0. In the
absence of oxidation suppressants, including a separate reaction (Scheme 2.1, R6),
described the data better than combining all oxidation reactions into a composite reaction
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for all three oxidation reactions in Scheme 2.1 (R5 and R6). For the oxidation of T21 to
form T21-T21 in the absence of oxidation suppressants (R6, Scheme 2.1), the estimated
value of rate constant k6 was 8.9±2.6 M-1s-1. In the presence of oxidation suppressants,
oxidation of T21 was not observed (k6 = 0). Rate constants for thiol-disulfide exchange
were similar with and without oxidation suppressants, while k5 increased 3.6-fold and k6
increased from 0 to 8.9±2.6 M-1s-1 (Figure 2.8). Statistical analysis showed no significant
difference in rate constants for thiol-disulfide exchange (p>0.05) and a significant
difference for the oxidation reaction rate constant (p<0.05) in the presence and absence of
EDTA and N2, indicating that the intrinsic rate of the disulfide exchange reactions are not
affected by the presence of oxidation side-reactions.
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Figure 2.7: The concentration of reactants and products for a kinetic study with T20 and
T20-T21 at pH 7.0, 10mM phosphate buffer with 0.5 mM EDTA and N2 sparging. Initial
concentrations of peptides were: [T20] = 350 µM; [T20-T21] = 250 µM. The symbols
represent actual data points obtained from samples at different times (n=3, +/- SD. Solid
lines are model predictions for the reactions in Scheme 2.1.
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Figure 2.8: Comparison of rate constants for reactions with and without oxidation
suppressants (0.5 mM EDTA and N2 sparging) at pH 7.0, 10 mM PB and 0.08 M ionic
strength at 22 oC. Initial concentrations of peptides were: [T20] = 350 µM and [T20-T21]
= 250 µM (n=3, +/- SD). Unit for k5 is M-3s-1.
2.7.4

Effect of pH on the reaction of T20 with T20-T21
Thiol-disulfide exchange reactions were monitored as a function of buffer

concentration to determine the effect of buffer catalysis. At pH 6.0, 8.0, 9.0 and 10.0, a
high buffer concentration (40 mM) appears to have had a moderate stabilizing effect
(Figure 2.9; A, C, D and E). Statistical analysis showed no significant difference between
extrapolated rate constants and the rate constants at 10 mM buffer (p>0.05). Nevertheless,
at all pH values, we report rate constants extrapolated to zero buffer concentration. An
example of the fit of the data to the model (Scheme 2.1) at pH 7.0 is shown in Figure 2.7;
similar fits were obtained at the other pH values (Figure 2.10; A, B, C and D). At pH 7.0,
the extrapolated rate constants of the reactions shown in Scheme 2.1 were: k1 = 5.0±0.2 M1 -1

s , k2 = 10.6±0.3 M-1s-1, k3 = 3.4±0.1 M-1s-1, k4 = 6.9±0.1 M-1s-1. Rate constants at other

pH values and buffer concentrations are in Table 2.2. A pH-rate profile for pH 6.0-10.0 is
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shown in Figure 2.11 for the extrapolated rate constants. Statistical analysis showed no
significant difference (p>0.05) in the rate constants for this pH range. This suggests that
the mechanism of thiol-disulfide exchange is independent of pH as reported by others [146,
147]. Although a change in solution pH did not affect the rate of thiol-disulfide exchange
in tryptic peptides, it can influence reaction kinetics in proteins, which can undergo pHinduced conformational changes that can alter the exposure of disulfides and/or free thiols.
The pseudo-first order rate constant (kobs) for the loss of T20-T21 was determined by
monitoring the change in concentration over time. Data at different pH values (6.0-10.0)
are shown as a pH-rate profile in Figure 2.12. The slope of the pH-rate profile in the
pharmaceutically relevant range of pH 6.0 to 8.0, below the thiol pKa (8.3), is ~ 1. The
change in kobs with increasing pH (i.e., the slope of the pH rate profile) decreases above pH
8.0. However, there is a slight increase in kobs above pH 8.0 as the population of thiolate
anion still changes, albeit at decreasing proportions at pH > thiol pKa. The observed pH
dependence of kobs and the pH independence of k1-k4 indicate that thiol-disulfide exchange
depends on the concentration of thiolate anion.
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Figure 2.9: Rate constants vs. buffer concentration. Rate constants were obtained from
model fits to reaction scheme 2.1 (n=3, +/-SD): A) pH 6.0, B) pH 7.0, C) pH 8.0, D) pH
9.0, and E) pH 10.0 at 0.08 M ionic strength, different buffer concentrations of 10, 20 and
40 mM (with EDTA and N2 sparging) and at 22 oC. Initial concentrations of peptides were:
[T20] = 350 µM; [T20-T21] = 250 µM. Dotted lines are trendlines.

68
A
400

T20
T21

Concentration (µM)

T20T20
T21T21

300

T20T21

200

100

0
0

1000

2000
Time (min)

3000

4000

B
T20

400

T21

Concentration (µM)

T20T20
T21T21
T20T21

300

200

100

0
0

50

100

150

Time (min)

200

250

300

69
Continued from previous page

Concentration (µM)

400

T20
T21
T20T20
T21T21
T20T21

C

300

200

100

0
0

20

40

60

80

Time (min)

400

T20
T21

D

Concentration (µM)

T20T20
300

T21T21
T20T21

200

100

0
0

5

10
Time (min)

15

20

Figure 2.10: Kinetic plots at different pH for the reaction of T20 with T20-T21 at 22 oC.
Symbols represent actual data points (n=3, +/- SD) and solid lines represent model fits.[T20]
= 350 µM; [T20-T21] = 250 µM. Buffer conditions: pH 6.0-8.0 is with 10 mM phosphate
buffer and pH 9.0-10.0 is with 10 mM carbonate buffer. Ionic strength (0.08 M) and EDTA
(0.5 mM) were the same at all pH values. A) pH 6.0, B) pH 8.0, C) pH 9.0, and D) pH 10.0.
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Table 2.2: Measured rate constants for all buffer concentrations for the reaction of T20
with T20-T21, 0.08 M ionic strength (with EDTA and N2 sparged) at 22 oC.

Rate constant (M-1 s-1)
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Figure 2.11: pH-rate profile for second order microscopic rate constants (see Scheme 2.1
and text for details) obtained for kinetic studies with T20 and T20-T21 at 22 oC. All rate
constants are values extrapolated to zero buffer concentration (n=3, +/- SD).
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Figure 2.12: Pseudo-first order rate constant for the loss of T20-T21 () at different pH
(10 mM buffer, 0.08 M ionic strength with oxidation suppressants) and at 22 oC. Rate
constants were determined by non-linear regression. Uncertainties are within the size of
the symbol (n=3, +/-SD).
2.7.5

Activation parameters for the reaction of T20 with T20-T21
Microscopic rate constants for thiol-disulfide exchange (k1, k2, k3, and k4) obtained

from model fits to data at 4, 15, 35, 40 and 50 oC were used to construct an Arrhenius plot
(Figure 2.13, see Figure 2.14 for Arrhenius plot of k5). The resulting Arrhenius parameters
can be used to predict the extent to which temperature changes during storage and
processing conditions can affect thiol-disulfide exchange. The thiol-disulfide exchange
reaction was found to follow linear Arrhenius behavior in the temperature range 4-50 oC.
Linear Arrhenius plots suggest that a change in temperature within this range does not
result in a change in the proposed reaction mechanism or the rate-limiting step (Scheme
2.1). There is no significant difference (p>0.05) in the activation energy values for the any
of the thiol-disulfide exchange reactions in Scheme 2.1 (R3 and R4) based on a one-way
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ANOVA. R3 and R4 represent two mechanistically equivalent reversible reactions and thus
would be expected to have similar activation energies. We estimated Arrhenius activation
energies for the reaction of T20 and T20-T21 to be in the range of 41-53 kJ/mol (Table
2.3). An Eyring plot (Figure 2.15) was used to estimate values for enthalpy (∆H‡), entropy
(∆S‡) and free energy of activation (∆G‡) at 25 oC (Table 2.3).
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Figure 2.13: Arrhenius plots for microscopic rate constants for the reaction of T20 and
T20-T21 (Scheme 2.1) at pH 7.0, 10 mM phosphate buffer and 0.08 M ionic strength with
0.5 M EDTA and N2 sparging (n=3, +/- SD). Solid lines represent trendlines.
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Figure 2.14: Arrhenius plot for microscopic rate constant k5 (●) for the reaction of T20
and T20-T21 (see 2.1). The reaction was monitored at pH 7.0, 10 mM buffer and 0.08 M
ionic strength (with EDTA and N2 sparging) (n=3, +/- SD). Solid lines represent trendlines.
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Figure 2.15: Eyring plot for microscopic rate constants for the reaction of T20 with T20T21 at pH 7.0, 10 mM buffer and 0.08 M ionic strength (with EDTA and N2 sparging) (n=3,
+/- SD). Solid lines represent trendlines.
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2.7.6

Effect of peptide cyclization on thiol-disulfide exchange
The non-cyclic model peptides (T20, T21, T20-T20, T21-T21 and T20-T21) do not

have any secondary structure, as confirmed by far-UV CD analysis. However, the CD
spectrum for cT20-T21 shows internal hydrogen bonding, possibly due to the presence of
a beta-turn-like structure (Figure 2.16). Initial studies carried out with T20 and cT20-T21
with the same molar ratios as the heterodimer study (thiol: disulfide = 1.4:1) showed no
reaction at 22, 40, or 60 oC. Thus, a higher thiol: disulfide ratio of 10:1 was used for kinetic
studies using cT20-T21. We compared the rate of reaction of T20 with cT20-T21 at two
different pH values and temperatures with that of T20-T21 under similar reaction
conditions (Table 2.4) to determine the effect of peptide secondary structure on reaction
kinetics. For scrambling reactions involving cT20-T21 and T20, rates were considerably
slower than for the linear form (Figure 2.17). Even with a 10:1 molar ratio of thiol: disulfide,
only a 26% decrease in disulfide content was observed after 6 hours at pH 9.0 and 22 oC,
as compared to an 86% decrease for the linear T20-T21. Our results suggest that secondary
structure has a marked effect on the reaction rate, and that secondary structural constraints
may attenuate thiol-disulfide exchange in intact hGH relative to the intrinsic exchange rate
of the peptides.
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Table 2.3: Activation parameters for thiol-disulfide exchange reactions and oxidation
reaction (k5). Values for ΔH‡, ΔS‡ and ΔG‡ were obtained from the Eyring plot shown in
Figure 2.15.

Rate constant

Ea (kJ/mol)

A

k1

46±4

7.5*10 ±4.2

41±2

k2

48±4

k3

‡

a
a

38±4

-96±15

66±6

8

a

50±6

-66±21

70±9

9

a

2.0*10 ±2.6
8.9*10 ±5.9

48±4

2.3*10 ±4.4

53±7

1.5*10 ±16.0

-1 -1
-3 -1

o

ΔG 25 C (kJ/mol)
68±9

8

k5
a

‡

ΔS (J/mol.K)
-83±20

8

k4

b

‡

ΔH (kJ/mol)
43±6

12

b

45±5

-75±16

67±7

51±6

134±19

11±8

units in M s
units in M s

Table 2.4: The change in cT20-T21 and T20-T21 concentrations obtained after 6 hours for
thiol-disulfide exchange reactions with T20 at different pH and temperature at thiol:
disulfide of 10:1.

Peptide
cT20-T21

T20-T21

pH
7.0
7.0
9.0
9.0
7.0
9.0

o

Temp ( C)
22
40
22
40
22
22

% decrease after 6 hours
17.3±3.3
18.6±2.4
26.0±3.6
23.6±3.2
79.9±9.8
86.4±2.9
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Figure 2.16: Far-UV CD spectra for A) T20-T21 and B) cT20-T21. The far-UV CD spectrum for
T20-T21 is representative of peptides T20, T21, T20-T20 and T20-T21.
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Figure 2.17: Observed pseudo-first order rate constants for the loss of cT20-T21 and T20T21 at different concentration ratios and temperatures. Ratios in figure legend represents
thiol:disulfide ratio (T20:T20-T21/cT20-T21). Initial concentrations of peptides were:
[T20] = 450 µM; [T20-T21] = 45 µM for 10:1 studies and [T20] = 350 µM; [T20-T21] =
250 µM for the 1.4:1 study. Uncertainties are within the size of the symbol (n=3).
2.8

Discussion

The mechanism of thiol-disulfide exchange involves reaction of the thiolate anion
(RS-) with a disulfide bond (R’SSR”) at neutral to alkaline pH [45, 46, 71]. The thiol group
undergoes deprotonation to form the reactive nucleophile (RS-), this step is followed by
the exchange of redox equivalents leading to oxidation of the attacking thiol and reduction
of R'SSR" [45]. In our studies with model peptides derived from hGH, products consistent
with this mechanism were detected, including T20-T20, T21, T21-T21 and rT20-T21. No
additional oxidation products such as cysteine sulfenic acid, cysteine sulfinic acid, cysteine
sulfonic acid or thiosulfinates were detected, either in the presence or absence of EDTA
and N2, as confirmed by MS analysis and mass balance upon completion of the kinetic
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studies. Here we report thiol-disulfide exchange using model peptides (T20-T21, cT20T21, T20) representative of proteins containing an unpaired Cys and disulfide bonds.
Although native hGH and most mAbs generally do not have unpaired Cys, these may be
generated by β-elimination, incomplete folding or disulfide bond reduction during
expression, folding, purification and/or fill-finish operations, and during storage in solution
or solid formulations.
The reaction between thiols and disulfides has been studied in detail by other groups
[50, 119, 120]. Previously Luo et al. used a data modeling approach to determine oxidation
reaction kinetics for the reaction of Cys-SH and H2O2 [140] and we have used a similar
approach to study thiol-disulfide exchange. To our knowledge, however, this is the first
report of a detailed kinetic model allowing the determination of both observed and
microscopic rate constants for thiol-disulfide exchange in peptide model compounds. In
the kinetic model, reactions R1-R5 (Scheme 2.1) were sufficient to describe both thioldisulfide exchange and thiol oxidation in studies with oxidation suppressants. Thiol
oxidation reactions R5 and R6 represent composite reactions that involve oxidation of T20
or T21 via a RSOH intermediate [140]. RSOH is a reactive species that is completely
consumed, was not detected analytically and as a result was excluded from the reaction
scheme. Excellent fits of the model to our data suggest that the reactions represented by
Scheme 2.1 effectively describe the mechanism for thiol-disulfide exchange between T20
and T20-T21 and oxidation of free thiols (T20, T21) to form homodimers (T20-T20, T21T21) and heterodimer (T20-T21). In the reaction of T20 with T20-T21, omitting oxidation
suppressants (EDTA and N2 sparging) resulted in an increase in the oxidation rate constant
k5 by 366% and k6 to 8.9±2.6M-1s-1 from ~0, while the other rate constants remained
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unchanged (Figure 2.8). The kobs value for the loss of T20 decreased by 130% in the
presence of oxidation suppressants while kobs for the loss of T20-T21 remained unchanged.
The results show that excluding oxidation suppressants accelerates the formation of
scrambled disulfides (T20-T20 and T21-T21) via oxidative pathways. Hydroxyl ion
mediated disulfide exchange and aggregation has been reported for atrial natriuretic peptide
(ANP), a cyclic peptide with 25 amino acids and a disulfide bond (C4-C28) in the solid
state [141]. However, alkaline hydrolysis of peptide bonds in T20-T21 and cT20-T21 was
not observed up to pH 10.0.
Rate constants obtained here for the reaction of T20 with T20-T21 are comparable
to previous reports. For example, Holmgren et al. studied disulfide bond reduction in
insulin with dithiothreitol (DTT) at neutral pH and determined a second-order rate constant
for the reaction of 5 M-1s-1 [47]. In another study with DTT, Wiita et al. studied forcedependent chemical kinetics of disulfide bond reduction [70]. In the absence of an external
force and at pH 7.2, a second-order rate constant of 6.45 M-1s-1 was obtained. These values
for thiol mediated disulfide exchange are similar to our model predictions for the reactions
of both T20 and T21 with T20-T21 (Scheme 2.1, R3 and R4) at pH 7.0 (3-11 M-1s-1).
Arrhenius activation energy values reported here (Table 2.3) are similar to those
obtained by Fernandes et al., who reported Ea values for thiol-disulfide exchange in
solution in the range 60-66 kJ/mol [148]. Wiita et al. assumed values for the Arrhenius
parameter (A) of 105-1012 M-1s-1, and obtained activation energies between 30-65 kJ/mol
for thiol-disulfide exchange [70]. Whitesides et al. determined activation parameters for
the reaction of Ellman’s reagent and glutathione with three different thiols in water at 30
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C [71]; ∆G‡ = 44.4 – 65.7 kJ/mol, ∆H‡ = 37.7 – 66.9 kJ/mol and ∆S‡ = -19.7 – +13.4

J/mol.K.
The activation parameters reported here, with the exception of more negative values
of ∆S‡, are similar to values cited above. Thiol-disulfide exchange proceeds via a linear
SN2 mechanism [149, 150], with greater translational and vibrational constraint of the
transition state than the reactants, resulting in a negative ∆S‡ and a positive ∆G‡. The values
of the activation parameters reported here are consistent with expected values of -85 – 125 J/mol.K for this mechanism [71] and suggest that translational and vibrational
constraints play a more significant role for thiol-disulfide exchange reactions involving
peptides than in small molecules. Youngman et al. have shown that carbamidomethylation
of all four Cys residues in hGH decreases stability by ~ 37.7 kJ/mol [151]. Protein
destabilization by disulfide bond reduction increased the population of self-associated
forms. This is similar to the activation energies reported here, suggesting that the activation
energy for thiol-disulfide exchange in model peptides is of the same order as the decrease
in stability that results from the reduction of disulfide bonds in native hGH.
The results also show that the reaction is ten-fold slower in the cyclic peptide
(cT20-T21) than in the linear form (T20-T21), suggesting that secondary structural
constraints in hGH slow thiol-disulfide exchange.

Interestingly, this observation is

contrary to previous reports. Rabenstein et al. determined observed rate constants for thioldisulfide exchange with Cys and Arg-vasopressin (AVP) at pH 7.0 and 25 oC [120]. AVP
is a cyclic peptide with 9 amino acid residues. The reaction of AVP with Cys (CysSH) was
100 times faster than the reaction between glutathione disulfide (GSSG) and CysSH. The
authors attributed this to several factors including a more accessible disulfide bond formed
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between two terminal Cys residues in AVP. The disulfide bond in cT20-T21 (C4-C11) is
somewhat removed from the N- and C-termini, and may be less solvent exposed than in
T20-T21, perhaps contributing to the reduction in rate observed here. Internal hydrogen
bonding in the cT20-T21 peptide (CD spectrum, Figure 2.16) could impose a structural
constraint which translates to reduced reactivity of the disulfide bond with T20.
Additionally, in peptides with 1-3 residues between the Cys, cyclization is unfavorable due
to geometric strain, while a stable disulfide bond is formed in peptides with 4-5 intervening
amino acids [50]. The differences in structural effects between the studies reported here
and previous reports indicate that the relationship between peptide secondary structure and
reactivity in thiol-disulfide exchange is not completely understood, and that further studies
are warranted, particularly given the relevance to therapeutic proteins such as hGH,
monoclonal antibodies (mAbs) and human serum albumin. The results can be extended to
therapeutic proteins and biosimilars to determine the influence of sequence, structure and
processing conditions on reaction mechanisms and disulfide-mediated aggregation
propensity and to improve candidate selection during development.

2.9

Conclusion

The studies reported here define the mechanistic details of thiol-disulfide exchange
and oxidation in hGH model peptides in solution. Microscopic and apparent rate constants
obtained from model predictions provide an insight into the effects of pH, temperature and
secondary structure on thiol-disulfide exchange. Detailed kinetic analysis of degradation
pathways like thiol-disulfide exchange is valuable for the development of protein drug
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formulations, both in solution and in the solid state. Further, the information can be used
to improve our understanding of the contributions of thiol-disulfide exchange to
aggregation in other therapeutic proteins with disulfide bonds and/or Cys residues.

83

CHAPTER 3. INVESTIGATING THE EFFECT OF LYOPHILIZATION AND
SUBSEQUENT STORAGE IN THE SOLID STATE ON THIOLDISULFIDE EXCHANGE IN PEPTIDES DERIVED FROM HUMAN
GROWTH HORMONE

This work was published in the Journal of Pharmaceutical
DOI: 10.1002/jps.24370, content reproduced with permission from Wiley.

3.1

Sciences

Abstract

Lyophilization (freeze-drying) is frequently used to stabilize protein therapeutics.
However, covalent modifications such as thiol-disulfide exchange and disulfide scrambling
can occur even in the solid-state. The effects of lyophilization and storage of lyophilized
powders on the mechanism and kinetics of thiol-disulfide exchange have not been
elucidated and were investigated in the studies presented here. Reaction kinetics were
monitored during different stages of lyophilization (freezing, primary drying and
secondary drying) and during storage of the lyophilized powders at 22 oC and ambient RH.
The concentrations of reactants and products were determined using RP-HPLC and product
identity confirmed using LC-MS. Loss of native disulfide was observed for both linear and
cyclic peptide during the primary drying step, however, the native disulfides were
regenerated during secondary drying with no further change till the end of lyophilization.
Deviations from Arrhenius parameters predicted from solution studies and the absence of
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buffer effects during lyophilization suggest that factors such as temperature, initial peptide
concentration, buffer type and concentration do not influence thiol-disulfide exchange
during lyophilization. Results from a ‘cold finger’ method used to study peptide adsorption
to ice indicate that there is no preferential peptide adsorption to the ice surface and the
presence of an ice surface may not influence disulfide reactivity during primary drying.
Overall, reaction rates and product distribution are different for the reaction of T20 with
T20-T21 or cT20-T21 in the solid-state and aqueous solution while the mechanism of thioldisulfide remains unchanged. Increased reactivity of the cyclic peptide in the solid-state
suggests that peptide cyclization does not offer protection against lyophilization and that
damage induced by a process stress further affects storage stability at 22 oC and ambient
RH.

3.2

Keywords

Lyophilization, freezing, cold finger, peptide, human growth hormone, kinetics and
thiol-disulfide exchange.

3.3

Introduction

Protein therapeutics continue to grow in commercial and therapeutic importance,
providing new treatments for cancer, cardiovascular and autoimmune diseases. The
biologics sector in the US grew by 18.2% between 2012-2013, with sales of $63.6 billion
in 2012 [1]. Nevertheless, the development of therapeutic proteins can be compromised by
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the inherent complexity and instability of these macromolecules [152, 153]. To improve
stability and retain potency, protein pharmaceuticals are often lyophilized [154-156].
Lyophilization (freeze- drying) produces solid powders with high surface area and is used
for storage of the protein following expression and for final marketed drug product [157].
Though lyophilization often reduces the rates of chemical and physical degradation,
chemical and physical degradation can still occur during processing and subsequent storage
in the solid state [132, 158, 159].
Lyophilization cycles typically consist of freezing, primary drying and secondary
drying steps [160]. The process can expose proteins to undesirable stresses such as cold
denaturation, increased concentration of solutes and protein (“freeze concentration”), pH
changes and dehydration, all of which can induce protein unfolding and/or structural
perturbations [161, 162]. Costantino et al. observed secondary structure changes, a
decrease in α-helicity and an increase in β-sheet and unordered structure, upon
lyophilization of human growth hormone (hGH) [163]. Lyophilization induced structural
changes have also been reported for recombinant human albumin (rHA) [95]. Such
structural and/or conformational changes can further lead to aggregation during storage [14]
and rehydration [164, 78]. Solid-phase aggregation of proteins can occur via different
mechanisms in the presence of moisture; namely, thiol-disulfide exchange, disulfide
scrambling, non-disulfide covalent aggregation and non-covalent aggregation [165].
While there are reports of disulfide-mediated aggregation in the solid state for
proteins that contain cysteines and/or disulfides [79, 166], the lack of a complete
understanding of factors that influence reactivity reduces formulation to trial-and-error,
informed by experience, in selecting composition and stabilizing excipients. Thus, an
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improved mechanistic understanding of aggregation-inducing processes such as thioldisulfide exchange will be beneficial for the rational design of formulations that stabilize
proteins during lyophilization and storage.
Native disulfide bonds scramble via oxidative and hydrolytic pathways to form
non-native bonds that can affect protein stability and activity. Two predominant pathways
lead to disulfide-mediated covalent aggregation: (i) thiol-disulfide exchange (RSH +
R1SSR2 ↔ R1SSR + R2SH) and (ii) disulfide scrambling (RSSR + R1SSR1 ↔ 2R1SSR) [2,
3, 141]. In solution at neutral to alkaline pH, the thiolate anion (RS-) is the reactive species
that initiates thiol-disulfide exchange. Nucleophilic attack of RS- on a native disulfide
(R1SSR2) generates a non-native disulfide (R1SSR) and a new thiol (R2S-) in an SN2
nucleophilic displacement reaction [45, 71]. Disulfide scrambling, a related reaction, is
initiated by disulfide bond cleavage to generate a thiolate that then initiates thiol-disulfide
or thiol-catalyzed exchange [165].
Disulfide-mediated aggregation has been reported in lyophilized bovine serum
albumin (BSA) [79] and β-galactosidase [166]. In rHA, lyophilization produced an
increase in both β-sheet content and unordered structural elements resulting in partial
protein unfolding, which further facilitated moisture-induced aggregation via thioldisulfide exchange upon storage [95]. Andya et al. observed disulfide linked dimers and
trimers in recombinant humanized monoclonal antibody (rhuMAb) formulations following
lyophilization and storage at 30 oC [167]. In the absence of excipients, reversible structural
alterations during lyophilization promoted covalent aggregate formation upon storage.
Degradation reactions can also occur in the solid state in the absence of process-induced
structural changes. For example, in the absence of a stabilizing excipient, a rhuMAb (IgG)
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aggregated in the solid state though native secondary structure was retained after spray
drying [163]. Reports of disulfide-linked aggregates in lyophilized protein samples [79,
166, 168] demonstrate the importance of designing processes and formulations that can
inhibit disulfide bond degradation.
Disulfide bonds can be cleaved under neutral to alkaline conditions via the attack
of a hydroxyl ion. Alkaline hydrolysis of disulfide bonds can be classified into three
pathways: i) direct attack-this results in the formation of sulfenic acid and a free thiol, ii)
α-elimination- where the β proton of Cys is attacked to produce thiolate and thioaldehyde
and iii) β-elimination- where the α proton of Cys is abstracted to produce dehydroalanine
and persulfide.
Human growth hormone (hGH) is a therapeutic protein used to treat growth
hormone deficiency and other growth disorders. It has two disulfide bonds and no free
thiols; with 191 amino acids the monomeric form has a molecular weight of 22 kDa.
Structural perturbations in hGH have been reported in the solid state [101] and could
further result in the formation of disulfide-linked aggregates during storage. A disulfidelinked dimer of hGH (45 kDa) was found to have diminished receptor binding affinity and
cell-proliferative activity [124]. Thus, given its relatively small size, therapeutic value and
tendency to aggregate [135, 136], hGH was chosen as a suitable model to study thioldisulfide exchange kinetics in the solid state.
The mechanistic information obtained from aqueous solution studies in Chapter 2
provided a basis for understanding the effects of lyophilization process stresses and the
solid environment on thiol-disulfide exchange. In this Chapter, studies pertaining to thioldisulfide exchange and disulfide scrambling in hGH-derived peptides during lyophilization
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and subsequent room temperature storage of the lyophilized powders are reported. The
hGH-derived peptides were lyophilized without excipients to determine process effects on
disulfide exchange and scrambling kinetics. The results demonstrate that the rate of thioldisulfide exchange is accelerated during primary drying, and that peptide secondary
structure does not influence reactivity during lyophilization. Factors such as temperature,
initial peptide concentration, buffer type and concentration and peptide adsorption to ice
did not influence thiol-disulfide exchange during primary drying. During storage in
lyophilized solids, both the rates and the distribution of products differed for linear and
cyclic disulfide-containing peptides when compared to those observed in aqueous solution.
Peptide cyclization does not offer protection against thiol-disulfide exchange in the solid
state, the observed rate constant (kobs) for the loss of cT20-T21 was 10-fold greater than
that in aqueous solution.

3.4

Materials

Model peptides T20, T21, T20-T21, rT20-T21 and cT20-T21 (see Table 3.1 for
structures) were purchased from GenScript (Piscataway, NJ) with >90% purity as a
lyophilized powder. HPLC grade acetonitrile (ACN), NaCl and KCl were purchased from
Fisher Scientific Co. (Pittsburgh, PA). K2HPO4, 5,5-dimethyl-1,3-cyclohexanedione
(dimedone), ethylenediaminetetraacetic acid (EDTA) and sodium citrate tribasic dihydrate
were purchased from Sigma Chemical Co. (St. Louis, MO). Trifluoroacetic acid (TFA) and
formic acid (FA) were obtained from Thermo Scientific (Rockford, IL). Double-distilled
water (DDI) used for buffer preparation and as HPLC mobile phase was deionized and
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purified using a Milli-Q water system, (Millipore Ltd., Billerica, MA) and filtered with a
0.2 µm filter. Glass vials (2 mL) and stoppers (13 mm gray butyl) for lyophilization were
purchased from Wheaton (Millville, NJ). Methods

3.4.1

Quantification of reactants and products by HPLC
Samples

were

analyzed

using

reverse-phase

high-performance

liquid

chromatography (RP-HPLC, Agilent 1200 series) with UV detection at 215 nm. Agilent
Chemstation software was used for data acquisition and analysis. A ZORBAX Eclipse plus
C18, 5 µm (4.6 X 250 mm) analytical column (Agilent Technologies, Santa Clara, CA)
was used with gradient elution and the column temperature maintained at 25 oC. The
gradient elution method and associated calibration plots were as described in our previous
work [169]. Identification of reactants and products on LC-MS: Samples were analyzed
using an ESI-LC/MS system (1200 series LC, 6520 qTOF; Agilent Technologies, Santa
Clara, CA) with a ZORBAX 300SB-C18 column (1.0 X 50 mm, 3.5 µm) with gradient
elution similar to that used in HPLC quantitation. Mobile phase A was 0.1% formic acid
in water and mobile phase B was 0.1% formic acid in acetonitrile. A gradient run was
initiated with 5% B, which was increased to 50% in 6.10 min, then held at 50% for 1 min
followed by an increase to 100% in 0.6 min, decreased to 0% in 0.6 min, increased again
to 100% in 0.6 min and finally returned to 5% in 0.6 min. The flow rate was maintained at
50 µL/min and the column temperature was not controlled. Data were analyzed using
MassHunter software. Reactants and products were identified using mass filters with
peptide masses corresponding to the different reaction mechanisms for thiol-disulfide
exchange and oxidation reactions.
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3.4.2

Thiol-disulfide exchange reactions
All peptides were used as provided by the manufacturer without further purification.

Stock solutions were prepared in a 0.1% formic acid solution in DDI. Reaction kinetics
were monitored during lyophilization and storage of lyophilized powders at 22 oC. For the
reaction, 1500 µL of T20 (1125 µM), 1500 µL of T20-T21/cT20-T21 (112.5 µM) and 750
µL of 50 mM phosphate buffer (PB) were added to a 15 mL BD falcon tube and mixed by
pipetting. The final pH of the reaction mixture was adjusted using NaOH or HCl (exact
volume to be added was determined from pilot studies) after a 100 µL aliquot was removed
and quenched with 10 µL 20% formic acid in DDI (FA) to verify initial concentrations (t
= 0 min before lyophilization). 200 µL aliquots of the reaction mixture were transferred
into vials (on ice) and placed inside the freeze-dryer; shelves were pre-cooled to -40 oC.
Frozen samples, collected during the freezing step, were thawed and quenched with 20 µL
of 20% FA to prevent disulfide exchange prior to analysis. Lyophilization samples at the
end of primary drying and during secondary drying were reconstituted with 200 µL of 0.1%
FA; 150 µL of the reconstituted sample was quenched with 15 µL of 20% FA. For storage
stability studies, reaction mixtures, solution and lyo samples were prepared as described
above. At the end of the lyophilization cycle, vials were capped under a vacuum (not sealed)
and stored at 22 oC. Samples were withdrawn in triplicate at each time point during
lyophilization and storage. 30 µL and 10 µL of the quenched solution were then used for
RP-HPLC and LC-MS analysis, respectively. Dilution factors from total reaction volume,
addition of NaOH/HCl for pH adjustment and quench solution were accounted for in
determining final peptide concentrations. No measurable changes in concentration were
observed in quenched samples within the time scale of the experiment.
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Buffer effect: T20 and T20-T21 were also lyophilized with 2.5 mM potassium
phosphate and 10 mM sodium citrate buffer at pH 7.0 to investigate the effect of buffer
type and concentration on thiol-disulfide exchange. Initial peptide concentrations and total
reaction volume were as described above. For 2.5 mM PB, 750 µL of 10 mM buffer stock
was used and for 10 mM sodium citrate, 750 µL of 50 mM buffer stock was used. Samples
were withdrawn in triplicate, quenched and analyzed as described above.

92
Table 3.1: Abbreviations and amino acid sequences of peptides detected in solid-state
studies with hGH-derived peptides.
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3.4.3

Lyophilization of peptide samples
Solid samples were prepared by lyophilization in a programmable benchtop VirTris

freeze-dryer (SP scientific, Gardiner, NY), using methods routine in our labs [129] (Table
3.2). Briefly, the lyophilization cycle consisted of the following steps; freezing at -40 oC,
then drying at -35 oC under vacuum (70 mTorr) for 2 h, -5 oC for 8 h, 5 oC for 8 h, 15 oC
for 6 h (100 mTorr) and 25 oC for 10 h (100 mTorr). The same lyophilization cycle was
used for all solid-state studies to eliminate processing conditions as a variable and was not
optimized. The instrument was operated in manual mode to monitor disulfide exchange
during lyophilization so that samples could be removed at the end of each step. Lyophilized
samples at the end of the cycle appeared as dried powders and did not form elegant cakes
due to the absence of any bulking agents. The glass transition temperature (Tg) of the
lyophilized samples was measured using a DSC Q2000 (TA instruments, New Castle, DE)
and moisture content was measured using TGA Q5000 (TA instruments, New Castle, DE)
and SGA-100 (VTI Corporation, Hialeah, FL).

Table 3.2: Lyophilization cycle used for solid-state studies with hGH-derived peptides

Step
o

Temperature ( C)
Duration (h)
Total time (h)
Vacuum (mTorr)

1

2

3

4

5

6

-40
2
2
N/A

-35
2
4
70

-5
8
12
70

5
8
20
70

15
6
26
100

25
10
36
100

N/A, not applicable
Step 1: Freezing, Step 2: primary drying and Steps 3-6: secondary drying
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3.4.4

Peptide adsorption to ice
The rates of thiol-disulfide exchange in hGH model peptides were affected by

lyophilization. The role of adsorption to ice in these effects was assessed using a cold finger.
A cold finger condenser (24/40 inner joints from Fisher Scientific) was connected with
insulated tubing to a circulating water bath (Thermo Scientific) containing an ethylene
glycol/water (1:1) mixture and the temperature set to -10 oC. This method was used
previously by Kuiper et. al for purification of antifreeze proteins by adsorption to ice [170].
The cold finger was first placed in DDI seeded with ice crystals for 10 minutes to form an
ice surface (Figure 3.1). Ice surface area and ice crystal morphology on the cold finger
were not controlled using this method. The cold finger was then placed in a solution of
peptides inside a Styrofoam box and the ice surface allowed to grow for 1 hour. A peptide
solution was prepared by adding 32 mL of T20 (1250 µM), 32 mL of T20-T21 (125 µM)
and 16 mL PB buffer (10 mM, pH 7.0, 0.08 M ionic strength, 0.5 mM EDTA and N2
sparged). After adsorption for 1 hour, the cold finger was removed from the solution and
placed inside an empty beaker (Figure 3.1). The coolant temperature was maintained at 10 oC for another 6 hours. 100 µL of the solution remaining in the beaker (not frozen) and
thawed ice surface on the cold finger were quenched with 10 µL of 20% FA and 30 µL of
the quenched samples were injected onto the RP-HPLC column and analyzed for free thiols,
native and scrambled disulfides using the method described above.
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Figure 3.1: Picture of an ice surface formed on the cold finger after 10 mins (left). Picture
of cold finger after adsorption of the peptide solution to the ice surface for one hour (right).
3.4.5

Method for detecting reaction intermediates
Sulfenic acid determination (reaction with dimedone): Dimedone was used as a

trapping reagent to detect the presence of sulfenic acids, potential intermediates in
oxidation-mediated thiol-disulfide exchange [52]. To detect sulfenic acids in lyophilized
samples, dimedone was co-lyophilized with model peptides. To 10 mM PB (0.08 M ionic
strength, 0.5 mM EDTA), 1.72 g of dimedone was added (total buffer volume = 200 mL)
and the buffer sparged with N2. 1500 µL of T20-T21 (625 µM) was then added to 1500 µL
of 0.1% formic acid in DDI and 750 µL of buffer with dimedone. The pH of the reaction
mixture was adjusted to 8.0 using NaOH/HCl and the final concentration of dimedone
before lyophilization was 12.5 mM (dimedone: T20-T21 = 50:1). 200 µL aliquots of the
reaction mixture were transferred into glass vials and the samples were lyophilized using
the cycle shown in Table 3.2. To compare with solution samples, 200 µL aliquots of the
same reaction mixture were transferred to glass vials, capped and stored at 22 oC. At
different time points during storage, samples were reconstituted with 200 µL 0.1% FA and
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analyzed using RP-HPLC and LC-MS. Dehydroalanine detection: To detect
dehydroalanine, an intermediate in the degradation of disulfide bonds via β-elimination [3],
LC-MS spectra were scanned for a characteristic mass loss of 34 Da as reported previously
[171].

3.4.6

Data analysis
For the reaction of T20 with linear T20-T21 in the solid state during storage, the

data were consistent with a reaction scheme involving: (i) equilibrium ionization of T20
and T21, (ii) irreversible thiol-disulfide exchange reaction of the ionized thiolate form of
T20 (T20-S-) with T20-T21 and (iii) oxidation of the ionized thiolate forms of T20 and T21
(Scheme 3.1). The scheme is similar to that reported earlier for the reaction in solution
[169], but with an irreversible thiol-disulfide exchange reaction rather than a reversible one.
The following equations were used to estimate microscopic rate constants:

T20S- = T20 / {1 + (10-7)/ (10-pKa)}

Eq.3.1

T21S- = T21 / {1 + (10-7)/ (10-pKa)}

Eq.3.2

d[T20-T21]/dt = -k1′ [T20S-][T20-T21] + k2′ [T20S-][T21S-]

Eq.3.3

d[T20-T20]/dt = k1′ [T20S-][T20-T21]

Eq.3.4

d[T20S-]/dt = -k1′ [T20S-][T20-T21] - k2′ [T20S-][T21S-]

Eq.3.5
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d[T21S-]/dt = k1′ [T20S-][T20-T21] - k2′ [T20S-][T21S-]

Eq.3.6

In the kinetic model, time is the independent variable, reactant and product
concentrations are dependent variables, and the rate constants (k1′ and k2′) are treated as
parameters to be determined by non-linear regression. The model returned a value of 8.3
for thiol pKa when it was defined as a parameter to be determined by regression of pH 7.0
data. Thus, the pKa values for the ionization of T20 and T21 (Ka20, Ka21) were fixed at 8.3,
consistent with previous reports for cysteine [143, 144] and with our previous model for
the solution-state reaction [169]. Rate constants k1′ and k2′ are second-order rate constants
for thiol-disulfide exchange and thiol oxidation, respectively (Scheme 3.1). Kinetic data
were fitted to the model (eqns. 4.1-4.6) using non-linear regression (SCIENTIST®,
Micromath Research, St. Louis, MO). Pertinent models in SCIENTIST® were selected
based on reported Model Selection Criterion (MSC) values; a greater MSC value represents
a better model. MSC is independent of the scaling of data points and is similar to the Akaike
Information Criterion (AIC), which is considered to be a better measure of model validity
than R2 values for non-linear regression [145]. For the reaction of T20 with T20-T21 or
cT20-T21 in lyophilized powders during storage at 22 oC, the data were fitted to an
equation (Eq.3.7) for first-order irreversible reaction to determine the observed rate
constant (kobs)

A/A0 = exp (-kobs t)

Eq.3.7
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Here, A = [T20-T21] or [cT20-T21], A0 is the initial concentration of the respective
disulfide and t is time.

3.5

Results

The mechanisms of thiol-disulfide exchange reactions between T20 and T20-T21
or cT20-T21 have been elucidated in aqueous solution [169] and provide a basis for the
quantitative analysis of thiol-disulfide exchange in the solid state. Here, thiol-disulfide
exchange reactions were investigated in tryptic peptides derived from hGH during
lyophilization and storage of lyophilized powders. Native disulfides are T20-T21 and
cT20-T21 and scrambled disulfides formed as products of thiol-disulfide exchange are
T20-T20, T21-T21, SMDs and DMD (amino acid sequence of all peptides are shown in
Table 3.1).

3.5.1

Effect of lyophilization on thiol-disulfide exchange
For the reaction of T20 with T20-T21 (thiol: disulfide = 1.4: 1(molar ratio)),

primary drying resulted in a 33% loss of native disulfide (Figure 3.2a). The subsequent
increase in T20-T21 levels during secondary drying (Figure 3.2a) can be attributed in part
to the reversibility of the thiol-disulfide exchange reaction. Despite this increase, a net 9%
loss remained at the end of secondary drying (Figure 3.2a). At a greater initial thiol:
disulfide ratio of 10:1 (molar ratio), a 24% decrease in T20-T21 was observed after primary
drying (Figure 3.2b). During secondary drying, T20-T21 was regenerated from the
monomers and scrambled disulfides, resulting in an overall decrease in native disulfide of
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10% at the end of the lyophilization cycle (Figure 3.2b). Black dotted lines in Figures 3.2a
and 3.2b are the predicted concentrations of T20-T21 based on solution-state model
predictions, adjusted for the changing temperature profile during lyophilization using
Arrhenius parameters (see below). The solution-state model provides reasonable
predictions during freezing and primary drying, but does not describe concentrations
during secondary drying. A mass balance from RP-HPLC and LC-MS data shows that
products other than T20-T20 and T21 were not generated in detectable quantities and that
≥ 96 % of the initial peptide mass was accounted for at all time points during lyophilization.
The distribution of free thiols (T20 and T21), native disulfide (T20-T21) and scrambled
disulfide (T20-T20) for the reaction of T20 with T20-T21 at 10:1 is shown in Figure 3.3.
For the cyclic peptide, a 29% decrease in native disulfide was observed after
primary drying (Figure 3.2b). Like the linear peptide, cT20-T21 was partially regenerated
during secondary drying, resulting in a 17% decrease overall in native disulfide content at
the end of lyophilization (Figure 3.2b). The distribution of free thiols (T20 and rT20-T21),
native disulfide (cT20-T21) and scrambled disulfide (T20-T20) is shown in Figure 3.3. In
addition to these species, small amounts of single mixed disulfides (SMD1, SMD2 ) and
double mixed disulfide (DMD) (structures in Table 3.1) were also detected on LC-MS and
RP-HPLC (data not shown), though these could not be analyzed quantitatively due to the
lack of synthetic standards. Mass balance from RP-HPLC data obtained during freezing,
primary and secondary drying accounts for ≥ 90% of the initial mass of cT20-T21
(determined from concentrations of cT20-T21 and rT20-T21). The distribution of free
thiols (T20 and rT20-T21), native disulfide (cT20-T21) and scrambled disulfide (T20-T20)
for the reaction of T20 with cT20-T21 at 10:1 is shown in Figure 3.4. The factors that may
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influence thiol-disulfide exchange during freeze-drying and the results of studies designed
to elucidate their effects are described in greater detail below.
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Figure 3.2: Change in native disulfide content during lyophilization (n=3, +/- SD) at pH
7.0 (10 mM PB, 0.08 M ionic strength, 0.5 mM EDTA and N2 sparged); I-freezing, IIprimary drying and III-secondary drying. Reaction of T20 with a) T20-T21 (thiol: disulfide
= 1.4:1), b) T20-T21 (♦) and cT20-T21 (■) at thiol: disulfide = 10:1. Black dashed lines
indicate the end of each stage during lyophilization and the black dotted lines represent
predicted values from solution Arrhenius parameters (see text).
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Figure 3.3: Change in concentrations of reactants and products during lyophilization (n=3,
+/- SD) for the reaction of T20 with T20-T21 (thiol: disulfide = 10:1, pH 7.0, 10 mM PB,
0.08 M ionic strength, 0.5 mM EDTA and N2 sparged); I-freezing, II-primary drying and
III-secondary drying. Symbols represent actual data points: T20 (■), T21 (●), T20-T20 (□),
T21-T21 (○) and T20-T21 (♦). Initial concentrations of reactants in solution (before
lyophilization): [T20] = 450 µM; [T20-T21] = 45 µM. On the plot, t=0 (min) represents
solution concentrations before lyophilization.
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Figure 3.4: Change in concentrations of reactants and products during lyophilization (n=3,
+/- SD) for the reaction of T20 with cT20-T21 (thiol: disulfide = 10:1, pH 7.0, 10 mM PB,
0.08 M ionic strength, 0.5 mM EDTA and N2 sparged); I-freezing, II-primary drying and
III-secondary drying. Symbols represent actual data points: T20 (■), T20-T20 (□), cT20T21 (♦) and rT20-T21 (◊). Initial concentrations of reactants in solution (before
lyophilization): [T20] = 450 µM; [T20-T21] = 45 µM. On the plot, t=0 (min) represents
solution concentrations before lyophilization.
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3.5.2

Disulfide bond stability during lyophilization
Lyophilization of hGH derived peptides showed a difference in the distribution of

scrambled disulfides when compared to solution studies. Native disulfides (T20-T21 and
cT20-T21) were regenerated during secondary drying. For the cyclic peptide, non-native
disulfides (SMDs and DMD, Table 3.1) were detected in the solid state in addition to T20T20. While previous studies have shown that lyophilization alters thiol-disulfide product
distribution [129], the factors contributing to these differences were not identified. Here,
we investigated the effects of temperature, peptide concentration, buffer and peptide
adsorption to ice on disulfide bond stability during lyophilization.
Effect of temperature and concentration: Arrhenius parameters determined from
thermal stress studies in aqueous solution (thiol: disulfide = 1.4:1) were used to predict
reaction kinetics at reactant concentrations and temperatures used in lyophilization (black
dotted line in Figures 3.2a and 3.2b). At a higher thiol: disulfide ratio (Figure 3.2b),
Arrhenius predictions agree well with data obtained during freezing and primary drying.
However, the solution-state model overestimates the extent of thiol-disulfide exchange
during secondary drying and does not account for the increase in native disulfide during
the transition from primary drying to secondary drying. Deviations from Arrhenius
behavior suggest that factors other than temperature and initial peptide concentrations (e.g.,
phase change, peptide adsorption to ice, peptide structural changes, changes in reaction
mechanism and/or freeze concentration) influence thiol-disulfide exchange during the
freeze-drying process, since the model predictions are based on both the concentrations of
the reactants and temperature.
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Effect of buffer type and buffer concentration: T20 was lyophilized with T20-T21
at pH 7.0 and 4-fold lower buffer concentration (2.5 mM PB, 0.04 M ionic strength, 0.5
mM EDTA and N2 sparged). The rate of loss of T20-T21 was similar to that observed
during lyophilization with 10 mM PB (Figure 3.5). Similarly, when T20 was co-lyophilized
with T20-T21 in sodium citrate buffer (10 mM, 0.5 mM EDTA and N2 sparged), the native
disulfide concentration decreased during primary drying and then increased during
secondary drying (Figure 3.5). While there are some differences in T20-T21 concentration
during primary drying, particularly at a low buffer concentration (2.5 mM PB), the T20T21 concentration is similar at the end of primary drying and after two hours of secondary
drying (-5 oC, 70 mTorr) in all three buffers (Figure 3.5). These results suggest that buffer
concentration and type (phosphate vs. citrate) do not contribute to the observed loss of
native disulfide during primary drying.
Lyophilization induced damage to disulfide bonds: To investigate the effect of
peptide adsorption to an ice surface on thiol-disulfide exchange, a “cold finger” was used
(see methods, Figure 3.1). The ice surface on the cold finger and the solution after
adsorption were analyzed using RP-HPLC (data not shown). Peptide concentrations on the
ice after adsorption for 1 hr were; [T20] = 326 µM and [cT20-T21] = 33 µM. The results
showed that the ratio of T20 to cT20-T21 on the ice (10:1) after adsorption for 1 hr is
similar to the molar ratio (10:1) in the initial reaction mixture before adsorption. Although
cT20-T21 does not adsorb preferentially to the ice surface, thiol-disulfide exchange
between T20 and cT20-T21 still occurs on ice (6 hr sample thawed and analyzed on the
HPLC, data not shown).
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Figure 3.5: Effect of buffer type and buffer concentration on thiol-disulfide exchange
during lyophilization; freezing (I), primary drying (II) and secondary drying (III). Plot
shows change in T20-T21 concentration (n=3, +/- SD), co-lyophilized with T20. All
buffers contain 0.5 mM EDTA and were sparged with N2, pH of reaction mixture was
adjusted to 7.0 before lyophilization. Initial concentrations of reactants in solution (before
lyophilization): [T20] = 450 µM; [T20-T21] = 45 µM. On the plot, t=0 (min) represents
solution concentrations before lyophilization.
Primary drying duration: The duration of the primary drying step (-35 oC, 70
mTorr) was increased from 2 to 6 hours to determine the effect of drying time on thioldisulfide exchange (Figure 3.6). The concentration of native disulfide decreases in the
initial 2 hours of primary drying. After this initial loss, the native disulfide is regenerated
with continued drying for another 2 hours. Between 4 and 6 hours, there is no further
change in T20-T21. While a longer primary drying step can preserve the native disulfide
to some extent, lyophilization induced damage to the disulfide bond still occurs and may
influence the storage stability of the resulting solids.
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Figure 3.6: Change in concentration of T20-T21 lyophilized with T20 ( thiol: disulfide =
6:1, pH 7.0, 10 mM PB, 0.08 M ionic strength, 0.5 mM EDTA and N2 sparged) during
freezing and primary drying (n=3) (♦). Primary drying time was increased from 2 to 6 hours.
On the plot, t=0 (min) represents solution concentrations before lyophilization.
3.5.3

Thiol-disulfide exchange in lyophilized powders during storage
The thiol-disulfide exchange reaction between T20 and T20-T21 or cT20-T21 at

pH 7.0 (pre-lyophilization) in lyophilized powders stored at 22 oC was monitored over 0-7
and 0-12 days for T20-T21 and cT20-T21, respectively. Storage stability studies were
truncated after 7 days for T20-T21, since oxidative pathways began to dominate (Figure
3.7). Tg measured for the lyophilized powder at the end of secondary drying was 20.6 oC,
and the moisture content at the end of secondary drying and after storage for 14 days at 22
o

C was 1-1.5%.
Reaction of T20 with T20-T21: The change in the concentration of T20-T21 during

storage is shown in Figure 3.8. Rate constants for the exchange (k1′) and oxidation reaction
(k2′) were estimated by fitting the data to the model of Scheme 3.1. Excellent model fits to
the data were obtained and these model fits are represented by solid lines in Figure 3.9.
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The rate constants for the reaction of T20 with T20-T21 in the solid state are shown in
(Table 3.3). Mass balance from RP-HPLC data at the end of 7 days accounts for 95% of
initial mass of peptides. The observed pseudo-first order rate constant (kobs) for the loss of
T20-T21 during storage in aqueous solution is of the same order as kobs in the solid state,
indicating that the reaction is not slowed appreciably in the lyophilized form.
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Figure 3.7: Concentration of scrambled and native disulfides formed via oxidative
pathways during storage of lyophilized powders (n=3, +/- SD). Inset zooms in to show
change in concentrations of T20-T21 and T21-T21. T20-T21 was co-lyophilized with T20
(thiol: disulfide = 10:1, pH 7.0, 10 mM PB, 0.08 M ionic strength, 0.5 mM EDTA and N2
sparged) (see text for details).
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Scheme 3.1. Thiol-disulfide exchange in T20-T21 during storage in the solid state.
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Figure 3.8: Reaction of T20 with T20-T21 in lyophilized powders stored at 22 oC (n=3,
+/- SD). Initial concentrations of reactants in solution (before lyophilization): [T20] = 450
µM; [T20-T21] = 45 µM. Buffer conditions: pH 7.0 , 10 mM phosphate buffer, 0.08 M
ionic strength, 0.5 mM EDTA and N2 sparged.
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Figure 3.9: Reaction of T20 with T20-T21 in lyophilized powders stored at 22 oC (n=3,
+/- SD). Initial concentrations of reactants in solution (before lyophilization): [T20] = 450
µM; [T20-T21] = 45 µM. Buffer conditions: pH 7.0 , 10 mM phosphate buffer, 0.08 M
ionic strength, 0.5 mM EDTA and N2 sparged. Plot shows concentrations of T20 (■), T21
(●), T20-T20 (□), T21-T21 (○) and T20-T21 (♦). Solid lines are non-linear regressions
based on the model in Scheme 3.1. Initial time point (t = 0 days) corresponds to a sample
reconstituted immediately after lyophilization.

Table 3.3: Microscopic and observed rate constants for thiol-disulfide exchange between
T20 and T20-T21 in lyophilized solids and aqueous solution.

o

Aqueous solution (22 C), pH 7.0

Lyophilized solids (22 C), pH 7.0

k1' (T20-T21)

n/a
n/a

0.45±0.04 M s

k2' (T20-T21)

-1 -1
-1 -1

9.57±1.00 M s

-4

-6 -1 a

1.78*10 ±1.84*10 s

-5

-6 -1 a

1.56*10 ±1.14*10 s

kobs (T20-T21)

1.00*10 ±4.00*10 s

kobs (cT20-T21)

1.15*10 ±1.00*10 s

n/a -not applicable, different model was used to determine k1' and k2'
a

o

Parameter

values obtained from Chapter 2, [169]

-4

-5 -1

-4

-5 -1
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Reaction of T20 with cT20-T21: During storage of the cyclic peptide cT20-T21 in
lyophilized powders containing T20, the loss of the disulfide bond was faster in the solid
state than in aqueous solutions stored at the same conditions (Figure 3.10). The
concentration of cT20-T21 in solution increases over time due to oxidation as rT20-T21 is
oxidized to cT20-T21, behavior similar to that observed for cT20-T21 in aqueous solution
studies [169]. Mixed disulfides (SMDs and DMD; structures in Table 3.1) were detected
on both RP-HPLC (Figure 3.11) and LC-MS (data not shown), consistent with the reaction
mechanism in Scheme 3.3b. No other oxidation products such as sulfenic, sulfinic or
sulfonic acid were detected. A mass balance from RP-HPLC data at the end of 12 days
accounts for 80% of all peptides present in the storage samples. This suggests that the
remaining 20% of the initial mass is present as SMDs or DMD, which are not quantitated
but detected on LC-MS and RP-HPLC, or as other undetected species. Figure 3.12 shows
a concentration vs. time plot for T20, rT20-T21, native (cT20-T21) and scrambled disulfide
(T20-T20) obtained during storage of cyclic peptide. Unlike T20-T21, the concentration of
cT20-T21 does not increase during storage after 7 days (Figure 3.10). This suggests that
lyophilization induced stresses favor thiol-disulfide exchange between T20 and cT20-T21,
as temperature and pH did not influence reactivity to as great an extent in solution [169].
Observed rate constants (kobs) for the loss of cT20-T21 during storage in lyophilized
powders are shown in Table 3.3. At a pH 7.0, the kobs value for cT20-T21 in the solid state
is ~10-fold greater than its kobs value in aqueous solution, and is comparable to kobs for T20T21 in lyophilized solids at pH 7.0. This suggests that structural constraints imposed by
cyclization slow the thiol-disulfide exchange reaction in solution but not in lyophilized
solids.
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Figure 3.10: Change in concentration of cT20-T21 lyophilized with T20 ( thiol: disulfide
= 10:1, pH 7.0, 10 mM PB, 0.08 M ionic strength, 0.5 mM EDTA and N2 sparged) during
storage (n=3, +/- SD) at 22 oC (■), and in solution (♦) (thiol: disulfide = 10:1, pH 7.0, 10
mM PB, 0.08 M ionic strength, 0.5 mM EDTA and N2 sparged). Both solid and solution
samples were stored at 22 oC in lyo vials, n = 3. Open symbols show the initial
concentration of cT20-T21 in solution before lyophilization (□) and before storage as
solution at 22 oC (◊). Initial data points (t = 0 days, filled symbols) represent solution
sample and lyophilized sample reconstituted immediately after lyophilization.
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Figure 3.11: HPLC chromatograms (215 nm) obtained at various times during storage of
lyophilized T20 and cT20-T21 at 22 oC (pH before lyophilization was 7.0). Solution sample
before lyophilization (A), solid sample immediately after lyophilization (B) and solid
sample after 3 days (C). Peak labels: 1) T20; 2) T20-T20; 3) DMD; 4) SMD 1&2; 5) cT20T21 and 6) rT20-T21.
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Figure 3.12: The concentration of reactants and products for a kinetic study with T20 and
cT20-T21 during storage at 22 oC. Buffer conditions before lyophilization: pH 7.0, 10mM
phosphate buffer with 0.5 mM EDTA and N2 sparging. Initial concentrations of peptides
were: [T20] = 450 µM (Δ); [cT20-T21] = 45 µM (). The symbols represent actual data
points obtained from samples at different times (n=3, +/- SD): T20 (■), cT20-T21 (♦), T20T20 (□) and rT20-T21 (◊).
To determine disulfide bond stability without a free thiol in the solid state, T20T21/cT20-T21 was lyophilized without T20. When T20-T21 was lyophilized without T20
at pH 7.0, only the two homodimers; T20-T20 and T21-T21 were detected as products of
disulfide bond scission on RP-HPLC. While cT20-T21 lyophilized without T20 at pH 7.0
was very stable even after a few weeks at 22 oC. To further elucidate the mechanism of
disulfide bond degradation in the solid state, T20-T21/cT20-T21 was co-lyophilized with
dimedone at pH 8.0 (see methods). Change in T20-T21 and cT20-T21 concentrations with
time at pH 8.0 (pH in solution before lyophilization) are shown in Figures 3.13 and 3.14.
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T20 sulfenic acid (T20-SOH) and dimedone adduct (m/z = 378.7059) was detected
in solid samples stored at 22 oC for 2 weeks using LC-MS after reconstitution and in
solution samples stored at the same conditions (Figure 3.15). In addition, T20-SO2H (T20
sulfinic acid) was detected in solution samples; this is formed by further reaction of T20SOH with a hydroxyl ion [172, 173]. These products of alkaline hydrolysis are consistent
with a direct attack of OH- on the disulfide bond in T20-T21 (Scheme 3.2). Damage to the
disulfide bond in the cyclic peptide at pH 8.0 by alkaline hydrolysis was lower than that of
the linear form. No dimedone adducts were detected on the LC-MS. However, small
amounts of cysteine dehydroalanine (Scheme 3.2) were observed. This is consistent with
disulfide bond degradation via β-elimination mechanism.
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Figure 3.13: Change in T20-T21 (pH 8.0, 10 mM PB, 0.08 M ionic strength, 0.5 mM
EDTA and N2 sparged) concentration during storage (n=3, +/- SD) without T20, as a
lyophilized powder (♦) and in solution (■). T = 0 (day) on plot represents solution sample
analyzed at the same time as samples reconstituted immediately after lyophilization. Initial
concentration of T20-T21 in solution before lyophilization is represented by ∆.
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Figure 3.14: Change in cT20-T21 (pH 8.0, 10 mM PB, 0.08 M ionic strength, 0.5 mM
EDTA and N2 sparged) concentration during storage (n=3, +/- SD) without T20, as a
lyophilized powder (♦) and in solution (■). T = 0 (day) on plot represents solution sample
analyzed at the same time as samples reconstituted immediately after lyophilization. Initial
concentration of cT20-T21 in solution before lyophilization is represented by ∆.
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Figure 3.15: Mass spectrum (extracted ion chromatogram) showing the T20-S-dimedone
adduct. Lyophilized T20-T21 (initial concentration = 250 µM, PB pH 8.0, 0.5 mM EDTA,
0.08 M ionic strength and N2 sparged) was analyzed on the LC-MS upon reconstitution
after storage at 22 oC for 2 weeks.
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Scheme 3.2. Alkaline hydrolysis of disulfide bonds in the linear and cyclic peptide.

3.6

Discussion

The mechanism of thiol-disulfide exchange is well established in aqueous solution.
In neutral to basic solution, the thiolate anion is the reactive nucleophile, attacking a
disulfide bond via an SN2 mechanism [45, 71]. Thiol-disulfide exchange is known to occur
in the solid state as well [14, 79, 95], though the reaction mechanisms have not been fully
elucidated. In the studies reported here, hGH-derived model peptides were lyophilized
without excipients to investigate the effect of lyophilization on thiol-disulfide exchange
kinetics and mechanisms. The amino acid sequences of the model and their masses are
shown in Table 3.1. In studies of the solution-state reaction of the linear peptide (T20-T21)
with T20, the T20-T20 homodimer and T21 were detected as the initial products, as we
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have reported previously [169]. At longer time points, the T21-T21 homodimer was also
observed. These products are consistent with two thiol-disulfide exchange reactions, in
which: (i) T20-T21 initially reacts with T20 to produce the T20-T20 homodimer and T21,
and (ii) T20-T21 reacts with T21 produced in the first reaction to produce the T21-T21
homodimer and regenerate T20 (Scheme 3.3a). Solution-state reaction kinetics were not
adequately described by a kinetic scheme based only on these two reactions, however, and
oxidative pathways were included. This suggests that even in the presence of oxidation
suppressants (EDTA and N2 sparging), T20 and T21 also undergo oxidation to form T20T20, T21-T21 and T20-T21 via a sulfenic acid intermediate. Kinetic models including both
thiol-disulfide exchange and oxidation steps provided excellent fits to data, both in the
presence and in the absence of oxidation suppressants [169].
When the reaction of T20-T21 with T20 was monitored during lyophilization and
storage in the solid state, T20-T20 and T21 were again detected as initial products,
consistent with reaction 1 in Scheme 3.3a. Reaction 2 in scheme 3.3a was not observed in
the solid state during storage (in the timeframe that the reaction was monitored) based on
model fits to the data in SCIENTIST®. As in solution [169], kinetic profiles suggested that
T20 and T21 were oxidized to T20-T20, T21-T21 and T20-T21 on extended storage in the
solid state (> 7days at 22 oC; Figure 3.7). Oxidation products such as cysteine sulfenic,
sulfinic and sulfonic acid and thiosulfinates were not detected for samples containing T20T21 co-lyophilized with T20. However, when T20-T21 was lyophilized without T20 (see
methods), sulfenic acid and a dimedone adduct were detected (Figure 3.15). The presence
of sulfenic acid as an intermediate suggests that disulfide linked peptides can undergo
alkaline hydrolysis when a free thiol (T20) is not present, as reported previously [172, 174].
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Kinetic analysis further suggests that, during lyophilization, T20-T20 and T21 are
generated (k1 > k-1) during primary drying and then partly consumed (k1 < k-1) during the
first step of secondary drying (Table 3.2), after which there is no appreciable change in
product distribution. During storage in the lyophilized solid, the product distribution is
altered and kinetic analysis suggests that thiol-disulfide exchange is essentially irreversible.
Possible physicochemical contributions to these kinetic effects are discussed below.
In solution-state reactions of the cyclic peptide (cT20-T21) with T20, only T20T20 and rT20-T21 were detected as products [169]. Mixed disulfides (SMDs and DMD;
Table 3.1) were not observed under any conditions in aqueous solution. After 6 hours,
oxidation of rT20-T21 to cT20-T21 was the dominant pathway even under oxidationsuppressed conditions. In contrast, SMDs, DMD, rT20-T21 and T20-T20 were identified
as products of the reaction of cT20-T21 with T20 in the solid state. Oxidation of rT20-T21
to cT20-T21 was not the dominant reaction even after 12 days of storage in lyophilized
solids at 22 0C, and the concentration of cT20-T21 did not increase with time (Figures 3.10
and 3.12). As with the linear peptide, oxidation products such as cysteine sulfenic, sulfinic
and sulfonic acid and thiosulfinates were not detected. While sulfenic acid and dimedone
adducts were not detected for cT20-T21 lyophilized without T20, trace amounts of cysteine
dehydroalanine were detected (data not shown), again suggestive of alkaline hydrolysis in
the absence of a free thiol.
In the reaction of the cyclic peptide cT20-T21 with T20 in the solid state, mixed
disulfides (SMDs and DMD) were detected in addition to T20-T20 and rT20-T21 during
lyophilization and storage (Figure 3.11, Scheme 3.3b). Mixed disulfides were not detected
in solution studies [169], suggesting that rates of loss from this pool (k-3, k4) are rapid
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relative to rates of formation (k3, k-4) so that these species do not accumulate in solution
(Scheme 3.3b). The absence of the double mixed disulfide (DMD) in solution can be
attributed to the decreased reactivity of cT20-T21 and hence lower concentrations of T20T20, which in solution did not accumulate to levels sufficient to drive the reaction towards
DMD. In contrast, both SMDs and DMD were detected during the primary drying stage of
lyophilization, and the native disulfide was regenerated during secondary drying (Table
3.2).
The observed mechanism of thiol-disulfide exchange between T20 and cT20-T21
is similar to that reported previously for tocinoic acid (TA (ox)) and glutathione (GSH)
during lyophilization, where both SMDs and the DMD were detected [129]. TA (ox) is a
cyclic peptide with 6 amino acids and terminal Cys residues linked by a disulfide bond
(Scheme 3.3b, Table 3.4). Though the mechanism remains unchanged here, the relative
rates of some thiol-disulfide exchange reactions (scheme 3.3b) are different for cT20-T21
and TA (ox). TA (ox) was consumed in an irreversible thiol-disulfide exchange reaction at
the end of lyophilization [129], while for cT20-T21 most of the native disulfide was
regenerated at the end of step 3 (Table 3.2). The results suggest that although the type of
disulfide and thiol containing peptides may play a role in reaction kinetics during
lyophilization, the overall mechanism for thiol-disulfide exchange in cyclic peptides can
be represented by Scheme 3.3b.
The loss of native disulfide for both T20-T21 and cT20-T21 during the freezing
step may be initiated by freeze-concentration, leading to high local concentrations of the
peptide reactants (T20 and T20-T21 or cT20-T21). The loss of disulfide bonds during
freezing is consistent with previous studies of tumor growth factor-β1, in which increased
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intra- and intermolecular disulfide bond exchange was observed during freezing and longterm storage at -70 oC [175]. Here, deviations from solution Arrhenius parameters (Figure
3.2) and the absence of a buffer effect (Figure 3.5) suggest that factors such as temperature,
peptide concentration, buffer type and concentration have no effect on thiol-disulfide
exchange observed during primary drying. Further, the absence of preferential peptide
adsorption to ice using the ‘cold finger’ method suggests that the ice surface itself does not
play a role in thiol-disulfide exchange. Instead, loss of the disulfide bond during primary
drying may be due to a reduced activation barrier for thiol-disulfide exchange as the
environment becomes less polar, as observed at the active site of ribonucleotide reductase
[148].
In the simple peptides studied here, most of the native disulfide in T20-T21 and
cT20-T21 is regenerated during secondary drying (Figure 3.2). In larger proteins with
multiple disulfide bonds, such reverse reactions may not regenerate the original disulfide
bond, but may instead result in intramolecular disulfide scrambling and/or covalent
aggregation, depending on the proximity of the groups involved. The role of thiol group
proximity to a disulfide bond was investigated previously for small heat shock protein and
glutathione [67]. The distance between thiols and disulfides, and their relative mobility,
can be affected by freeze-drying induced unfolding, particularly for hGH, which is known
to undergo structural perturbations during lyophilization [101]. The formation of
intermolecular disulfide bonds can further lead to aggregation during storage and/or
rehydration. Here, the reactivity of the native disulfide bonds in T20-T21 and cT20-T21
appears to decrease as drying proceeds (Figure 3.2 and Steps 4, 5 and 6, Table 3.2), perhaps
the result of reduced mobility of the reactive species in the solid state.
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The results suggest that, at neutral to slightly alkaline pH, proteins with free thiols
and disulfides can undergo thiol-disulfide exchange during lyophilization and storage in
the solid state, which can further lead to the formation of disulfide-linked aggregates.
Though peptide cyclization retards disulfide exchange in solution, in the solid state the
observed disulfide bond degradation for cT20-T21 is greater than in solution and similar
to that of the linear peptide, T20-T21. Thus, increased stability of a disulfide bond
conferred by secondary structure in solution may not necessarily translate to increased
stability in the solid state. Further, structural constraints may not influence disulfide
degradation kinetics during lyophilization and storage in the solid state, especially when
free thiols are present on the surface of proteins and are in close proximity to a disulfide
bond. Thus, the use of lyophilization alone as a stabilizing strategy may not be sufficient
to retard thiol-disulfide exchange and offer protection against chemical degradation during
storage. Reasonable formulation strategies include restricting free thiol content before
lyophilization, using suitable excipients to stabilize protein structure when free thiols are
not present on the surface, excluding O2 from formulations (if products of oxidative
pathways are detected) and formulating proteins at low pH followed by reconstitution at
near neutral pH (these strategies are discussed in detail in Chapter 5).
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Scheme 3.3. Reaction schemes for thiol-disulfide exchange in a) T20-T21 and b) cT20T21
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Table 3.4: Abbreviations and amino acid sequences of tocinoic acid, glutathione and their
mixed disulfides.

Abbreviation

Description

Designation in
general reaction
scheme

Amino acid sequence

GSH

Monomeric
peptide, free SH
group

R1

NH2- ECG-OH

GSSG

Homodimer,
disulfide-linked

TA(ox)

TA(red)

Cyclic peptide,
disulfide linked

Linear peptide,
free SH groups

NH2- ECG-OH
R1SSR1
NH2- ECG-OH
R2S
NH2-CNQIYC -OH
R3S
R2SH

NH2-CNQIYC -OH

R3SH
R2 SSR1

linear peptide,
Single mixed
disulfide linked to
disulfide (SMD)
GSH

R 3 S-

OR
R 2 SR3 SSR1

Double mixed
disulfide
(DMD)

linear peptide,
disulfide linked
to two GSH
peptides

NH2-CNQIYC-OH
NH2-ECG-OH
OR
NH2-CNQIYC-OH
NH2-ECG-OH

R2SSR1

NH2-CNQIYC-OH

R3SSR1

NH2-ECG-OH

NH2-ECG-OH
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3.7

Conclusion

The studies reported here detail the effects of lyophilization and storage of
lyophilized powders on the mechanisms and rates of thiol-disulfide exchange. Peptide
secondary structure does not influence disulfide (T20-T21 or cT20-T21) reactivity in the
solid state when co-lyophilized with a free thiol (T20). Further, lyophilization does not
retard thiol-disulfide exchange during storage in the solid state. The results obtained
provide an insight into the effect of process stresses on disulfide exchange and are valuable
to the design of robust lyophilization processes for the development of stable peptide and
protein drug products that contain free thiols and/or disulfide bonds.
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CHAPTER 4. THIOL-DISULFIDE EXCHANGE IN HUMAN GROWTH
HORMONE

This work has been submitted to the FEBS Journal.

4.1

Abstract

Protein therapeutics such as hormones and monoclonal antibodies contain thiols
and/or disulfides that can participate in thiol-disulfide exchange reactions at neutral to
alkaline pH. This can result in the formation of mixed/scrambled disulfides that affect
protein therapeutic efficacy and elicit undesirable immunogenic responses upon
administration. Thiol-disulfide exchange reactions were monitored in recombinant human
growth hormone (rhGH) and model tryptic peptides derived from hGH (cT20-T21 and
T20-T21pep) to investigate higher-order structure effects on reaction kinetics. Different free
thiol-containing peptides (varying length and amino acid sequence) were used to initiate
thiol-disulfide exchange in intact hGH and in model peptides at pH 7.0 and 37 oC. Protein
samples were digested with trypsin and analyzed for native disulfides, scrambled disulfides
and free thiols on the LC-MS. For peptide-level studies, concentration of disulfide-linked
peptides were determined using RP-HPLC and product identity was confirmed on the LCMS. Loss of native disulfide in cT20-T21 and T20-T21pep within 60 min of reaction was
greater than loss of the C-terminal disulfide in hGH, consistent with higher-order structural
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effects. Of all the peptides tested, GSH was the most reactive, forming the highest
percentage of mixed disulfides in intact hGH and in the model peptides. At longer timepoints (>240 min) during the reaction, native disulfides in both hGH and cT20-T21 were
regenerated and the fastest rates of regeneration were observed for cysteine  and the
dipeptide CR. Tripeptides, RCR and QCR, had lower reactivity towards native disulfides
but facilitated faster regeneration of native disulfides compared to GSH.

4.2

Keywords

Human growth hormone, protein, peptide, kinetics, thiol-disulfide exchange,
glutathione

4.3

Introduction

In the biopharmaceutical industry, formation of correct disulfide links in
recombinant proteins is central to the development of safe and efficacious protein
therapeutics. While perturbation of native disulfide bonds is advantageous for regulating
the biological activity of enzymes such as thioredoxin reductase, disulfide bond disruption
is undesirable in protein drugs; mismatched disulfides can result in misfolding, aggregation,
loss of biological activity and stability [54]. To ensure drug quality and product
homogeneity, particularly with an increase in the development of biosimilars globally, the
presence of these scrambled disulfides and the extent of scrambling need to be determined
in protein therapeutics. A detailed mechanistic understanding of degradation pathways like
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thiol-disulfide exchange is expected to reduce attrition rates during drug development and
decrease the time to market protein drug products.
Formation of protein mixed disulfides (P-S-S-R) is not uncommon and occurs in
all biological environments, typically by two mechanisms; a) thiol-disulfide exchange; PS-S-P + R-SH ↔ P-S-S-R + P-SH and b) via sulfenic acid formation; P-SOH + R-SH →
P-S-S-R + H2O [61], where R-SH is any low-molecular weight thiol (reduced), P-S-S-P is
the native disulfide bond in a protein, P-SH is the protein with a free thiol, P-SOH is protein
sulfenic acid and P-S-S-R is the mixed disulfide. Thiol-disulfide exchange reactions are
favored at neutral to alkaline pH and the reaction proceeds via an SN2 nucleophilic
displacement. The oxidized form of low-molecular weight thiols (R-S-S-R) are used to
form protein disulfide bonds via oxidation while the reduced forms (R-SH) are used to
rearrange scrambled disulfide bonds in vivo. The leaving group typically has a lower pKa
compared to the central sulfur atom that is attacked by a thiolate anion [61]. For example,
small molecule catalysts that facilitate folding of proteins contain thiol groups with a low
pKa [176], which enhances the leaving group ability of the corresponding thiolate anion
(RS-) and increases the redox potential.
Intrinsic factors other than thiol pKa are also known to affect thiol-disulfide
exchange; these include ionic strength of the medium [63], geometric strain imposed on
the disulfide bond by higher-order structure [66] and stability of the native disulfide bond
relative to a non-native bond [65].
Proteins can form mixed/scrambled disulfides with other thiols, that are either
present as an impurity or in the protein as a free Cys [177,178]. The sulfur group that has
better exposure to the attacking nucleophile is more prone to undergo thiol-disulfide
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exchange reactions in comparison to more buried residues, even if it exists as a free Cys
[179]. These protein mixed disulfides can then initiate other thiol-disulfide exchange
reactions resulting in the formation of disulfide-linked aggregates. Disulfide bond
degradation in therapeutic proteins can also occur via β-elimination [3] and thiol-catalyzed
exchange [78] during processing and storage or after administration in vivo in the presence
of low-molecular weight thiols in serum [49]. In some proteins like monoclonal antibodies,
incomplete disulfide bond formation also results in free Cys [123] that can then initiate
disulfide-mediated degradation events.
Rearrangement of native disulfide bonds to form mixed disulfides via thioldisulfide exchange has been reported in a number of therapeutic proteins [14, 72, 78].
Disulfide-linked isomers of interleukin-2 (IL-2) were observed in the presence of a
chaotrope under alkaline conditions. IL-2 has one free Cys and one disulfide bond in its
native form, alkaline and denaturing conditions deprotonate the free thiol thus mediating
thiol-disulfide exchange reactions that generate less active disulfide-linked isomers [90].
Thiol-disulfide exchange reactions have also been observed in monoclonal antibodies, the
CH1 domain of IgG2 contains a free Cys that is involved in the formation of disulfidelinked oligomers (intermolecular disulfides) upon agitation stress [178]. While thioldisulfide exchange is known to occur in proteins and peptides, the effects of protein higherorder structure and peptide primary structure on reaction kinetics are not as well understood
and are the focus of studies reported here.
Human growth hormone is a therapeutic protein that is used for the treatment of a
number of growth related disorders; these include Turner’s syndrome, Prader-Will
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syndrome, chronic kidney insufficiency and hGH deficiencies. In 2012, hGH was one of
the top 200 pharmaceutical products by retail sales in the US [180]. Amino acid sequences
of the two native disulfide-containing tryptic peptides are shown in Table 4.1. There are no
free Cys residues in hGH, however, a free thiol group maybe generated via β-elimination
[3, 141] and can facilitate disulfide exchange and lead to loss of therapeutic efficacy. With
access to cDNA for hGH expression in-house, relatively small size of the protein and
results obtained previously for model tryptic peptides derived from hGH, hGH was the
model protein of choice for investigating thiol-disulfide exchange.
In our previous studies (Chapters 2 and 3), we investigated the mechanism and
kinetics of thiol-disulfide exchange in tryptic peptides derived from human growth
hormone in aqueous solution and in the solid state at a thiol: disulfide = 10: 1 (molar ratio)
[69, 181]. Results showed that peptide secondary structure (peptide cyclized by a disulfide
bond) offers protection against thiol-disulfide exchange in solution [69]. However, in the
solid state, no protection was observed and reaction kinetics were similar for both linear
and cyclic peptides while the mechanism remained unchanged [181]. Here, we report
experimental data for the effect of higher order structure and peptide primary structure on
thiol-disulfide exchange using model peptides and recombinant human growth hormone
(rhGH). Thiol-disulfide exchange reactions were monitored at a thiol: disulfide molar ratio
of 100: 1 at pH 7.0 and 37 oC. Results show that loss of native disulfide via thiol-disulfide
exchange in cT20-T21 and T20-T21pep (peptides mimicking native C-terminal disulfide in
hGH) is greater than loss of native disulfide in hGH in the presence of T20a, GSH, RCR,
CR and C, indicating the role of higher-order structure. GSH was the most reactive of all
free-thiol containing peptides used to initiate thiol-disulfide exchange, resulting in 84.7%
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and 57.7% loss of native disulfide in cT20-T21 and hGH respectively. Tripeptides, RCR
and QCR had lower reactivites towards the native disulfide when compared to GSH but
favored faster (>GSH) regeneration of native disulfides in hGH. In the presence of RCR,
native disulfide was faster than with QCR. Loss of native disulfide was the lowest and
regeneration of the native disulfide was the fastest with free thiols CR and C.

4.4

Materials

HPLC grade acetonitrile (ACN), NaCl and KCl were purchased from Fisher
Scientific Co. (Pittsburgh, PA). H2O2 and Na2CO3 (anhydrous granules) were obtained
from Mallinckrodt Baker Inc. (Phillipsburg, NJ). K2HPO4, ethylenediaminetetraacetic acid
(EDTA), Trizma® hydrochloride (Tris.HCl), urea, sucrose, glutathione (oxidized-GSSG),
glutathione (reduced-GSH), L-Cysteine (Cys/C) and glycerol were purchased from Sigma
Chemical Co. (St. Louis, MO). Trifluoroacetic acid (TFA) and formic acid (FA) were
obtained from Thermo Scientific (Rockford, IL). Double-distilled water (DDI) used for
buffer preparation and as HPLC mobile phase was deionized and purified using a Milli-Q
water system, Millipore Ltd (Billerica, MA) and filtered with a 0.2 µm filter. Flash digest
kit (trypsin) for protein digestion was obtained from Perfinity Biosciences (West Lafayette,
IN). Human growth hormone (1 mg/mL) was purchased as a lyophilized powder (0.34 mg
phosphate buffer and 8 mg mannitol) from ProSpec-Tany TechnoGene Ltd., Ness Ziona,
Israel. Synthetic peptides were obtained from GenScript (Piscataway, NJ).
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4.5

4.5.1

Method

hGH expression and purification
The plasmid containing the recombinant human growth hormone (r-hGH)

expression gene was obtained from Dr. J. Laurence (Kansas University). This plasmid
codes for hGH with an additional 28 amino acids at the N-terminus with a molecular weight
of 25 kDa (Figure 4.1). The plasmid was transformed into the BL21 (DE3) E.coli cells for
protein expression, using the protocol provided by New England BioLabs. Cells carrying
the plasmid for hGH were grown in terrific broth media containing 100 µg/ mL ampicillin
in an incubator shaker at 37° C. The cells were induced at OD600 = 0.8 with 1 mM IPTG.
Post-induction was carried out in incubator shaker at 20° C for 16 hours. Expression of rhGH in the induced cells was checked with 12% SDS-PAGE and was found to be overexpressed as inclusion bodies (Figure 4.2a).
Purification of rhGH: rhGH was purified using the method as described previously
[182]. Induced E.coli cells were harvested by centrifugation at 6500 rpm for 15 min. The
cell pellet was resuspended in 50 mM Tris-HCl, 100 mM NaCl, 5 mM EDTA at pH 8.0
and sonicated to lyse the cells. r-hGH inclusion bodies were separated from the soluble cell
lysate by centrifugation at 13, 000 rpm for 30 mins. The pellet with cell debris was
resuspended in buffer, 50 mM Tris-HCl, 5 mM EDTA, 1% deoxycholate (DOC) at pH 8.0,
sonicated and centrifuged to further clarify the inclusion bodies. The pellet was washed
with buffer, 50 mM Tris-HCl at pH 8.0 and centrifuged to remove any DOC from the
previous step. Pure inclusion bodies were solubilized in buffer containing 100 mM TrisHCl and 2 M Urea at pH 12.5. The solution were further diluted 10 times in a buffer
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containing, 50 mM Tris-HCl, 2 M Urea, 0.5 mM EDTA, 3 mM GSH, 0.6 mM GSSG, 10%
Glycerol and 2% sucrose at pH 8.0. Refolding of r-hGH was carried out by the step-wise
dialysis of the protein solution against buffer 50 mM Tris-HCl, 0.5 mM EDTA, 10%
Glycerol, 2% sucrose at pH 8.0 by descending the concentration of urea from 2-0 M at each
step (1.5, 0.5 and 0 M). The refolded r-hGH was filtered and purified further using a HiPrep
26/60 Sephacryl S-100 high resolution column (Amersham Biosciences) equilibrated with
50 mM Tris-HCl, 2% sucrose at pH 8.0 and the fraction containing the monomeric r-hGH
were checked with 12% SDS-PAGE for the purity (Figure 4.2b). Concentration of purified
hGH was determined using a UV-Vis spectrophotometer (Agilent Technologies, Santa
Clara, CA). MS analysis of the purified protein confirms the presence of two native
disulfide bonds as found in the commercially available recombinant hGH (Figure 4.3 and
Table 4.1). Near-UV CD analysis with a J-815 CD spectrometer (JASCO, Easton, MD)
was used to assess protein tertiary structure.

H2N-MKYLLPTAAAGLLLLAAQPAMAMAHHHHFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQN
PQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGR

LEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF-COOH

Figure 4.1: Amino acid sequence of hGH expressed and purified in our lab (MW = 25
kDa). Sequence highlighted in blue shows the additional 28 amino acids at the N-terminus.
Highlighted in yellow are the four Cys residues and the native disulfide bonds are
represented by the red dotted lines.
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Figure 4.2: Expression and purification of rhGH: (A) Expression of r-hGH in uninduced (lane
1) and induced (lane 2) culture was checked with 12% SDS-PAGE. (B) Purification of refolded
r-hGH in HiPrep 26/60 Sephacryl S-100 high resolution column (Amersham Biosciences,
Piscataway, NJ). Gel filtration chromatogram showing the resolved monomeric r-hGH. Inset,
12% SDS-PAGE shows the purified r-hGH (lane 1). (M: Molecular weight marker).

Figure 4.3: Total ion chromatogram for the tryptic digest of r-hGH. The two native disulfide
bonds are in peptides T6-T16 and T20-T21 with retention times 26.1 and 12.17 min respectively.
The figure insets show the isotope pattern and charge states of the two disulfide-containing
peptides.

134
4.5.2

Thiol-disulfide exchange in model peptides
RP-HPLC analysis: peptide samples were analyzed using an Agilent 1200 series

HPLC system equipped with a UV-detector operated at 215 nm. Analytical column and
gradient elution were the same as described previously [69]. Calibration plots were linear
in the following concentration ranges; 5-500 µM (T20-T21pep), 20-200 µM (T20), 20-200
µM (T21), 5-500 µM (cT20-T21), and 5-500 µM (rT20-T21).

Sample preparation: Peptides T20a (GIVQCR), T20 (IVQCR), CR, RCR, QCR,
cT20-T21, T20-T21pep and rT20-T21 (Table 4.2) were obtained from GenScript
(Piscataway, NJ) with >90% purity as lyophilized powders. Stock solutions were made in
0.1% formic acid in DDI (pH ~ 2.5) to minimize oxidation of free thiols. Peptide T20a was
synthesized to study thiol-disulfide exchange in intact hGH and draw comparisons to
previous studies with model peptides, where T20 was used as the reactive thiol [69, 181].
Using T20 to initiate disulfide exchange in hGH would make differentiation of scrambled
and native disulfides difficult, for example, T20-T21 could be the native disulfide, product
of disulfide exchange with T20 or an intermolecular disulfide (between two protein
molecules). T20a is similar in sequence to T20 with the addition of a Gly at the N-terminal,
this difference allows easy identification of scrambled disulfides with T20a. To determine
reactivity of T20a and to investigate buffer effect, reaction of T20a with T20-T21 peptide
(thiol: disulfide = 10: 1) was monitored kinetically in 10 mM phosphate buffer (PB) and
50 mM Tris.Hcl with 2% sucrose at 22 oC. Final pH of the reaction mixture was 7.0,
samples were analyzed as described previously [69]. kobs (Pseudo-first order) for the loss
of T20-T21 is similar in PB and Tris.HCl with 2% sucrose (Figure 4.4). Thus all peptide-
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level studies were monitored kinetically in 10 mM PB to quantitate thiol-disulfide
exchange.
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Figure 4.4: Change in concentration of T20-T21 (♦) for the reaction with A) T20a (10 mM
PB, pH 7.0, 0.08 M ionic strength, 0.5 mM EDTA and N2 sparged) and with B) T20a (50
mM Tris.HCl and 2% sucrose, pH 7.0) at 22 oC (n=3, +/- SD). Initial concentration of
peptides were; [T20a] = 500 µM and [T20-T21] = 50 µM.
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Investigating the effect of amino acid sequence and peptide length on thioldisulfide exchange: reaction kinetics were monitored at pH 7.0 and 37 oC in aqueous
solution. For the reaction, 1500 µL of T20a/T20/GSH/RCR/QCR/CR/C (12500 µM), 1500
µL of T20-T21pep/cT20-T21 (125 µM) and 750 µL of 50 mM phosphate buffer (0.08 M
ionic strength and 0.5 mM EDTA) were added to a 15 mL BD falcon tube and mixed by
pipetting. The final pH of the reaction mixture was adjusted to 7.0 using NaOH or HCl
(exact volume to be added was determined from pilot studies) after a 100 µL aliquot was
removed and quenched with 10 µL 20% formic acid in DDI (FA) to verify initial
concentrations (t=0 min). Samples were withdrawn in triplicate at different time points,
quenched with 20% FA, analyzed and quantitated using RP-HPLC as described in Chapters
2 and 3.

4.5.3

Enzymatic digestion using the Perfinity flash digest protocol
hGH samples were added to the Perfinity flash digest kit tubes with digestion buffer

(ratio of sample to buffer was 1:2.4). Digestion was performed at 60 oC and 1400 rpm using
a ThermoMixer C (Eppendorf, Hauppauge, NY) for 15-17 mins. Digested samples were
then transferred to microcentrifuge tubes and centrifuged at 14000 rpm for 2 mins. After
centrifugation, the supernatant was removed, quenched with 10 µL of 20% FA in DDI and
analyzed on the LC-MS (~20 µL).

4.5.4

Removal of unreacted peptides using a desalting column
To minimize scrambling during digestion, ZebaTM spin desalting columns with 7K

MWCO (Pierce Biotechnonogy, Rockland, IL) were used to remove any unreacted
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peptides from the reaction mixture with hGH. The spin columns were first placed in an
empty collection tube (1.5-2 mL) and centrifuged at 4700 rpm using an Eppendorf
centrifuge (Eppendorf, Hauppauge, NY) equipped with a F45-11-12 rotor for 1 min to
remove the storage buffer. Reacted samples (80-85 µL) were then added carefully to the
center of the resin bed. After the sample had adsorbed onto the resin bed, the spin columns
were then placed inside new collection tubes and centrifuged at 4700 rpm for 2 mins.
Desalted sample was collected and digested using the Perfinity flash digest kit as described
above and analyzed on the LC-MS.

4.5.5

LC-MS analysis and disulfide bond identification using MassHunter software
Mass analyses were carried out on an LC-MS system (1200 series LC, 6520 qTOF,

Agilent Technologies, Santa Clara, CA). Peptides in the digested samples were separated
prior to MS analysis using a Zorbax 300SB-C18 column from Agilent Technologies.
Solvent A was 0.1% FA in water and solvent B was 0.1% FA in ACN. A gradient run was
initiated with 5% B then held at 5% for 5 min and increased to 20% in 8 min, in the next
step gradient was increased to 25% in 10 min and to 60% in 5 min. followed by an increase
to 100% in 0.6 min, decreased to 0% in 0.6 min and finally returned to 5% in 2.4 min. The
flow rate was maintained at 50 µL/min and the column temperature was not controlled. To
determine native and scrambled disulfide species, a library of all peptides containing a
disulfide bond and/or free Cys was generated. Briefly, amino acid sequence of hGH was
entered into the software and after selecting the digestion enzyme and missed cleavages,
an in silico digest was performed. We used trypsin as the enzyme and the number of missed
cleavages was set to four to generate a list of all possible tryptic fragments. The same
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process was then repeated by switching out native disulfides to scrambled disulfides and
free thiols. From these lists, all peptides with disulfide bonds and/or free cysteines were
selected and combined to create a mass filter list. Mass spectra of all digested hGH samples
were then scanned against the mass filter list to determine the presence of scrambled
disulfides and the extent of disulfide scrambling. Loss of native disulfide (T20-T21) was
monitored at different reaction times using peak areas from extracted ion chromatograms
(XIC); concentration was calculated using the calibration plot (Figure 4.5) constructed with
a peptide standard from GenScript (Piscataway, NJ). Similar calibration plots were
constructed for T20 and T21 using peptide standards.

4.5.6

Thiol-disulfide exchange in hGH
For the reaction of hGH with thiol-containing peptides (T20a, GSH RCR or CR)

and C, 280 µL of hGH purified in-house (0.56 mg/mL or 22.4 µM) in 50 mM Tris.HCl
buffer and 2% sucrose (pH 8.0) was mixed with 70 µL T20a/GSH/RCR/CR/C (8950 µM
in 0.1% FA in DDI). The pH of the final reaction mixture was 7.0 and the final molar ratio
of peptide to protein was 100:1 (1790 µM: 17.9 µM). 90 µL aliquots of the reaction mixture
were then transferred to microfuge tubes (n=3 for each time point) and placed in an
incubator at 37 oC. Samples were withdrawn in triplicate at various times, desalted,
digested and analyzed using LC/MS as described above. Control samples (hGH alone or
model disulfide peptides alone) were diluted, desalted and digested as for the reaction
samples at other time points. To determine contributions from the additional 28 amino
acids in the modified hGH expressed in-house, the reaction of Prospec hGH with GSH was
also monitored. Prospec hGH was first buffer exchanged (overnight at 4 oC) into 50 mM
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Tris.HCl and 2% sucrose before reaction with GSH. Sample dilution and analysis were
carried out as above.
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Figure 4.5: Calibration plot for T20-T21 (synthetic standard from GenScript); constructed
using peak areas (n=3, +/- SD) from XIC at different peptide concentrations.
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Table 4.1: Amino acid sequence of disulfide-linked peptides in hGH: native and scrambled
disulfides

Tryptic peptide

Description

T6-T16

Native
disulfide- linked
peptide

T20-T21

Native
disulfide- linked
peptide

Amino acid sequence

Theoretical
mass (Da)

Observed
mass (Da)

3760.766

3760.7903

1399.6225

1399.6243

NH2- YSFLQNPQTSLCFSESIPTPSNR-OH
NH2- NYGLLYCFR-OH
NH2- IVQCR-OH
NH2- SVEGSCGF-OH

T6

Monomer, free
thiol group

NH2- YSFLQNPQTSLCFSESIPTPSNR-OH

2615.233

2615.2284

T16

Monomer, free
thiol group

NH2- NYGLLYCFR-OH

1147.549

1147.5412

T20

Monomer, free
thiol group

NH2- IVQCR-OH

617.3319

617.33

T21

Monomer, free
thiol group

NH2- SVEGSCGF-OH

784.3061

784.3017
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Table 4.2: Amino acid sequence of model peptides used to investigate thiol-disulfide
exchange reactions

Peptide

Description

Amino acid sequence

Disulfide-linked peptides
cT20-T21

Cyclic peptide

T20-T21pep

Heterodimer,
disulfide-linked
peptide

NH2-IVQCRSVEGSCGF -OH
NH2- IVQCR-OH
NH2- SVEGSCGF-OH

Free thiol-containing peptides
rT20-T21

Monomer, free
thiol group

NH2- IVQCRSVEGSCGF-OH

T20a

Monomer, free
thiol group

NH2- GIVQCR-OH

T20

Monomer, free
thiol group

NH2- IVQCR-OH

GSH

Monomer, free
thiol group

NH2- ECG-OH

RCR

Monomer, free
thiol group

NH2- RCR-OH

QCR

Monomer, free
thiol group

NH2- QCR-OH

Monomer, free
thiol group

NH2- CR-OH

CR

4.5.7

Near-UV CD measurement
Near-UV CD spectroscopy was used to assess the effects of disulfide reduction on

the tertiary structure of hGH. Samples with and without 5 mM β-mercaptoethanol were
diluted to 2 μM final hGH concentration. Molar ellipticity was measured on a JASCO J815 spectrometer (JASCO Analytical Instruments, Easton, MD) in a 10 mm path length
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quartz cuvette. Spectra were acquired for wavelengths of 250 nm to 350 nm at a scanning
speed of 50 nm/min.

4.5.8

Amide hydrogen-deuterium exchange mass spectrometry (HDX-MS)
HDX-MS was conducted to determine the solvent accessibility of hGH under native

and reduced conditions. A 2 mg/mL solution of hGH was prepared in buffer containing 10
mM sodium phosphate, 1.6 % mannitol, pH 7.0 (buffer A). To obtain reduced hGH, a 2
mg/mL solution was prepared in buffer containing 10 mM sodium phosphate, 1.6 %
mannitol, 10 mM DTT, pH 7.0 (buffer B) and incubated on ice for 1 h. HDX was initiated
by mixing 3 μL of the sample with 27 μL of deuterated buffer A and buffer B for native
and reduced hGH, respectively. Exchange was carried out at 23 ˚C for 10 s to 10 min.
Reactions were quenched by adding 30 μL of ice cold buffer containing 0.2 M sodium
phosphate, 0.5 M Tris(2-carboxyethyl)phosphine hydrochloride, 6 M guanidine
hydrochloride to a final pH of 2.5. Deuterium uptake was measured using a the LC/MS
system described above and equipped with a custom-built column refrigeration unit (0 ˚C)
to minimize back exchange. Approximately 50 pmol of protein was injected onto to an
immobilized pepsin column. The digests were desalted and trapped in a peptide microtrap
(Michrom Bioresources, Auburn, CA) with 10% ACN, 90% water, and 0.1% for 4 min.
Peptides were eluted onto a reverse phase analytical column (Zorbax 300SB-C18; Agilent
Technologies, Santa Clara, CA) for 4.3 min using a gradient to 60% ACN, 40% water, and
0.1% FA. Mass spectra were acquired in the m/z range 200-1700. Peptic digests of
undeuterated hGH were analyzed and their mass identified using the MassHunter software
(Agilent). Peptides identified from undeuterated hGH were mapped onto data from
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deuterated samples using HDExaminer software (Sierra Analytics, Modesto, CA) to
determine the level of deuterium uptake. The analysis times for all HDX samples were very
similar, so that the observed deuterium uptake values were not subjected to back-exchange
corrections. Data from 5 min HDX were mapped onto the crystal structure of hGH (PDB
ID: 1 HGU) using PyMOL software (PyMOL Molecular Graphics System, Version 1.3,
Schrodinger, LLC).

4.6

4.6.1

Results

Thiol-disulfide exchange in hGH: product identification
Thiol-disulfide exchange in hGH was investigated using T20a, GSH, cysteine (C)

and several small Cys-containing peptides such as CR and RCR (Table 4.2), to explore the
effects of different thiol containing molecules on reaction kinetics. Control samples
containing hGH alone incubated at 37 oC and analyzed after 60 mins and 1 day did not
show scrambled species (data not shown), indicating that disulfide exchange does not occur
under the conditions investigated here in the absence of a free thiol group. LC/MS analysis
of intact protein samples during the reaction of hGH with T20a showed peaks
corresponding to protein mixed disulfides with T20a (data not shown), confirming that
thiol-disulfide exchange does not occur during digestion. The list of scrambled species
observed for hGH in reaction with various thiol-containing peptides, the amino acid
sequences of the scrambled products, their molecular weights and their chromatographic
retention times are listed in Table 4.3, 4.4 and 4.5, respectively.
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For the reaction of hGH with T20a (at thiol: disulfide = 100:1), four scrambled
disulfides; T20a-T20, T20a-T21, T20a-T6 and T20a-T16 (Table 4.3) and free thiols; T6,
T16, T20 and T21 (Table 4.1) were identified. No inter- or intra-molecular disulfides were
detected at any time point during the reaction. GSH is commonly used in protein refolding
and is also known to form mixed disulfides with proteins [61, 67]. In the reaction of hGH
with GSH, the loss of both native disulfides (T20-T21, T6-T16) was observed within a few
minutes resulting in the detection of mixed disulfides (Table 4.3) and free thiols (Table
4.1). The data are consistent with a reaction mechanism identical to that proposed for T20a
(Scheme 4.1), since no other degradation products were detected.
Interestingly, for the reaction with CR, the mixed disulfide (T20-CR) and free thiols
(T6, T16 and T21) were not detected in any of the samples. All the other mixed disulfides,
T21-CR, T6-CR and T16-CR and T20 were detected (Table 4.4). Mixed disulfides (T6RCR, T16-RCR and T21-RCR) and free thiols (T20 and T6) were detected for the reaction
of hGH with RCR (Table 4.5). With C as the thiol reagent, the loss of the native disulfide
was slower than for T20a, GSH or CR. Only T21-C and T20 were detected (Table 4.5);
mixed disulfides (T20-C, T6-C and T16-C) and free thiols (T6, T16 and T21) were not
detected. The detection of scrambled disulfides at all four Cys residues in hGH suggests
that both native disulfides are prone to attack by a reactive thiolate anion in aqueous
solution at pH 7.0. It is interesting that in the presence of C, scrambling was detected only
at the C-terminal disulfide bond. This may be due to rapid regeneration of the native
disulfides, so that the mixed disulfides go undetected at the reaction times monitored here.
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Table 4.3: Amino acid sequence of mixed disulfide-linked peptides from hGH: for the
reaction of hGH with T20a.

Table 4.4: Amino acid sequence of mixed disulfide-linked peptides from hGH: for the
reaction of hGH with GSH.
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Table 4.5: Amino acid sequence of mixed disulfide-linked peptides from hGH: for the
reaction of hGH with CR, C and RCR.

4.6.2

Thiol-disulfide exchange in hGH: product quantitation
Thiol-disulfide exchange in hGH was quantified for the C-terminal disulfide bond,

which links the tryptic peptides T20 and T21. Quantitative analysis of disulfide scrambling
in T6-T16 was not performed due to the lack of peptide standards (i.e., for T6-T16, T6 and
T16) and the low aqueous solubility of T6. At the C-terminal disulfide bond (T20-T21),
the concentrations of T20-T21, T20 and T21 were determined using XIC peak areas and
calibration curves prepared using synthetic peptide standards. The concentrations of
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protein-thiol mixed disulfides were determined from mass balance: [Mixed disulfides] =
[T20-T21]total – ([T20-T21]t + ([T20] + [T21])/2). Intra- and intermolecular disulfides and
products of thiol oxidation such as sulfenic, sulfinic and sulfonic acid were not detected.
Thus, it was assumed that disulfide bond cleavage of 1 mol of T20-T21 releases 1 mol of
T20 and 1 mol of T21 that are present either in their free thiol form or in mixed disulfides.
The percent loss of native disulfide at different times during the reaction was determined
from [T20-T21] in the control sample (i.e., at t = 0) and [T20-T21] at time, t.
The distributions of mixed disulfides, free thiols and the native disulfide (T20-T21)
over time for the reaction of hGH with different thiols are shown in Figures 4.6 and 4.7.
Loss of native disulfide (%) in the presence of free thiol-containing peptides and C is
reported in Table 4.6. After 60 min, T20-T21 showed the greatest loss with with GSH and
the least with C. After 1 day, the native disulfide was regenerated to a greater extent with
C followed by CR and RCR (Table 4.6). The presence of an Arg residue adjacent to Cys
was found to favor regeneration of the native disulfide over GSH. A similar product profile
was obtained for Prospec hGH (22kDa) for the reaction with GSH (Figure 4.8), suggesting
that the leader sequence at the N-terminus in the hGH expressed in-house (25 kDa) does
not influence thiol-disulfide exchange appreciably.
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Figure 4.6: Concentrations of T20-T21 (♦), T20 (■), T21 (●) and T20a-T20+T20a-T21 or
T20-S-S-G+T21-S-S-G (▲) for the reaction of hGH with T20a (A) and GSH (B) at pH 7.0
(40 mM Tris.HCl and 1.6% sucrose) and 37 oC (n=3, +/- SD). Initial molar ratio of thiol:
hGH was 100:1. Concentration of hGH alone before reaction with T20a is represented by
◊. Lines on plot are to improve readability and do not represent regression analysis.
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Figure 4.7: Concentrations of T20-T21 (), T20 (), T21 (●) and mixed disulfides (▲)
for the reaction of hGH with (A) RCR, (B) CR and (C) C at pH 7.0 (40 mM Tris.HCl and
1.6% sucrose) and 37 oC (n=3, +/- SD). Initial molar ratio of thiol: hGH was 100:1. Control
sample represents hGH alone before reaction with CR. Lines on plot are to improve
readability and do not represent regression analysis.
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Figure 4.8: Concentrations of T20-T21 (), T20 (), T21 (●) and T20-S-S-G+T21-S-SG (▲) for the reaction of Prospec hGH with GSH at pH 7.0 (40 mM Tris.HCl and 1.6%
sucrose) and 37 oC (n=3, +/- SD). Initial molar ratio of thiol: hGH was 100:1. T=0 min
sample represents hGH alone before reaction with GSH. Lines on plot are to improve
readability and do not represent regression analysis.
4.6.3

Effect of higher order structure on thiol-disulfide exchange
To investigate the effects of higher order structure on thiol-disulfide exchange and

to show that close proximity of a free thiol group to a disulfide bond is a prerequisite for
regeneration of native disulfide bonds, model disulfide-linked peptides were used. Thioldisulfide exchange was monitored in cT20-T21 and T20-T21pep at pH 7.0 and 37 oC. For
cT20-T21, the concentrations of the single mixed disulfides (SMDs) and the double mixed
disulfide (DMD) (Scheme 4.1) were determined from mass balance; [SMDs + DMD] =
[cT20-T21]o –([cT20-T21]t + [rT20-T21]t) as synthetic peptide standards for SMDs and
DMD were not available. For T20-T21pep, the same mass balance equation described above
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was used for quantitation. In the presence of GSH (Table 4.2), SMDs and DMD and rT20T21 were formed via thiol-disulfide exchange of the native bond in cT20-T21 (Scheme 4.1;
Figure 4.9a). Though similar products (SMDs, DMD and rT20-T21) were observed for the
reaction of cT20-T21 with all free thiols (Figure 4.10), the time courses of product
distribution differed. As in hGH, the native disulfide was regenerated in cT20-T21 after 1
day (Table 4.6).
Thiol-disulfide exchange in T20-T21pep: Disulfide bond cleavage in T20-T21pep via
thiol-disulfide exchange resulted in the formation of mixed disulfides with GSH (T20-SS-G & T21-S-S-G), free thiols (T20 & T21) and trace amounts of homodimers (T20-T20
& T21-T21) (Figure 4.9b). At the end of 2 days, T20-T21pep was consumed completely,
unlike thiol-disulfide exchange studies with cT20-T21 and hGH in which the native
disulfides were regenerated. These results obtained with disulfide-linked peptides suggest
that the higher order structure influences reactivity, making the native disulfides less
accessible to attack by a thiolate anion in hGH (determined by % loss of native disulfide
shown in Table 4.6) but does not inhibit the reaction completely. Thus, proximity of thiol
groups to a disulfide bond (dictated by peptide/protein structure) determines the type of
disulfide bond (intra vs. inter) that can be re-formed. The presence of an Arg residue
adjacent to Cys in the thiol influences the rate and extent of regeneration.
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Figure 4.9: Concentrations of species for the reaction of cT20-T21/T20-T21pep with GSH
at pH 7.0 (10 mM phosphate buffer) and 37 oC (n=3, +/- SD), initial molar ratio of GSH:
cT20-T21/T20-T21pep was 100:1. A) Concentrations of cT20-T21 (♦), rT20-T21 (■) and
SMDs + DMD (▲). B) Concentrations of T20-T21pep (♦), T20 (■), T21 (●) and mixed
disulfides (▲). T=0 min represents concentration of native disulfide (cT20-T21/T20T21pep) before initiation of reaction by adjusting the pH to 7.0. Lines on plot are to improve
readability and do not represent regression analysis.
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Figure 4.10: Distribution of cT20-T21 (♦), rT20-T21 (■) and SMDs+DMD (▲) for the
reaction of cT20-21 with A) T20a, B) CR, C) RCR, D) QCR and E) C and F) T20 at pH
7.0 and 37 oC in 10 mM PB (0.08 M ionic strength, 0.5 mM EDTA and N2 sparged). T=0
min represents sample collected before reaction was initiated by adjusting pH to 7.0, thiol:
disulfide ratio was 100: 1 (molar ratio).
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Table 4.6: The change in native disulfide concentration in peptides and hGH obtained after 1 hour
and 1 day for thiol-disulfide exchange reactions with different free thiols at pH 7.0 and 37 oC.
Disulfide

% decrease of native
disulfide after 60 mins

% decrease of native
disulfide after 1 day

GIVQCR (T20a)

61.9±4.8

53.7±1.7

IVQCR (T20)

70.5±1.1

64.5±1.2

Thiol

pH

o

Temp ( C)

GSH
cT20-T21

T20-T21 in
hGH (intact)

4.6.4

84.7±3.5

76.8±1.2

49.9±0.1

23.9±0.1

QCR

59.2±1.3

39.3±0.5

CR

66.2±0.9

8.3±0.5

C

57.3±0.4

13.7±0.2

GIVQCR (T20a)

37.5±6.8

37.1±5.8

GSH

57.7±6.1

23.9±4.4

35.8±7.9

11.4±1.4

CR

20.7±5.5

6.8±1.8

C

16.7±0.5

3.8±2.6

RCR

RCR

7

7

37

37

Effect of hGH structure on regeneration of native disulfide
To measure the extent of loss of hGH native structure upon disulfide bond cleavage

breakage, and to correlate the regeneration of native disulfides following thiol-disulfide
exchange, near-UV CD spectroscopy and amide HDX-MS were conducted for hGH in both
oxidized and reduced states. Near-UV CD showed no appreciable differences in tertiary
structure between the native and reduced forms (Figure 4.11).
HDX-MS has been widely used to study protein structure and conformation at
peptide level resolution [183]. Here, a total of 31 peptic peptides covering 100% of hGH
sequence were identified and analyzed. Comparison of the level of deuterium uptake
between the native and reduced state showed no appreciable differences (Figure 4.12),
suggesting that hGH retains its native structure after disulfide bond cleavage. The Cterminal peptide fragment, 182-191 containing the two cysteine residues (C182 and C189)
are involved in disulfide formation is ~ 50% deuterated in both the native and reduced
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states. Similarly, peptide fragment 47-53 containing C53 and fragment 160-172 containing
C165 showed 53% and 38% deuterium uptake, respectively. Subtractive analysis of peptide
fragments 160-172 and 166-175 shows that residues 160-165 are more than 60% deuterated.
Overall, the near-UV CD and HDX-MS results suggest that the disulfide containing regions
in hGH are highly solvent accessible and that the structure of fully reduced hGH is close
to the native state. This suggests that the regeneration of native disulfide bonds following
disulfide exchange may be favored by the orientations of the native Cys partners in close
proximity to one another.

20000
0

Molar ellipticity

-20000
-40000
-60000
-80000
-100000
-120000
-140000
-160000
250

260

270

280
290
Wavelength (nm)

300

310

320

Figure 4.11: Near-UV CD spectra for hGH native (solid line) and reduced (dotted line).
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Figure 4.12: Crystal structure of hGH (PDB ID: 1 HGU) representing the percent
deuterium uptake in native (A) and reduced (B) state following 5 min of HDX. Data from
31 overlapping peptic fragments were mapped onto the structure.
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Scheme 4.1: Thiol-disulfide exchange at the C-terminal disulfide bond (T20-T21) in
hGH/disulfide bond in cT20-T21; R-S- is the thiolate form of the free thiol-containing
peptide (Table 4.2) and R-S-S-R is the oxidized form. The blue dashed lines represent a
trypsin cleavage site in hGH.
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Figure 4.13: Concentration vs time plot for the loss of cT20-T21 (n=3, +/- SD) during the
reaction with GSH, CR, RCR, QCR and C at pH 7.0 and 37 oC in 10 mM PB (0.08 M ionic
strength, 0.5 mM EDTA and N2 sparged). Initial thiol: disulfide was 100:1 (molar ratio).
Lines on plot are to improve readability and do not represent regression analysis.
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4.7

Discussion

In the studies reported here, thiol-disulfide exchange reactions between intact
hGH/cT20-T21/T20-T21pep and free thiol-containing peptides (Table 4.2) were
investigated in aqueous solution at pH 7.0 and 37 oC. The amino acid sequences of native,
scrambled and free thiol containing peptides and their masses are shown in Tables 4.1, 4.2,
4.3, 4.4, 4.5 and C.2. From our previous studies with hGH-derived peptides [69, 181] and
other reports [45, 71], it is well known that thiol-disulfide exchange is favored at neutral to
alkaline conditions. Although thiol-disulfide exchange was observed at both the native
disulfides in hGH (T20-T21 and T6-T16), quantitative analysis of disulfide scrambling was
performed only for the C-terminal disulfide.
After purification, hGH was digested using the Perfinity flash digest kit and
analyzed using LC/MS for the presence of native, scrambled disulfides and free thiols.
Perfinity digestion was compared with overnight digestion with trypsin in solution and
with digestion with trypsin immobilized on magnetic and agarose beads to determine
digestion efficiency (Table C.1, Appendix C). For all digestion protocols except the flash
digest kit, scrambled disulfides were detected and digestion was incomplete after 60 min
(Table C.1). In contrast, digestion with the flash digest kit was complete in 17 min and no
scrambled disulfides were detected.
For the reaction of hGH with different thiol-containing peptides, products generally
conforming to Scheme 4.1 were detected (except intermolecular disulfides), and the
distribution of these species varied with reaction time. Mixed disulfides were detected at
both the disulfide bonds (T20-T21 and T6-T16) and fully reduced forms of the native
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disulfides (Table 4.1) were also observed. The reactivity of the C-terminal native disulfide
(T20-T21) in hGH decreased in the order GSH>T20a>RCR>CR≈C and regeneration of
native disulfides was favored over the formation of mixed disulfides in the order
C≈CR>RCR>GSH>T20a (Table 4.6). Though most of the native disulfides were
regenerated in the presence of GSH (75-80%), RCR (85-90%), CR (92-95%) and C (9499%), the presence of even low levels of mixed disulfides may be detrimental to the
therapeutic efficacy and stability of hGH, given the functional roles of the two native
disulfide bonds. The C-terminal disulfide bond (T20-T21) is required for binding to the
growth hormone receptor and to maintain normal stability, while the disulfide bond in T6T16 is necessary for biological activity [91].
The concentration of hGH can also influence thiol-disulfide exchange and/or
disulfide scrambling, though these effects were not investigated here. For example, in
studies of porcine somatotropin (porcine hGH), disulfide exchange led to the formation of
irreversible thixotropic gels (disulfide-linked aggregates) at concentrations > 25 mg/mL
during storage at 39 oC for 14 days [184]. Initial concentrations used in our studies range
from 0.3 to 0.45 mg/mL, concentrations ~ 100-fold lower than those used by Buckwalter
et al. High hGH concentrations within the secretory granules (50-100 mg/mL) also favor
intermolecular exchange and result in the formation of disulfide-linked dimers and
oligomers [137, 185]. Due to the low yield of hGH purified in-house (<0.6 mg/mL) and
the cost of commercially available hGH, studies at higher concentrations were not practical
here, and the absence of any intermolecular disulfides (Table C.2 in Appendix C) may
reflect low hGH concentrations.
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SMDs, DMD and rT20-T21 were identified as products of the reaction of cT20T21 with all the free thiol-containing peptides (Table 4.2). Oxidation products such as
cysteine sulfenic, sulfinic and sulfonic acid and thiosulfinates were not detected, and
Scheme 4.1 effectively describes the products observed. Overall, the loss of native disulfide
in cT20-T21 after 60 min decreases in the order GSH>T20>CR>T20a>QCR>C>RCR and
regeneration

of

native

disulfide

is

favored

after

1

day

in

the

order

CR>C>RCR>QCR>T20a>T20>GSH. The amino acid length of all peptides used here
ranges from 1-5. The results suggest that thiol size in this range has no effect on reactivity.
In contrast primary sequence, particularly the presence of Arg adjacent to a Cys, promotes
the reformation of the native disulfide. The loss of native disulfide (% loss in 60 min) in
cT20-T21 is greater than the loss of native disulfide (T20-T21) in hGH with GSH, T20a,
RCR, CR and C (Table 4.6).
Native disulfides in hGH were re-formed in the presence of GSH, RCR, CR, C and
to a lesser extent with T20a. Rabenstein et al. made a similar observation with somatostatin
and GSH. At concentrations of GSH less than 4 mM, Rabenstein et al observed that the
rate of thiol-disulfide exchange to re-form the native disulfide was faster than the rate of
thiol-disulfide exchange to form the fully reduced form [119]. The authors also concluded
that the conformational properties of the mixed disulfides may place the mixed disulfide in
close proximity to the thiol group that then regenerates the native disulfide. Similar results
have been reported for the reaction of small heat shock protein 25 (Hsp25) with GSH,
where the formation of an intersubunit protein disulfide (native disulfide) is preferred over
the mixed disulfides [67]. Here, near-UV CD and HDX-MS of both reduced (with BME)
and non-reduced hGH (Figures 4.11 and 4.12) showed no differences in higher order
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structure, thus favoring regeneration of native disulfides. Youngman et al. have shown that
folding of hGH is similar in the presence and absence of disulfide bonds [151], further
suggesting that disulfide bond reduction does not affect protein structure.
Regeneration of native disulfides was fastest in the presence of RCR, CR and C.
For the reaction of hGH with C, formation of mixed disulfides was minimal and most of
the native disulfide remained intact (no thiol-disulfide exchange at T6-T16) after 60 mins
and 1 day. Previously, Raman et al. have shown that the Cysteine/Cystine redox system is
more efficient in the oxidative folding of high concentrations (0.05 mg/mL) of lysozyme
when compared to GSH/GSSG [186]. Though only Cysteine was added to the studies here,
oxidation of Cys over time can result in the formation of Cystine thus providing a
Cystine/Cystine redox system. This observation with lysozyme and our results suggest that
Cys favors the formation of native disulfides over mixed disulfides such that the rate of
formation of mixed disulfides << the rate of regeneration of native disulfides, attributing
to the detection of only one of the mixed disulfides (T21-C). Also, the thiol group in Cys
itself has a low pKa (8.3) that would make it a better leaving group.
With RCR and CR, the presence of a positively charged group adjacent to the Cys
would be expected to increase reactivity of the thiol group by lowering thiol pKa. A thiol
group with low pKa makes a better leaving group [61] as the charge stabilizes the thiolate
form over the mixed disulfide [62] thus favoring reformation of native disulfides in both
cT20-21 and hGH. The presence of an Arg adjacent to Cys182 in growth hormone is highly
conserved among different species; the positively charged residue lowers pKa of the thiol
group making it the most reactive of the four Cys residues [137]. Having two Arg residues
flanking the reactive Cys not increase reactivity over having just one, however; similar
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reactivities of CR and RCR were observed for cT20-T21 (Figure 4.13). However, with
QCR, the regeneration is not as fast as it is with RCR and CR (Figure 4.13). In agreement
with the results obtained here, Okumura et al. observed that with a glutathione derivative,
RCG (oxidized and reduced), prouroguanylin folded into its native conformation more
efficiently than with GSH [187]. The increase in folding efficiency was attributed to the
presence of a positive charge (from Arg) adjacent to the Cys residue. T20a is similar in
sequence to the tryptic fragment, T20, in hGH and this could explain why the native
disulfide in cT20-T21 and hGH (Table 4.6) is not regenerated faster than with GSH as
observed for other peptides with a neighboring Arg.
The unified software package DiANNA was used to determine the Cys state in all
the free thiol-containing peptides to gain a better understanding of the observed differences
in reactivities. The algorithm predicts the susceptibility of Cys residues to either participate
in a disulfide bond or to be in the reduced state with 76-81 % accuracy [188]. Scores
obtained for the different peptides used to initiate thiol-disulfide exchange are shown in
Table 4.7. A higher score corresponds to an increased susceptibility to be in that state. The
lowest scores for half Cys were obtained for C and CR, suggesting that in the presence of
these thiols, regeneration of the native disulfide will be favored over mixed disulfides, in
accordance with the results obtained here (Figure 4.13). However, similar half Cys scores
were obtained for RCR, QCR and GSH and no correlations could be made to the results
reported here. rT20-T21, reduced form of cT20-T21 had the highest half Cys score,
suggesting that the disulfide bond in cT20-T21 would be favored over its reduced form or
a mixed disulfide with another free thiol-containing peptide. The differences in peptide
reactivity between DiANNA scores and the reactivities reported here suggest that, in

164
addition to the influence of primary structure on thiol pKa, higher order structure also plays
a role and can determine the type of disulfide bond that can be regenerated.

Table 4.7: Oxidation state prediction for thiol-containing peptides using DiANNA

Peptide

Free Cys

Half Cys

C
CR
RCR
QCR
GSH
T20
T20a
rT20-T21

0.869
0.835
0.711
0.799
0.798
0.608
0.692
0.546

0.131
0.165
0.289
0.201
0.202
0.392
0.308
0.454

values represented as scores obtained using DiANNA

4.8

Conclusion

The studies reported in this chapter using intact hGH, disulfide-linked and free
thiol-containing peptides as model compounds, demonstrate that higher-order structure,
proximity of thiols to a disulfide and primary structure influence thiol-disulfide exchange.
Higher-order structure was found to protect the native disulfides to some extent, however,
thiol-disulfide exchange still occurs at both the native disulfides in intact hGH. Loss of the
native disulfides in hGH did not result in structural changes as observed using CD and
HDX. Regeneration of the native disulfide was favored in the presence of peptides that
contain an Arg residue adjacent to the reactive Cys for both hGH and a cyclic peptide
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(cT20-T21). These results provide an improved understanding of thiol-disulfide exchange
reactions in hGH and are valuable to the development of protein drugs that contain
disulfide bonds.
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CHAPTER 5. CONCLUSIONS AND SUGGESTIONS FOR FUTURE WORK

In order to improve stability of therapeutic proteins during the manufacturing
process and storage, it is important to understand the mechanisms of degradation pathways
both in aqueous solution and in the solid state. These deleterious degradation reactions can
significantly affect the therapeutic value of proteins. The studies reported in this
dissertation have elucidated the mechanism of one such pathway, thiol-disulfide exchange,
in human growth hormone. Model tryptic peptides derived from hGH were used to
investigate reaction mechanisms and kinetics in Chapters 2 and 3, providing mechanistic
details on the reaction in the absence of higher order structure and other degradation
pathways. Chapter 4 provided insight into the effects of higher-order structure on thioldisulfide exchange using intact hGH as a model protein.

5.1

Thiol-disulfide exchange in aqueous solution (Chapter 2)

The results presented in chapter 2 demonstrated that in aqueous solution,
microscopic rate constants for thiol-disulfide exchange are pH independent while the
observed rate constants for the loss of native disulfide are pH dependent. Further, thioldisulfide exchange follows Arrhenius behavior and the calculated activation parameters
are similar to previous reports in the literature for low-molecular weight thiols and proteins
[71]. The activation energy values for all four reversible thiol-disulfide exchange reactions
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(R3 and R4, Scheme 2.1) were similar suggesting that they are all essentially the same
reaction. The negative entropy of activation values that were obtained (Table 2.3) for thioldisulfide exchange reactions (R3 and R4, Scheme 2.1) are representative of SN2
nucleophilic displacement reactions. Though the presence of oxidation suppressants
(EDTA and N2 sparging) did not completely inhibit oxidation reactions (R5 and R6,
Scheme 2.1), the oxidation reactions did not affect the intrinsic rates of thiol-disulfide
exchange. Finally, peptide secondary structure was shown to influence reactivity of the
disulfide bond; loss of native disulfide in the linear peptide was ~10-fold greater than in
the cyclic peptide.

5.2

Thiol-disulfide exchange during lyophilization and storage in the solid state
(Chapter 3)

These studies explored the effects of a process stress (lyophilization) and
subsequent storage in the solid state on thiol-disulfide exchange in hGH-derived peptides.
The results from Chapter 3 demonstrate that the mechanism of thiol-disulfide exchange is
similar in aqueous solution and in the solid state. However, differences in reaction rates
and distribution of products were observed. Further, peptide cyclization offered little or no
protection from thiol-disulfide exchange during lyophilization and storage. Increased
reactivity of the cyclic peptide in the solid state shows that lyophilization may not always
be a suitable approach to improve the stability of peptide and protein formulations. This
information is valuable to the pharmaceutical industry, especially when protein
formulations are switched from solution to the solid state with the assumption that they are
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more stable during storage in the solid state. The ‘cold finger’ was used to study adsorption
of peptides and proteins to ice surfaces and evaluate the role of surfactants in protein
formulations where ice-induced degradation is suspected. A general reaction scheme for
the reaction of linear or cyclic peptides that contain disulfide bonds with a free thiol
(Scheme 3.3, Chapter 3) was also proposed. This reaction scheme can be used as a guide
to identify scrambled species when the reactive thiol group and disulfide-containing moiety
(linear or cyclic) are known. The relative rates of these reactions may vary between solution
and the solid state and will be influenced by the type of thiol/disulfide, pH and temperature.

5.3

Thiol-disulfide exchange in human growth hormone (Chapter 4)

The results presented in Chapter 4 show that thiol-disulfide exchange also occurs
in intact hGH in the presence of reactive thiolate anions. By using the Perfinity flash digest
protocol, scrambled disulfides were not produced during digestion, allowing analysis of
hGH samples. However, scrambling may occur during digestion for proteins that have a
free Cys in their native form (not tested here) and suitable alkylating agents need to be
evaluated for their ability to minimize disulfide exchange in parallel with their effect on
digestion efficiency and digestion times.
For the protein concentrations tested here, no intermolecular or intramolecular
disulfides were detected. Protein mixed-disulfides were detected with GSH, free thiolcontaining peptides and cysteine. However, most of the native disulfide was regenerated at
the end of one day. A similar trend was observed with the cyclic peptide, suggesting that
the proximity of free Cys residues in hGH and cT20-T21 favors reformation of the native
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disulfide. Overall, loss of native disulfide in cT20-T21 and T20-T21pep was greater than
loss of native disulfide in hGH. Further, the presence of an Arg residue neighboring the
reactive Cys was found to favor regeneration of the native disulfide over GSH. Together,
the results suggest that protein higher order structure and peptide secondary structure
influence thiol-disulfide exchange.

5.4

Recommendations for future work

The stabilizing effects of excipients on thiol-disulfide exchange are not well known;
this is an area for future investigation. A previous report of thiol-disulfide exchange
examined the effect of sucrose on the reaction during lyophilization [129]. Though some
protection was observed during the freezing and primary drying steps, loss of native
disulfide during secondary drying in the presence of sucrose was similar to vials
lyophilized without sucrose [129]. It would also be interesting to study thiol-disulfide
exchange in intact hGH in the solid state both in the presence and absence of excipients,
since hGH is known to undergo structural changes upon lyophilization. Though an
excipient may have a stabilizing effect on thiol/disulfide mediated degradation, it may
facilitate degradation via a different mechanism. Thus, the compatibilities of excipients
with different proteins and potential degradation pathways (both physical and chemical)
have to be carefully assessed in aqueous solution and in solid-state formulations.
The effects of glass transition temperature (Tg) and moisture content on thioldisulfide exchange were not investigated here. Incorporation of some excipients in
formulations will increase Tg, thus improving storage stability while others may have a
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negative effect (e.g., low Tg, change in pH and/or loss of structure). The moisture content
of lyophilized peptide samples in Chapter 2 was 1-1.5% immediately after lyophilization
and after storage for 14 days. Even with such low moisture content, the cyclic peptide
degraded more rapidly in the solid state than in solution samples. It is possible that as the
moisture content increases, sample dilution with water molecules protects the native
disulfide bond from thiol-disulfide exchange as reported previously for recombinant
human albumin [95]. Thus, studies relating the kinetics of thiol-disulfide exchange and the
kinetics of water sorption are needed, in order to identify the particular moisture content
that can lead to protein instability.
The results obtained in Chapter 4 with intact hGH showed that no structural changes
were observed upon disulfide bond cleavage thus favoring regeneration of the native
disulfide over inter-/intramolecular scrambled disulfides. Even though lyophilization is
known to induce structural changes in hGH [101], denaturants (e.g., GdnHCl, urea),
mechanical force and agitation may have different effects on higher-order structure that
can result in an altered distribution of scrambled disulfides in the presence of reactive thiols.
It would be interesting to monitor thiol-disulfide exchange in hGH with different
denaturing agents/stresses and to identify conditions in which disulfide degradation is
favored.
The results reported in this dissertation can also be extended to understand the
effects of primary structure and length of the attacking thiol groups on thiol-disulfide
exchange. Though steric effects related to the size of the reactive nucleophile are known to
influence reaction kinetics to a greater extent than the size of disulfide-containing moiety
and/or the pH [179], this is still an area that has not been explored extensively as it has
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been for deamidation in peptides and proteins [189, 190]. For example, the effects of amino
acids flanking the Cys residue are not well understood except for the presence of an
arginine, which was shown to favor regeneration of the native disulfides, as reported here
and by Okumura et al [187]. Other positively charged amino acids such as His and Lys
may have similar effects and are yet to be investigated. Another area for future work is to
use the information presented here to study therapeutic proteins with similar and distinct
higher order structures, e.g., using model peptides from a protein that is rich in β-sheets
instead of α-helices.
Finally, since serum is known to contain low molecular weight thiols such as Cys
and GSH [72], the mechanistic details of thiol-disulfide exchange reported here can be
extended to understand the reaction in therapeutic proteins in vivo after administration.
Jiang et al. have used a continuous flow dialysis system to evaluate protein disulfide
conversion [191]; a similar system can be used for other therapeutic proteins to evaluate
the potential for loss of native protein disulfides. This can provide an insight into the
formation of modified forms of the protein drug that may have altered properties. It is
already known that monoclonal antibodies of the IgG4 class undergo Fab-arm exchange, a
disulfide rearrangement phenomena, in serum and these modified molecules have been
shown to have therapeutic effects that differ from those of the native protein.

5.5

Implications for protein formulation

The results obtained in Chapter 3 with both the linear and cyclic peptides suggest
that lyophilization at near neutral pH does not inhibit thiol-disulfide exchange. A common
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approach to inhibiting thiol-disulfide exchange and β-elimination is to formulate proteins
and peptides that contain thiols and disulfides at low pH prior to lyophilization, followed
by reconstitution in near neutral buffer before administration. Low pH prior to
lyophilization has been shown to arrest β-elimination in insulin during storage in the solid
state [79]. This approach may work well for some proteins when compared to others
depending on inherent protein stability at low pH. Thermal stability of proteins varies with
pH [192] and may further facilitate disulfide-mediated degradation events during and after
lyophilization. Overall, the effect of pH on the conformational stability of a protein and
excipients must be well understood before this approach can be employed.
Another stabilization strategy is to use excipients in peptide and protein
formulations before lyophilization. In the absence of excipients, proteins can undergo
structural changes during processing that may favor thiol and/or disulfide-mediated
degradation. For example, upon structural changes, a buried Cys residue may be exposed
to oxidative agents or be brought in close proximity to a native disulfide bond resulting in
the formation of intermolecular bonds, high molecular weight aggregated and/or nonnative intramolecular disulfides. Increasing the buffer concentration is another strategy that
can be used to control thiol-disulfide exchange. The buffer concentrations tested in the
studies reported here (10 – 40 mM) did not have a significant effect on thiol-disulfide
exchange in the linear peptide (Chapter 2). However, in a study with bovine serum albumin,
disulfide-mediated aggregation was reduced when 1 M sodium phosphate was added to the
initiating buffer (5 mM phosphate, 150 mM NaCl, pH = 7.3). A possible explanation for
the observed reduction is that phosphate anions prevent the attack of thiolate anions on the
disulfide bond [96].
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For proteins that contain free thiols such as human serum albumin, protein tyrosine
phosphatases and recombinant human α1-antitrypsin, thiol derivatizing agents and protein
engineering approaches can be employed to retain biological activity and improve stability
[3]. These approaches are discussed in detail in Chapter 1 and can be used when the free
Cys residues are known to have no functional role. Thiol derivatization, however, is not a
suitable strategy for proteins where the role of Cys is unknown. Derivatization restricts free
thiol content and will minimize thiol-catalyzed and thiol-disulfide exchange reactions
during lyophilization and storage. Protein concentration may also influence the formation
of disulfide-linked aggregates. For example, at high concentrations of porcine
somatotropin (>25 mg/mL), disulfide-linked aggregates were detected at 39 oC after 14
days during storage [184]. Optimizing protein concentrations to a range that delivers an
effective dose and provides stability during storage is essential to developing safe and
effective protein therapeutics.
The presence of oxygen, metal ions (CuII and FeIII) and reactive oxygen species
(ROS) such as peroxides, superoxide and hydroxyl radical can result in the formation of
sulfenic, sulfinic and sulfonic acids and thiolsulfinate or a new non-native disulfide bond
[140, 193, 194]. Although oxidative pathways were found to have no effect on the intrinsic
rates of thiol-disulfide exchange (Chapter 2), these products of oxidative pathways can
diminish the therapeutic efficacy of protein and peptide drugs that contain free thiols.
Nitrogen sparging and storage of protein formulations in a nitrogen atmosphere will inhibit
O2-mediated oxidative pathways. Some common excipients like polyvinyl pyrrolidone and
polyethylene glycol contain peroxides as impurities. These excipients should be excluded
from protein formulations and suitable antioxidants can be employed as stabilizers when
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peroxides are detected. If metal-catalyzed thiol oxidation is suspected, EDTA can be used
as a metal ion chelator to stabilize thiol containing peptides and proteins. In some cases
however, the presence of transition metal cations (Cu2+) can be beneficial when used as an
oxidizing agent to minimize free thiol groups prior to lyophilization [78]. The addition of
divalent metal ions (Cu2+) catalyzed thiol oxidation at a rapid rate relative to thiol-disulfide
exchange and stabilized insulin from aggregation [78].
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Appendix A: Data modeling with SCIENTIST®
// Micromath Scientist Model File for the reaction of T20 with T20-T21 at pH 7.0 in
aqueous solution
IndVars: T
DepVars: T20,T21,T20T20,T21T21,T20T21,T20S,T21S
Params: K1,K2,K3,K4,K5,pKa,pKb
T20T20' = K1*T20S*T20T21-K2*T20T20*T21S+K5*T20S*T20S*T20S*T21S
T21T21' = K3*T21S*T20T21-K4*T21T21*T20S
T20T21' = - K1*T20S*T20T21 + K2*T20T20*T21S - K3*T21S*T20T21 +
K4*T21T21*T20S+K5*T20S*T20S*T20S*T21S
T20' = -K1*T20S*T20T21+K2*T20T20*T21S+K3*T21S*T20T21-K4*T20S*T21T21K5*T20S*T20S*T20S*T21S
T21' = K1*T20S*T20T21-K2*T20T20*T21S-K3*T21S*T20T21+K4*T20S*T21T21K5*T20S*T20S*T20S*T21S
//Parameter values:
K1 = 0.0004
K2 = 0.0006
K3 = 0.0002
K4 = 0.0006
pKa = 8.3
pKb = 8.3
// Initial conditions:
T = 0.0
T20 = 350.00
T20T21 = 250.00
T21 = 0.0
T20T20 = 0.0
T21T21 = 0.0
T20S = T20/(1+((10^(-7))/(10^(-pKa))))
T21S = T21/(1+((10^(-7))/(10^(-pKb))))
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Appendix B: SGA and DSC measurements for lyophilized samples
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Figure B.1: VTI data for lyo sample (T20 and cT20-T21, pH 7.0, 10 mM PB, 0.08 M ionic
strength and 0.5 mM EDTA) collected on SGA-100 (VTI Corporation, Hialeah, FL). Data
was measured at 0% RH and at 25 oC at the end of secondary drying.

Figure B.2: DSC data for lyo sample (T20 and cT20-T21, pH 7.0, 10 mM PB, 0.08 M
ionic strength and 0.5 mM EDTA) collected on DSC Q-2000 (TA instruments, New Castle,
DE).
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Appendix C: Purification and digestion optmization of hGH
rhGH was purified from E.coli after cell harvesting using the protocol shown in the flow
chart below.
Day 1

Cell pellet
4 cycles

1 cycle
50 mM Tris.HCl
100 mM NaCl
5 mM EDTA
pH 8.0

2 cycles

1 cycle

50 mM Tris.HCl
1% DOC
pH 8.5

50 mM Tris.HCl
pH 8.5

Add 50 mL

Sonication

Solubilization
of inclusion
bodies

100 mM Tris.HCl
2 M Urea
pH 12.5

Add 10 or 5 mL

Day 1 (O/N)

Dilution

50 mM Tris.HCl
2 M Urea
0.5 mM EDTA
10% glycerol

Day 2

Refolding with
dialysis

50 mM Tris.HCl
1 M Urea
0.5 mM EDTA
2% sucrose
pH 8.0

5% sucrose
3 mM GSH
0.6 mM GSSG
pH 8.0

Add 40 or 45 mL

Day 3
50 mM Tris.HCl
0.5 M Urea
0.5 mM EDTA
2% sucrose
pH 8.0

Day 4
50 mM Tris.HCl
0.5 mM EDTA
2% sucrose
pH 8.0

2.5 L for dialysis

Day 5

Gel filtration

50 mM Tris.HCl
2% sucrose
pH 8.0

2 L for column
equilibration and elution

Figure C.1: Flow chart showing purification steps for hGH from the cell pellet. Buffers
used for each step are shown in boxes and amount of each buffer added are in green next
to the boxes.
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Table C.1: Comparing different digestion protocols for hGH

Digestion protocol

Disulfide
scrambling

Digestion complete
in less than 60 mins

Tr ypsin digestion in
solution

Y

N

Tr ypsin immobilized
on magnetic beads

Y

N

Tr ypsin immobilized
on agarose beads

Y

N

Perfinity flash digest
protocol

N

Y
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Table C.2: Amino acid sequence of all possible scrambled intra-and intermolecular
disulfide-linked peptides from hGH.

Tryptic peptide

Description

T6-T20

Scrambled
disulfidelinked peptide

T6-T21

Scrambled
disulfidelinked peptide

Amino acid sequence

Theoretical
mass (Da)

Observed
mass (Da)

3230.549

nd

3397.523

nd

1762.865

nd

NH2- YSFLQNPQTSLCFSESIPTPSNR-OH
NH2- IVQCR-OH
NH2- YSFLQNPQTSLCFSESIPTPSNR-OH
NH2- SVEGSCGF-OH

T16-T20

Scrambled
disulfidelinked peptide

NH2- NYGLLYCFR-OH
NH2- IVQCR-OH

T16-T21

Scrambled
disulfidelinked peptide

NH2- NYGLLYCFR-OH
1929.839

nd

NH2- SVEGSCGF-OH

T6-T6

Homodimer,
Scrambled
disulfidelinked peptide

NH2- YSFLQNPQTSLCFSESIPTPSNR-OH
5228.45

nd

NH2- YSFLQNPQTSLCFSESIPTPSNR-OH

T16-T16

T20-T20

T21-T21

nd- not detected

Homodimer,
Scrambled
disulfidelinked peptide
Homodimer,
Scrambled
disulfidelinked peptide
Homodimer,
Scrambled
disulfidelinked peptide

NH2- NYGLLYCFR-OH
2293.081

nd

NH2- NYGLLYCFR-OH
NH2- IVQCR-OH
1232.648

nd

NH2- IVQCR-OH
NH2- SVEGSCGF-OH
1566.597
NH2- SVEGSCGF-OH

nd
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